Protein production in the body

By designing and modifying mRNA, the inefficiency and safety of mRNA translation and expression in cells are solved, and efficient and stable peptide expression and immune response are achieved, which enhances the development potential of therapeutic agents.

CN104870022BInactive Publication Date: 2024-11-12MODERNATX INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN201380028186.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2013-03-09
Filing Date
2013-03-15
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art has the risk of integration into the host genome, errors and cell damage when introducing mRNA into cells, and it is difficult to effectively regulate translation and protein expression, resulting in many challenges in the development of therapeutic agents.

Method used

By designing and preparing modified mRNAs (mmRNAs), using specific structural and chemical modifications, optimizing their formulation and delivery, avoiding immune responses and degradation pathways, improving protein expression rates and concentrations, and ensuring structural and functional integrity.

Benefits of technology

The efficient and stable expression of the target polypeptide in cells is achieved, reducing the risk of immune response and cell damage, and improving the effectiveness and safety of the therapeutic agent.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN104870022B_ABST
    Figure CN104870022B_ABST
Patent Text Reader

Abstract

The present invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of polynucleotides, primary transcripts, and mmRNA molecules.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Sequence Listing Reference

[0002] This application is filed with a sequence listing in electronic format. The sequence listing file, named M313SQLST.txt, was created on March 15, 2013 and is 240,793 bytes in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS

[0004] This application is related to the following: International Application No. PCT / US2012 / 069610, entitled Modified Nucleoside, Nucleotide, and Nucleic Acid Compositions, filed on December 14, 2012, U.S. Provisional Patent Application No. 61 / 618,862, entitled Modified Polynucleotides for the Production of Biologics, filed on April 2, 2012, U.S. Provisional Patent Application No. 61 / 681,645, entitled Modified Polynucleotides for the Production of Biologics, filed on August 10, 2012, U.S. Provisional Patent Application No. 61 / 737,130, entitled Modified Polynucleotides for the Production of Biologics, filed on December 14, 2012, U.S. Provisional Patent Application No. 61 / 618,866, entitled Modified Polynucleotides for the Production of Antibodies, filed on April 2, 2012, U.S. Provisional Patent Application No. 61 / 681,647, entitled Polynucleotides for the Production of Antibodies, filed December 14, 2012, U.S. Provisional Patent Application No. 61 / 737,134, entitled Modified Polynucleotides for the Production of Antibodies, filed April 2, 2012, U.S. Provisional Patent Application No. 61 / 618,868, entitled Modified Polynucleotides for the Production of Vaccines, filed August 10, 2012, U.S. Provisional Patent Application No. 61 / 681,648, entitled Modified Polynucleotides for the Production of Vaccines, filed December 14, 2012, U.S. Provisional Patent Application No. 61 / 737,135, entitled Modified Polynucleotides for the Production of Vaccines, filed April 2, 2012and U.S. Provisional Patent Application No. 61 / 618,870, entitled "Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides," filed on August 10, 2012; U.S. Provisional Patent Application No. 61 / 681,649, entitled "Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides," filed on December 14, 2012; U.S. Provisional Patent Application No. 61 / 737,139, entitled "Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides," filed on April 2, 2012; U.S. Provisional Patent Application No. 61 / 618,873, entitled "Modified Polynucleotides for the Production of Secreted Proteins," filed on August 10, 2012; U.S. Provisional Patent Application No. 61 / 681,650, entitled "Modified Polynucleotides for the Production of Secreted Proteins," filed on December 14, 2012; and U.S. Provisional Patent Application No. 61 / 737,147, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, filed April 2, 2012; U.S. Provisional Patent Application No. 61 / 618,878, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, filed August 10, 2012; U.S. Provisional Patent Application No. 61 / 681,654, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, filed December 14, 2012; U.S. Provisional Patent Application No. 61 / 737,152, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, filed April 2, 2012;U.S. Provisional Patent Application No. 61 / 618,885, entitled "Cytoskeletal Proteins," U.S. Provisional Patent Application No. 61 / 681,658, filed on August 10, 2012, entitled "Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins," U.S. Provisional Patent Application No. 61 / 737,155, filed on December 14, 2012, entitled "Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins," U.S. Provisional Patent Application No. 61 / 618,896, filed on April 2, 2012, entitled "Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins," U.S. Provisional Patent Application No. 61 / 668,157, filed on July 5, 2012, entitled "Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins," and U.S. Provisional Patent Application No. 61 / 681,658, filed on August 10, 2012, entitled "Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins." U.S. Provisional Patent Application No. 61 / 681,661, entitled Polynucleotides for the Production of Intracellular Membrane Bound Proteins, filed December 14, 2012; U.S. Provisional Patent Application No. 61 / 737,160, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins, filed April 2, 2012; U.S. Provisional Patent Application No. 61 / 618,911, entitled Modified Polynucleotides for the Production of Nuclear Proteins, filed August 10, 2012; U.S. Provisional Patent Application No. 61 / 681,667, entitled Modified Polynucleotides for the Production of Nuclear Proteins, filed December 14, 2012;U.S. Provisional Patent Application No. 61 / 737,168, entitled "Modified Polynucleotides for the Production of Nuclear Proteins," filed April 2, 2012, U.S. Provisional Patent Application No. 61 / 618,922, entitled "Modified Polynucleotides for the Production of Proteins," filed August 10, 2012, U.S. Provisional Patent Application No. 61 / 681,675, entitled "Modified Polynucleotides for the Production of Proteins," filed December 14, 2012, U.S. Provisional Patent Application No. 61 / 737,174, entitled "Modified Polynucleotides for the Production of Proteins," filed April 2, 2012, U.S. Provisional Patent Application No. 61 / 618,935, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," filed August 10, 2012, Disease, U.S. Provisional Patent Application No. 61 / 681,687, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 737,184, filed December 14, 2012, Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 618,945, filed April 2, 2012, Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 681,696, filed August 10, 2012, Modified Polynucleotides for the Production of Proteins Associated with HumanDisease,U.S. Provisional Patent Application No. 61 / 737,191, entitled "Proteins Associated with Human Disease," U.S. Provisional Patent Application No. 61 / 618,953, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," U.S. Provisional Patent Application No. 61 / 681,704, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," U.S. Provisional Patent Application No. 61 / 737,203, filed December 14, 2012, U.S. Provisional Patent Application No. 61 / 753,661, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," U.S. Provisional Patent Application No. 61 / 618,961, filed April 2, 2012, and U.S. Provisional Patent Application No. 61 / 618,961, filed May 17, 2012, entitled "Dosing Methods for Modified mRNA," mRNA, International Application No. PCT / US2013 / 030062, filed March 9, 2013, entitled Modified Polynucleotides for the Production of Biologics and Proteins Associated with Human Disease, International Application No. PCT / US2013 / 030063, filed March 9, 2013, entitled Modified Polynucloetides, International Application No. PCT / US2013 / 030064, filed March 9, 2013, entitled Modified Polynucleotides for the Production of Secreted Proteins, International Application No. PCT / US2013 / 030059, filed March 9, 2013, entitled Modified Polynucleotides for the Production of Membrane Proteins,International Application No. PCT / US2013 / 030066, entitled Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins, filed on March 9, 2013, International Application No. PCT / US2013 / 030067, entitled Modified Polynucleotides for the Production of Nuclear Proteins, filed on March 9, 2013, International Application No. PCT / US2013 / 030060, entitled Modified Polynucleotides for the Production of Proteins, filed on March 9, 2013, International Application No. PCT / US2013 / 030061, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, filed on March 9, 2013, International Application No. PCT / US2013 / 030062, entitled Modified Polynucleotides for the Production of Cosmetic Proteins and International application number PCT / US2013 / 030068, entitled "Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides," and International application number PCT / US2013 / 030070, filed on March 9, 2013, entitled "Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides," the contents of each of which are incorporated herein by reference in their entirety.

[0005] This application is also related to International Publication No. PCT / US2012 / 58519, filed on October 3, 2012, entitled Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof, and International Publication No. PCT / US2012 / 69610, filed on December 14, 2012, entitled Modified Nucleoside, Nucleotide, and Nucleic Acid Compositions, the contents of each of which are incorporated herein by reference in their entirety. Field of the Invention

[0006] The present invention relates to compositions, methods, processes, kits and devices for designing, preparing, manufacturing and / or formulating polynucleotides, primary constructs and modified mRNA molecules (mmRNA). Background of the Invention

[0008] There are multiple problems in the existing methodology that affects protein expression. For example, the DNA introduced can be integrated into the host cell genomic DNA at some frequencies, thereby causing changes and / or damage to the host cell genomic DNA. Alternatively, the heterologous deoxyribonucleic acid (DNA) introduced into the cell can be inherited by daughter cells (regardless of whether the heterologous DNA is integrated into the chromosome) or by offspring. In addition, assuming that it is appropriately delivered and is not damaged or integrated into the host genome, multiple steps must occur before the encoded protein is made. Once inside the cell, the DNA must be transported into the nucleus, where it is transcribed into RNA. The RNA transcribed from the DNA must then enter the cytoplasm, where it is translated into protein. The multiple processing steps from the DNA used to the protein not only form a delay time before producing a functional protein, but each step also means an error and the chance of causing damage to the cell. In addition, it is known to be difficult to obtain DNA expression in cells because DNA frequently enters cells but is not expressed or expressed at a reasonable rate or concentration. When DNA is introduced into primary cells or modified cell lines, this is particularly problematic.

[0009] In the early 1990s, Bloom and colleagues successfully rescued vasopressin-deficient rats by injecting in vitro transcribed vasopressin mRNA into the hypothalamus (Science 255:996–998; 1992). However, low translation levels and the molecule's immunogenicity hampered the development of mRNA as a therapeutic agent, and subsequent work has focused on alternative applications that could exploit these deficiencies: immunization with mRNA encoding cancer antigens.

[0010] Others have investigated the use of mRNA to deliver polypeptides of interest and have shown that certain chemical modifications of mRNA molecules, particularly pseudouridine and 5-methyl-cytosine, reduce immunostimulatory effects.

[0011] These studies are disclosed, for example, in UK patent application serial number 0316089.2 filed on July 9, 2003 by Ribostem Limited (now abandoned), PCT application number PCT / GB2004 / 002981 filed on July 9, 2004, published as WO2005005622, U.S. patent application national phase entry serial number 10 / 563,897 filed on June 8, 2006, published as US20060247195 (now abandoned), and European patent application national phase entry serial number EP1646714 filed on July 9, 2004, published as EP1646714 (now withdrawn). 2004743322; PCT Application No. PCT / US2007 / 88060 filed by Novozymes, Inc. on December 19, 2007, published as WO2008140615, U.S. Patent Application National Phase Entry No. 12 / 520,072 filed on July 2, 2009, published as US20100028943, and European Patent Application National Phase Entry No. EP2007874376 filed on July 7, 2009, published as EP2104739; University of Rochester of Rochester, OH, filed on December 4, 2006, PCT Application No. PCT / US2006 / 46120, published as WO2007064952, and U.S. Patent Application Serial No. 11 / 606,995, filed on December 1, 2006, published as US20070141030; BioNTech AG's European patent application serial number EP2007024312 filed on December 14, 2007 (now abandoned), PCT application number PCT / EP2008 / 01059 filed on December 12, 2008, published as WO2009077134, European patent application national phase entry number EP2008861423 filed on June 2, 2010, published as EP2240572, U.S. patent application national phase entry number 12 / 735,060 filed on November 24, 2010, published as US20110065103, German patent application serial number DE 10 2005 046 filed on September 28, 2005 490, PCT application PCT / EP2006 / 0448 filed on September 28, 2006, published as WO2007036366, national phase European patent EP1934345 published on March 21, 2012, and national phase U.S. patent application serial number 11 / 992,638 filed on August 14, 2009, published as 20100129877; Immune Disease Institute Inc.) in U.S. patent application serial number 13 / 088,009, filed on April 15, 2011, and published as US20120046346, and PCT application PCT / US2011 / 32679, filed on April 15, 2011, and published as WO20110130624; in U.S. patent application serial number 12 / 957,340, filed on November 20, 2010, and published as US20110244026, by Shire Human Genetic Therapeutics; in PCT application PCT / US1998 / 019492, filed on September 18, 1998, and published as WO1999014346, by Sequitur Inc.; and in PCT application PCT / US1998 / 019492, filed on September 18, 1998, and published as WO1999014346, by The Scripps Research Institute’s PCT Application No. PCT / US2010 / 00567, filed on February 24, 2010, and published as WO2010098861, and U.S. Patent Application National Phase Entry No. 13 / 203,229, filed on November 3, 2011, and published as US20120053333; Ludwig-Maximillians University’s PCT Application No. PCT / EP2010 / 004681, filed on July 30, 2010, and published as WO2011012316; and Cellscript Inc., U.S. Patent No. 8,039,214 filed on June 30, 2008 and issued on October 18, 2011, U.S. Patent Application Serial Nos. 12 / 962,498 filed on December 7, 2010, published as US20110143436, 12 / 962,468 filed on December 7, 2010, published as US20110143397, 13 / 237,451 filed on September 20, 2011, published as US20120009649, and PCT Application Nos. PCT / US2010 / 59305 filed on December 7, 2010, published as WO2011071931, and PCT / US2010 / 59317 filed on December 7, 2010, published as WO2011071936; Trustees of the University of Pennsylvania filed PCT application No. PCT / US2006 / 32372, published as WO2007024708, on August 21, 2006, and U.S. patent application national phase entry No. 11 / 990,646, filed on March 27, 2009, and published as US20090286852; and Curevac GMBH filed German patent application serial No. DE10 2001 027 283, filed on June 5, 2001.9. DE10 2001062 480.8 filed on December 19, 2001, and DE 20 2006 051 516 filed on October 31, 2006 (both abandoned), European Patent Nos. EP1392341 granted on March 30, 2005, and EP1458410 granted on January 2, 2008, PCT Application No. PCT / EP2002 / 06180 filed on June 5, 2002, published as WO2002098443, PCT / EP2002 / 14577 filed on December 19, 2002, published as WO2003051401, and PCT / EP2002 / 14577 filed on December 31, 2007, published as WO200805277 0, PCT / EP2007 / 09469 filed on April 16, 2008, published as WO2009127230, PCT / EP2008 / 03033 filed on April 16, 2008, published as WO2009127230, PCT / EP2006 / 004784 filed on May 19, 2005, published as WO2006122828, PCT / EP2008 / 00081 filed on January 9, 2007, published as WO2008083949, and U.S. Patent Application Serial No. US2003 / 2004 filed on December 5, 2003, published as US2004 050032730, 10 / 729,830 filed on June 18, 2004, published as US20050059624, 10 / 870,110 filed on July 7, 2008, published as US20080267873, 12 / 446,912 filed on October 27, 2009, published as US2010047261 (now abandoned), 12 / 522,2 filed on January 4, 2010, published as US20100189729 14. 12 / 787,566, filed May 26, 2010, published as US20110077287, 12 / 787,755, filed May 26, 2010, published as US20100239608, 13 / 185,119, filed July 18, 2011, published as US20110269950, and 13 / 106,548, filed May 12, 2011, published as US20110311472, all of which are incorporated herein by reference in their entirety.

[0012] Despite these reports, which are limited to a selection of chemical modifications including pseudouridine and 5-methyl-cytosine, there remains a need in the art for therapeutic modalities that address the numerous obstacles surrounding efficient regulation of translation within cells and processing of nucleic acids encoding polypeptides or fragments thereof.

[0013] For this reason, the inventor has confirmed that some modified mRNA sequence has the potentiality of the therapeutic agent that exceeds only escaping, avoiding or weakening immune response as benefit.This type of research is described in detail in the international application number PCT / US2011 / 054617 of the PCT / US2011 / 046861 of the co-pending application international application of announcement on August 5, 2011 and the PCT / US2011 / 054636 of submission on October 3, 2011, submission on October 3, 2011, the content of described application is incorporated into this paper in its entirety by reference.

[0014] The present invention addresses this need by providing nucleic acid-based compounds or polynucleotides that encode a polypeptide of interest (e.g., modified mRNA or mmRNA) and have structural and / or chemical features that avoid one or more problems in the art, such as features suitable for optimizing the formulation and delivery of nucleic acid-based therapeutics while maintaining structural and functional integrity, overcoming thresholds for expression, improving expression rate, half-life and / or protein concentration, optimizing protein localization, and avoiding deleterious biological responses such as immune responses and / or degradation pathways. SUMMARY OF THE INVENTION

[0016] Described herein are compositions, methods, processes, kits, and apparatuses for designing, preparing, manufacturing, and / or formulating modified mRNA (mmRNA) molecules.

[0017] The details of various embodiments of the present invention are set forth in the following description. Other features, objects, and advantages of the present invention will be apparent from the description and drawings of the present invention, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] The foregoing and other objects, features, and advantages will be apparent from the following description of specific embodiments of the present invention as illustrated in the accompanying drawings, in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily drawn to scale, emphasis instead being placed upon illustrating the principles of the various embodiments of the invention.

[0020] Figure 1 is a schematic diagram of a primary construct of the present invention.

[0021] Figure 2 The lipid structures suitable for use in the present invention are shown in the prior art. The structures of 98N12-5 (TETA5-LAP), DLin-DMA, DLin-K-DMA (2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane), DLin-KC2-DMA, DLin-MC3-DMA, and C12-200 are shown.

[0022] Figure 3 is a representative liposome suitable for use in the IVT reactions taught herein. The liposome contains insert 64818 designed by the present inventors.

[0023] Figure 4 Gel profile of modified mRNA encapsulated in PLGA microspheres.

[0024] Figure 5 Figure 1 is a histogram of Factor IX protein production and Factor IX modified mRNA in PLGA formulations.

[0025] Figure 6 is a histogram showing VEGF protein production in human keratinocytes following transfection with a range of doses of modified mRNA. Figure 6 A shows protein production following transfection of modified mRNA containing natural nucleoside triphosphates (NTPs). Figure 6 B shows protein production after transfection with modified mRNA fully modified with pseudouridine (pseudo-U) and 5-methylcytosine (5mC). Figure 6 C shows protein production after transfection with modified mRNA fully modified with N1-methyl-pseudouridine (N1-methyl-pseudo-U) and 5-methylcytosine (5mC).

[0026] Figure 7 is a histogram of VEGF protein production in HEK293 cells.

[0027] Figure 8 is a gel profile of GLA protein production in mammals. Figure 8 A shows the expected size of GLA. Figure 8 B shows the expected size of GLA.

[0028] Figure 9 Shown is a gel profile of ARSB protein production in mammals. Figure 9 A shows the expected size of the ARSB. Figure 9 B shows the expected size of the ARSB.

[0029] Figure 10 This is a gel profile of IFNB1 protein production in mammals. Figure 10 A shows the expected size of IFNB1. Figure 10 B shows the expected size of IFNB1.

[0030] Figure 11 Gel profile of Factor XI protein production in mammals. Figure 11 A shows the expected size of Factor XI. Figure 11 B shows the expected size of Factor XI.

[0031] Figure 12 This is a gel profile of TP53 protein production in mammals. Figure 11 A shows the expected size of TP53. Figure 11 B shows the expected size of TP53.

[0032] Figure 13 Gel profile of TGFβ protein production in mammals. Figure 13 A shows the expected size of TGFβ. Figure 11 B shows the expected size of TGFβ.

[0033] Figure 14 Shown is a gel profile of SIRT6 protein production in mammals. Figure 16 A shows the expected size of SIRT6. Figure 16 B shows the expected size of SIRT6.

[0034] Figure 15 is a gel profile of NAGS protein production in mammals. Figure 15 A shows the expected size of NAGS. Figure 15 B shows the expected size of NAGS.

[0035] Figure 16 Shown is a gel profile of SORT1 protein production in mammals. Figure 16 A shows the expected size of SORT1. Figure 16 B shows the expected size of SORT1.

[0036] Figure 17 Gel profile of GM-CSF protein production in mammals. Figure 17 A shows the expected size of GM-CSF. Figure 17 B shows the expected size of GM-CSF.

[0037] Figure 18 A gel profile of Klotho protein production in mammals. Figure 18 A shows the expected size of Klotho. Figure 18B shows the expected size of Klotho.

[0038] Figure 19 Gel profile of GALK1 protein production in mammals. Figure 19 A shows the expected size of GALK1. Figure 19 B shows the expected size of GALK1.

[0039] Figure 20 is a gel profile of SERPINF2 protein production in mammals. Figure 20 A shows the expected size of SERPINF2. Figure 20 B shows the expected size of SERPINF2.

[0040] Figure 21 is a gel profile of ALDOA protein production in mammals.

[0041] Figure 22 is a gel profile of TYR protein production in mammals. Figure 22 A shows the expected size of TYR. Figure 22 B shows the expected size of TYR.

[0042] Figure 23 Gel profile of BMP7 protein production in mammals. Figure 23 A shows the expected size of BMP7. Figure 23 B shows the expected size of BMP7.

[0043] Figure 24 A gel profile of NRG1 protein production in mammals. Figure 24 A shows the expected size of NRG1. Figure 24 B shows the expected size of NRG1.

[0044] Figure 25 Gel profile of protein production in mammalian APCS. Figure 25 A shows the expected size of the APCS. Figure 25 B shows the expected size of the APCS.

[0045] Figure 26 is a gel profile of LCAT protein production in mammals. Figure 26 A shows the expected size of LCAT. Figure 26 B shows the expected size of LCAT.

[0046] Figure 27 is a gel profile of ARTN protein production in mammals. Figure 27 A shows the expected size of ARTN. Figure 27 B shows the expected size of ARTN.

[0047] Figure 28 is a gel profile of HGF protein production in mammals. Figure 28 A shows the expected size of HGF. Figure 28 B shows the expected size of HGF.

[0048] Figure 29 is a gel profile of EPO protein production in mammals. Figure 29 A shows the expected size of EPO. Figure 29 B shows the expected size of EPO.

[0049] Figure 30 is a gel profile of IL-7 protein production in mammals. Figure 30 A shows the expected size of IL-7. Figure 30 B shows the expected size of IL-7.

[0050] Figure 31 Gel profile of LIPA protein production in mammalian cells. Figure 31 A shows the expected size of LIPA. Figure 31 B shows the expected size of LIPA.

[0051] Figure 32 Gel profile of DNAse1 protein production in mammalian cells. Figure 32 A shows the expected size of DNAse1. Figure 32 B shows the expected size of DNAse1.

[0052] Figure 33 This is a gel profile of APOA1Milano protein production in mammalian cells. Figure 33 A shows the expected size of APOA1 Milano. Figure 33 B shows the expected size of APOA1 Milano.

[0053] Figure 34 is a gel profile of TUFT1 protein production in mammals. Figure 34 A shows the expected size of TUFT1. Figure 34 B shows the expected size of TUFT1.

[0054] Figure 35 This is a gel profile of APOA1 Paris protein production in mammals. Figure 35 A shows the expected size of APOA1 Paris. Figure 35 B shows the expected size of APOA1 Paris.

[0055] Figure 36 This is a gel profile of APOA1 protein production in mammals. Figure 36A shows the expected size of APOA1. Figure 36 B shows the expected size of APOA1.

[0056] Figure 37 Gel profile of UGT1A1 protein production in mammals. Figure 37 A shows the expected size of UGT1A1. Figure 37 B shows the expected size of UGT1A1.

[0057] Figure 38 is a gel profile of THPO protein production in mammals. Figure 38 A shows the expected size of THPO. Figure 38 B shows the expected size of THPO.

[0058] Figure 39 is a gel profile of ASL protein production in mammals. Figure 39 A shows the expected size of the ASL. Figure 39 B shows the expected size of the ASL.

[0059] Figure 40 Gel profile of FSHα protein production in mammals.

[0060] Figure 41 Gel profile of BMP2 protein production in mammals. Figure 41 A shows the expected size of BMP2. Figure 41 B shows the expected size of BMP2.

[0061] Figure 42 is a gel profile of PLG protein production in mammals. Figure 42 A shows the expected size of PLG. Figure 42 B shows the expected size of PLG.

[0062] Figure 43 is a gel profile of FGA protein production in mammals. Figure 43 A shows the expected size of the FGA. Figure 43 B shows the expected size of the FGA.

[0063] Figure 44 is a gel profile of SERPINC1 protein production in mammals. Figure 44 A shows the expected size of SERPINC1. Figure 44 B shows the expected size of SERPINC1.

[0064] Figure 45 Gel profile of MTTP protein production in mammals. Figure 45 A shows the expected size of the MTTP. Figure 45B shows the expected size of the MTTP.

[0065] Figure 46 This is a gel profile of SEPT4 protein production in mammals. Figure 46 A shows the expected size of SEPT4. Figure 46 B shows the expected size of SEPT4.

[0066] Figure 47 is a gel profile of XIAP protein production in mammals. Figure 47 A shows the expected size of XIAP. Figure 47 B shows the expected size of XIAP.

[0067] Figure 48 Shown is a gel profile of SLC16A3 protein production in mammals. Figure 48 A shows the expected size of SLC16A3. Figure 48 B shows the expected size of SLC16A3.

[0068] Figure 49 A gel profile of ANGPT1 protein production in mammals. Figure 49 A shows the expected size of ANGPT1. Figure 49 B shows the expected size of ANGPT1.

[0069] Figure 50 is a gel profile of IL-10 protein production in mammals. Figure 50 A shows the expected size of IL-10. Figure 50 B shows the expected size of IL-10.

[0070] Figure 51 is a histogram showing insulin protein production in mammals.

[0071] Figure 52 is a histogram showing Factor XI protein production in HEK293 cells.

[0072] Figure 53 is a histogram showing Factor XI protein production in HeLa cells.

[0073] Figure 54 is a histogram showing Factor XI protein production in HeLa cells.

[0074] Figure 55 is a histogram showing Factor XI protein production in HeLa supernatant.

[0075] Figure 56 is a histogram showing HGH protein production in HeLa.

[0076] Details

[0077] In the field of therapeutics, diagnostics, reagents and for biological assays, it is of great significance to be able to deliver nucleic acids (e.g., ribonucleic acids (RNA)) to the interior of cells (whether in vitro, in vivo, in situ or ex vivo), for example, to cause intracellular translation of the nucleic acid and production of the encoded target polypeptide. Of particular importance is the delivery and function of non-integrating polynucleotides.

[0078] Described herein are compositions (including pharmaceutical compositions) and methods for designing, preparing, manufacturing, and / or formulating polynucleotides encoding one or more target polypeptides. Also provided are systems, processes, devices, and kits for selecting, designing, and / or using polynucleotides encoding target polypeptides described herein.

[0079] According to the present invention, these polynucleotides are preferably modified to avoid the drawbacks of other polypeptide encoding molecules known in the art. Therefore, these polynucleotides are referred to as modified mRNA or mmRNA.

[0080] The present inventors have explored the use of modified polynucleotides in the fields of antibodies, viruses, veterinary applications, and various in vivo settings and these studies are disclosed, for example, in co-pending and commonly owned U.S. Provisional Patent Application Serial Nos. 61 / 470,451, filed March 31, 2011, which teaches in vivo applications of mmRNA; 61 / 517,784, filed April 26, 2011, which teaches engineered nucleic acids for producing antibody polypeptides; and 61 / 519,154, filed May 17, 2011. 8, which teaches veterinary applications of mmRNA technology; 61 / 533,537, filed September 12, 2011, which teaches antimicrobial applications of mmRNA technology; 61 / 533,554, filed September 12, 2011, which teaches viral applications of mmRNA technology; 61 / 542,533, filed October 3, 2011, which teaches various chemical modifications for use in mmRNA technology; 61 / 570,690, filed December 14, 2011, which teaches Mobile devices for use in making or using mmRNA technology; 61 / 570,708, filed December 14, 2011, which teaches the use of mmRNA in acute care settings; 61 / 576,651, filed December 16, 2011, which teaches terminally modified configurations of mmRNA; 61 / 576,705, filed December 16, 2011, which teaches a method for delivering mmRNA using liposomes; 61 / 578, filed December 21, 2011, which teaches a method for delivering mmRNA using liposomes; 271, which teaches methods of using mmRNA to increase the viability of an organ or tissue; 61 / 581,322, filed December 29, 2011, which teaches mmRNA encoding a cell penetrating peptide; 61 / 581,352, filed December 29, 2011, which teaches the incorporation of cytotoxic nucleosides; and 61 / 631,729, filed January 10, 2012, which teaches methods of using mmRNA for crossing the blood-brain barrier; all of which are incorporated herein by reference in their entirety.

[0081] Provided herein, in part, are polynucleotides, primary constructs, and / or mmRNA encoding polypeptides of interest that have been designed to improve one or more of: stability and / or clearance in tissues, receptor uptake and / or kinetics, cellular pathway of the composition, engagement with the translation machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency (where applicable), circulation accessibility, protein half-life, and / or modulation of cellular state, function, and / or activity.

[0082] I. Compositions of the Invention (mmRNA)

[0083] The present invention provides nucleic acid molecules encoding one or more target polypeptides, specifically polynucleotides, primary constructs and / or mmRNA. The term "nucleic acid" in its broad sense includes any compound and / or substance comprising a nucleotide polymer. These polymers are often referred to as polynucleotides. Exemplary nucleic acids or polynucleotides of the present invention include, but are not limited to, ribonucleic acid (RNA), deoxyribonucleic acid (DNA), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA, including LNA with a β-D-ribose configuration, α-LNA with an α-L-ribose configuration (diastereomer of LNA), 2'-amino-LNA with 2'-amino functionalization, and 2'-amino-α-LNA with 2'-amino functionalization) or their hybrids.

[0084] In a preferred embodiment, the nucleic acid molecule is a messenger RNA (mRNA). As used herein, the term "messenger RNA" (mRNA) refers to any polynucleotide that encodes a polypeptide of interest and can be translated to produce the encoded polypeptide of interest in vitro, in vivo, in situ, or ex vivo.

[0085] Traditionally, the basic components of an mRNA molecule include at least a coding region, a 5' UTR, a 3' UTR, a 5' cap, and a poly-A tail. Building on this wild-type modular structure, the present invention expands the functional scope of traditional mRNA molecules by providing polynucleotides or primary RNA constructs that maintain this modular organization but contain one or more structural and / or chemical modifications or alterations that impart useful properties to the polynucleotide, including, in some embodiments, a substantial lack of induction of an innate immune response in cells into which the polynucleotide has been introduced. Thus, the modified mRNA molecules of the present invention are referred to as "mmRNA." As used herein, a "structural" feature or modification is one in which two or more linked nucleotides are inserted, deleted, duplicated, inverted, or randomized within a polynucleotide, primary construct, or mmRNA without significant chemical modification of the nucleotides themselves. Because chemical bonds must be broken and reformed to achieve structural modifications, structural modifications are chemical in nature and are therefore chemical modifications. However, structural modifications will result in different nucleotide sequences. For example, the polynucleotide "ATCG" can be chemically modified to "AT-5meC-G." The same polynucleotide can be modified from an "ATCG" structure to an "ATCCCG" structure. Here, the dinucleotide "CC" has been inserted, resulting in a structural modification of the polynucleotide.

[0086] mmRNA constructs

[0087] The mmRNA of the present invention differ from wild-type mRNA in their functional and / or structural design features, which, as demonstrated herein, serve to overcome current problems with efficient polypeptide production using nucleic acid-based therapeutics.

[0088] Figure 1 A representative polynucleotide primary construct 100 of the present invention is shown. As used herein, the term "primary construct" or "primary mRNA construct" refers to a polynucleotide transcript that encodes one or more polypeptides of interest and retains sufficient structural and / or chemical characteristics to allow translation of the polypeptide of interest encoded therein. The primary construct can be a polynucleotide of the present invention. When structurally or chemically modified, the primary construct can be referred to as mmRNA.

[0089] See also Figure 1 , the primary construct 100 herein comprises a first region 102 of linked nucleotides, flanked by a first flanking region 104 and a second flanking region 106. As used herein, the "first region" may be referred to as a "coding region," a "region encoding...", or simply a "first region." This first region may include, but is not limited to, an encoded polypeptide of interest. The polypeptide of interest may comprise one or more signal sequences encoded by a signal sequence region 103 at its 5' end. The flanking region 104 may comprise a region of linked nucleotides comprising one or more complete or incomplete 5' UTR sequences. The flanking region 104 may also comprise a 5' end cap 108. The second flanking region 106 may comprise a region of linked nucleotides comprising one or more complete or incomplete 3' UTR sequences. The flanking region 106 may also comprise a 3' tailing sequence 110.

[0090] The first operational region 105 bridges the 5' end of the first region 102 to the first flanking region 104. Traditionally, this operational region comprises a start codon. Alternatively, the operational region may comprise any translation initiation sequence or signal including a start codon.

[0091] The second operational region 107 bridges the 3' end of the first region 102 to the second flanking region 106. Traditionally, this operational region includes a stop codon. Alternatively, the operational region may include any translation initiation sequence or signal containing a stop codon. In accordance with the present invention, multiple consecutive stop codons may also be used.

[0092] In general, the shortest length in the first district of a primary construct of the present invention can be the length of a nucleic acid sequence that is sufficient to encode a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide or decapeptide. In another embodiment, the length can be sufficient to encode 2 to 30 amino acids, for example 5 to 30, 10 to 30, 2 to 25, 5 to 25, 10 to 25 or 10 to 20 amino acid peptides. The length can be sufficient to encode at least 11, 12, 13, 14, 15, 17, 20, 25 or 30 amino acid peptides, or no more than 40 amino acids, for example no more than 35, 30, 25, 20, 17, 15, 14, 13, 12, 11 or 10 amino acid peptides. Examples of dipeptides that can be encoded by a polynucleotide sequence include, but are not limited to, carnosine and anserine.

[0093] Typically, the length of the first region encoding the polypeptide of interest of the present invention is greater than about 30 nucleotides (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 00, 500, 600, 700, 800, 900, 000 or up to and including 100,000 nucleotides). As used herein, the "first region" may be referred to as the "coding region" or "region encoding..." or simply the "first region."

[0094] In some embodiments, the polynucleotide, primary construct, or mmRNA includes about 30 to about 100,000 nucleotides (e.g., 30 to 50, 30 to 100, 30 to 250, 30 to 500, 30 to 1,000, 30 to 1,500, 30 to 3,000, 30 to 5,000, 30 to 7,000, 30 to 10,000, 30 to 25,000, 30 to 50,000, 30 to 70,000, 100 to 250, 100 to 500, 100 to 1,0 00, 100 to 1,500, 100 to 3,000, 100 to 5,000, 100 to 7,000, 100 to 10,000, 100 to 25,000, 100 to 50,000, 100 to 70,000, 100 to 100,000, 500 to 1,000, 500 to 1,500, 500 to 2,000, 500 to 3,000, 500 to 5,000, 500 to 7,000, 500 to 10,000, 500 to 25,000, 500 0 to 50,000, 500 to 70,000, 500 to 100,000, 1,000 to 1,500, 1,000 to 2,000, 1,000 to 3,000, 1,000 to 5,000, 1,000 to 7,000, 1,000 to 10,000, 1,000 to 25,000, 1,000 to 50,000, 1,000 to 70,000, 1,000 to 100,000, 1,500 to 3,000, 1,500 to 5,000, 00, 1,500 to 7,000, 1,500 to 10,000, 1,500 to 25,000, 1,500 to 50,000, 1,500 to 70,000, 1,500 to 100,000, 2,000 to 3,000, 2,000 to 5,000, 2,000 to 7,000, 2,000 to 10,000, 2,000 to 25,000, 2,000 to 50,000, 2,000 to 70,000, and 2,000 to 100,000).

[0095] According to the present invention, the length of the first and second flanking regions can independently range from 15 to 1,000 nucleotides (e.g., greater than 30, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, and 900 nucleotides, or at least 30, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, and 1,000 nucleotides).

[0096] According to the present invention, the length of the tailing sequence can range from absent to 500 nucleotides (e.g., at least 60, 70, 80, 90, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, or 500 nucleotides). In the case where the tailing region is a polyA tail, the length can be determined in units of polyA binding protein binding or as a function of polyA binding protein binding. In this embodiment, the polyA tail is long enough to bind at least 4 monomers of the polyA binding protein. The polyA binding protein monomers bind to segments of approximately 38 nucleotides. Thus, polyA tails of approximately 80 nucleotides and 160 nucleotides have been observed to be functional.

[0097] According to the present invention, the capping region may comprise a single cap or a series of nucleotides that form a cap. In this embodiment, the length of the capping region may be 1 to 10, such as 2 to 9, 3 to 8, 4 to 7, 1 to 5, 5 to 10, or at least 2 or 10 or fewer nucleotides. In some embodiments, the cap is absent.

[0098] According to the present invention, the first and second operational regions may be in the range of 3 to 40, e.g., 5 to 30, 10 to 20, 15, or at least 4 or 30 or fewer nucleotides in length and may additionally comprise start and / or stop codons, one or more signal sequences and / or restriction sequences.

[0099] circular mmRNA

[0100] According to the present invention, primary constructs or mmRNA can be circularized or concatemerized to generate translationally competent molecules that facilitate the interaction between poly-A binding protein and 5′-binding protein. The mechanism of circularization or concatemerization can occur through at least three different pathways: 1) chemical, 2) enzymatic, and 3) ribozyme catalysis. The newly formed 5′- / 3′-linkage can be intramolecular or intermolecular.

[0101] In the first approach, the 5′ and 3′ ends of the nucleic acid contain chemically reactive groups that, when brought into close proximity, form a new covalent linkage between the 5′ and 3′ ends of the molecule. The 5′ end may contain an NHS-ester reactive group and the 3′ end may contain a 3′-amino-terminated nucleotide, such that the 3′-amino-terminated nucleotide on the 3′ end of an mRNA molecule synthesized in an organic solvent will undergo nucleophilic attack on the 5′-NHS-ester moiety, thereby forming a new 5′- / 3′-amide bond.

[0102] In the second approach, T4 RNA ligase can be used to enzymatically ligate 5'-phosphorylated nucleic acid molecules to the 3'-hydroxyl end of the nucleic acid, thereby forming a new phosphodiester linkage. In an exemplary reaction, 1 μg of nucleic acid molecules was incubated with 1 to 10 units of T4 RNA ligase (New England Biolabs, Ipswich, MA) at 37°C for 1 hour according to the manufacturer's protocol. The ligation reaction can occur in the presence of a separate oligonucleotide capable of base pairing with both the juxtaposed 5'- and 3'-regions to aid in the enzymatic ligation reaction.

[0103] In the third approach, the 5'- or 3'-end of the cDNA template encodes a ligase ribozyme sequence so that during in vitro transcription, the resulting nucleic acid molecule may contain an active ribozyme sequence capable of ligating the 5' end of the nucleic acid molecule to the 3' end of the nucleic acid molecule. The ligase ribozyme may be derived from a group I intron, a group I intron, hepatitis D virus, a hairpin ribozyme, or may be selected by SELEX (systematic evolution of ligands by exponential enrichment). The ribozyme ligase reaction may be carried out at a temperature between 0°C and 37°C for 1 to 24 hours.

[0104] mmRNA polysomes

[0105] According to the present invention, a variety of different polynucleotides, primary constructs or mmRNA can be connected together by 3'ends using nucleotides modified at the 3'ends. Chemical conjugation can be used to control the stoichiometry of delivery to cells. For example, glyoxylate cycle enzymes, i.e., isocitrate lyase and malate synthase, can be supplied to HepG2 cells in a 1:1 ratio to change cellular fatty acid metabolism. This ratio can be controlled by chemically connecting polynucleotides, primary constructs or mmRNA using 3'-azido-terminated nucleotides on a polynucleotide, primary construct or mmRNA species and nucleotides containing C5-ethynyl or alkynyl on the relative polynucleotide, primary construct or mmRNA species. Modified nucleotides are added after transcription using terminal transferase (New England Biolabs, Ipswich, MA) according to the manufacturer's protocol. After adding 3'-modified nucleotides, two polynucleotides, primary constructs or mmRNA species can be combined in an aqueous solution in the presence or absence of copper to form a new covalent linkage via a click chemistry mechanism as described in the literature.

[0106] In another example, more than two polynucleotides can be linked together using a functionalized linker molecule. For example, a functionalized sugar molecule can be chemically modified to contain multiple chemically reactive groups (SH-, NH2-, N3, etc.) to react with the homologous moiety on the 3'-functionalized mRNA molecule (i.e., 3'-maleimide ester, 3'-NHS-ester, alkyne). The number of reactive groups on the modified sugar can be controlled in a stoichiometric manner to directly control the stoichiometric ratio of the conjugated polynucleotides, primary constructs, or mmRNA.

[0107] mmRNA conjugates and combinations

[0108] To further enhance protein production, the primary constructs or mmRNA of the present invention can be designed to be conjugated to: other polynucleotides, dyes, intercalating agents, agents) (e.g., acridine), cross-linking agents (e.g., psoralen, mitomycin C), porphyrins (TPPC4, texaphyrin, sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g., EDTA), alkylating agents, phosphates, amino groups, sulfhydryl groups, PEG (e.g., PEG-40K), MPEG, [MPEG]2, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g., biotin), transport / absorption enhancers (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases, proteins (e.g., glycoproteins) or peptides (e.g., molecules with specific affinity for a co-ligand) or antibodies (e.g., antibodies that bind to a specified cell type, such as cancer cells, endothelial cells, or bone cells), hormones and hormone receptors, non-peptide species such as lipids, lectins, carbohydrates, vitamins, cofactors, or drugs.

[0109] Conjugation may result in increased stability and / or half-life and may be particularly useful for targeting polynucleotides, primary constructs, or mmRNA to specific sites in cells, tissues, or organs.

[0110] According to the present invention, the mmRNA or primary constructs can be administered with or further encode one or more of the following: RNAi agents, siRNA, shRNA, miRNA, miRNA binding sites, antisense RNA, ribozymes, catalytic DNA, tRNA, RNA that induces triple helix formation, aptamers, or vectors, among others.

[0111] Dual-function mmRNA

[0112] In one embodiment of the present invention, it is a bifunctional polynucleotide (e.g., a bifunctional primary construct or a bifunctional mmRNA). As the name implies, bifunctional polynucleotides are those polynucleotides that have or are capable of having at least two functions. These molecules may also be referred to as multifunctional according to convention.

[0113] The multiple functionalities of a bifunctional polynucleotide may be encoded by the RNA (the function may not be apparent until the encoded product is translated) or may be a property of the polynucleotide itself. It may be structural or chemical. Bifunctional modified polynucleotides may contain a function covalently or electrostatically associated with the polynucleotide. Furthermore, both functions may be provided in the context of a complex of mmRNA with another molecule.

[0114] Bifunctional polynucleotides can encode antiproliferative peptides. These peptides can be linear, cyclic, constrained, or random coiled. They can act as aptamers, signaling molecules, ligands, or mimetics or mimetics thereof. Antiproliferative peptides can be 3 to 50 amino acids in length when translated. They can be 5 to 40, 10 to 30, or approximately 15 amino acids long. They can be single-stranded, multi-stranded, or branched and, once translated, can form complexes, aggregates, or any multiunit structures.

[0115] Non-coding polynucleotides and primary constructs

[0116] As described herein, there are provided sequences that are partially translatable or substantially untranslatable, for example, polynucleotides and primary constructs having non-coding regions. This non-coding region can be the "first region" of a primary construct. Alternatively, the non-coding region can be a region different from the first region. Such molecules are generally not translated, but can produce proteins by binding to and chelating one or more translation machinery components (such as ribosomal proteins or transfer RNA (tRNA)), thereby effectively reducing protein expression in cells or regulating one or more pathways or cascades in cells, which in turn change protein levels. The polynucleotides or primary constructs may contain or encode one or more long non-coding RNAs (lncRNA or lincRNA) or portions thereof, small nucleolar RNAs (sno-RNAs), microRNAs (miRNAs), small interfering RNAs (siRNAs), or Piwi-interacting RNAs (piRNAs).

[0117] Target peptide

[0118] According to the present invention, primary constructs are designed to encode one or more target polypeptides or fragments thereof. Target polypeptides may include, but are not limited to, full polypeptides, multiple polypeptides, or fragments of polypeptides, which may be independently encoded by one or more nucleic acids, multiple nucleic acids, fragments of nucleic acids, or any of the above-mentioned variants. As used herein, the term "target polypeptide" refers to any polypeptide selected to be encoded in the primary constructs of the present invention. As used herein, "polypeptide" means a polymer of amino acid residues (natural or unnatural) most often linked together by peptide bonds. As used herein, the term refers to proteins, polypeptides, and peptides of any size, structure, or function. In some cases, the encoded polypeptide is less than about 50 amino acids and the polypeptide is then referred to as a peptide. If the polypeptide is a peptide, it will be at least about 2, 3, 4, or at least 5 amino acid residues long. Therefore, polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologues, orthologues, transverse homologues, the aforementioned fragments, and other equivalents, variants, and analogs. A polypeptide may be a single molecule or a multimolecular complex such as a dimer, trimer, or tetramer. They may also comprise single-chain or multi-chain polypeptides such as antibodies or insulin and may be associated or linked. Most commonly, disulfide bonds are found in multi-chain polypeptides. The term polypeptide may also be applied to amino acid polymers in which one or more amino acid residues is an artificial chemical analog of a corresponding naturally occurring amino acid.

[0119] The term "polypeptide variant" refers to a molecule that differs in its amino acid sequence from a native or reference sequence. Amino acid sequence variants may have substitutions, deletions, and / or insertions at certain positions within the amino acid sequence compared to the native or reference sequence. Typically, variants will have at least about 50% identity (homology) with the native or reference sequence, and preferably they will be at least about 80%, more preferably at least about 90% identical (homologous) to the native or reference sequence.

[0120] In some embodiments, "variant mimetics" are provided. As used herein, the term "variant mimetic" is a variant mimetic comprising one or more amino acids that mimic the activated sequence. For example, glutamate can be used as a mimetic for phospho-threonine and / or phospho-serine. Alternatively, a variant mimetic can cause deactivation or contain an inactivated product of the mimetic, for example, phenylalanine can serve as an inactivating substitution for tyrosine; or alanine can serve as an inactivating substitution for serine.

[0121] "Homology," as it applies to amino acid sequences, is defined as the percentage of residues in a candidate amino acid sequence that are identical with the residues in the amino acid sequence of a second sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Methods and computer programs for alignment are well known in the art. It will be understood that homology is determined by calculation of percent identity, but that different values ​​may be obtained due to gaps and penalties introduced in the calculation.

[0122] "Homolog," as it applies to polypeptide sequences, means a corresponding sequence in another species that has substantial identity to a second sequence in a second species.

[0123] "Analogs" are intended to include polypeptide variants that differ by one or more amino acid changes (eg, substitutions, additions, or deletions of amino acid residues) but still retain one or more properties of the parent or starting polypeptide.

[0124] The present invention contemplates several types of compositions based on polypeptides, including variants and derivatives. These include substitution, insertion, deletion, and covalent variants and derivatives. The term "derivative" is used synonymously with the term "variant," but generally refers to a molecule that has been modified and / or altered in any way relative to a reference or starting molecule.

[0125] Thus, mmRNA encoding polypeptides containing substitutions, insertions and / or additions, deletions and covalent modifications relative to a reference sequence, specifically the polypeptide sequences disclosed herein, are included within the scope of the present invention. For example, a sequence tag or amino acid (such as one or more lysines) may be added to the peptide sequence of the present invention (e.g., at the N-terminus or C-terminus). Sequence tags can be used for peptide purification or positioning. Lysine can be used to increase peptide solubility or allow biotinylation. Alternatively, amino acid residues located at the carboxyl and amino terminal regions of the amino acid sequence of a peptide or protein may be optionally deleted, thereby providing a truncated sequence. Certain amino acids (e.g., C-terminal or N-terminal residues) may alternatively be deleted, depending on the use of the sequence, such as expression of a sequence as part of a larger sequence that is soluble or attached to a solid support.

[0126] A "substitution variant" when referring to a polypeptide is a polypeptide in which at least one amino acid residue in the native or starting sequence has been removed and a different amino acid has been inserted in its place. The substitution may be single, in which only one amino acid in the molecule has been substituted, or multiple, in which two or more amino acids in the same molecule have been substituted.

[0127] As used herein, the term "conservative amino acid substitution" refers to that the amino acid that is typically present in the sequence is replaced by a different amino acid of similar size, charge or polarity. The example of conservative substitution includes that non-polar (hydrophobic) residues such as isoleucine, valine and leucine replace another non-polar residue. Similarly, the example of conservative substitution includes that a polar (hydrophilic) residue replaces another, such as between arginine and lysine, between glutamine and asparagine and between glycine and serine. In addition, it is another example of conservative substitution that basic residues such as lysine, arginine or histidine replace another basic residue or a kind of acidic residue such as aspartic acid or glutamic acid replaces another acidic residue. The example of non-conservative substitution includes that non-polar (hydrophobic) amino acid residues such as isoleucine, valine, leucine, alanine, methionine replace polar (hydrophilic) residues such as cysteine, glutamine, glutamic acid or lysine, and / or polar residue replaces non-polar residue.

[0128] "Insertion variants" when referring to polypeptides are those with one or more amino acids inserted immediately adjacent to the amino acid at a particular position in the native or starting sequence. "Immediately adjacent" an amino acid means the α-carboxyl or α-amino functional group attached to the amino acid.

[0129] "Deletion variants" when referring to polypeptides are those in which one or more amino acids in the native or starting amino acid sequence are removed. Typically, deletion variants will have one or more amino acids deleted in a specific region of the molecule.

[0130] When referring to polypeptides, "covalent derivatives" include modifications of native or starting proteins with organic protein or non-protein derivatizing agents, and / or post-translational modifications. Covalent modifications are traditionally introduced by reacting target amino acid residues of a protein with an organic derivatizing agent capable of reacting with selected side chains or terminal residues, or by utilizing the mechanisms of post-translational modifications that function in selected recombinant host cells. The resulting covalent derivatives are suitable for use in procedures designed to identify residues important for biological activity, for immunoassays, or for the preparation of anti-protein antibodies for immunoaffinity purification of recombinant glycoproteins. Such modifications are within the ordinary skill of the art and are performed without undue experimentation.

[0131] Certain post-translational modifications are the result of the action of the recombinant host cell on the expressed polypeptide. Glutaminyl and asparaginyl residues are often deamidated after translation to form corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mild acidic conditions. Any form of these residues may be present in the polypeptides produced according to the present invention.

[0132] Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of the hydroxyl groups of seryl or threonyl residues, and methylation of the α-amino groups of lysine, arginine, and histidine side chains (TE Creighton, Proteins: Structure and Molecular Properties, WH Freeman & Co., San Francisco, pp. 79-86 (1983)).

[0133] When referring to a polypeptide, "features" are defined as distinct components of a molecule based on its amino acid sequence. Features of the polypeptides encoded by the mmRNA of the present invention include surface appearance, local conformational shape, fold, loop, half-loop, domain, half-domain, site, terminus, or any combination thereof.

[0134] As used herein when referring to polypeptides, the term "surface appearance" refers to the polypeptide-based component of a protein that appears on the outermost surface.

[0135] As used herein, the term "local conformational shape" when referring to a polypeptide refers to the polypeptide-based structural appearance of a protein within its definable space.

[0136] As used herein, when referring to polypeptides, the term "fold" refers to the resulting conformation of an amino acid sequence when its energy is minimized. Folding can occur at either the secondary or tertiary level of the folding process. Examples of secondary-level folds include beta sheets and alpha helices. Examples of tertiary folds include domains and regions formed due to high-energy aggregation or dissociation. Regions formed in this manner include hydrophobic pockets and hydrophilic pockets, among others.

[0137] As used herein, the term "turn" as it relates to protein conformation means a bend that changes the direction of the backbone of a peptide or polypeptide and may involve one, two, three or more amino acid residues.

[0138] As used herein, when referring to polypeptides, the term "loop" refers to a structural feature of a polypeptide that can be used to reverse the direction of the main chain of a peptide or polypeptide. When a loop is present in a polypeptide and only changes the direction of the main chain, it may comprise four or more amino acid residues. Oliva et al. have identified at least five types of protein loops (J. Mol Biol 266(4):814-830; 1997). Loops can be open or closed. Closed loops or "cyclic" loops can contain 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids between the bridging moiety. Such bridging moieties may be comprised of a cysteine-cysteine ​​bridge (Cys-Cys), typical of disulfide bridges in polypeptides, or alternatively, the bridging moiety may be non-protein-based, such as the dibromozylyl reagent used herein.

[0139] As used herein, the term "half-ring" when referring to a polypeptide refers to a portion of an identified ring having at least half the number of amino acid residues of the ring from which it is derived. It should be understood that a ring may not always contain an even number of amino acid residues. Thus, in those cases where a ring contains or is identified as containing an odd number of amino acids, the half-ring of the odd number of rings will contain the integer portion of the ring or the next integer portion (the number of amino acids of the ring / 2+ / -0.5 amino acids). For example, a ring identified as a 7 amino acid ring can produce a half-ring of 3 amino acids or 4 amino acids (7 / 2=3.5+ / -0.5 is 3 or 4).

[0140] As used herein, the term "domain" when referring to a polypeptide refers to a motif of a polypeptide having one or more identifiable structural or functional characteristics or properties (e.g., binding ability, serving as a site for protein-protein interactions).

[0141] As used herein, the term "half-domain" when referring to a polypeptide means a portion of an identified domain having at least half the number of amino acid residues of the domain from which it is derived. It will be understood that a domain may not always contain an even number of amino acid residues. Thus, in those cases where a domain contains or is identified as containing an odd number of amino acids, a half-domain of the odd-numbered domain will contain an integer portion or the next integer portion of the domain (the number of amino acids in the domain / 2 + / - 0.5 amino acids). For example, a domain identified as a 7 amino acid domain may yield a half-domain of 3 amino acids or 4 amino acids (7 / 2 = 3.5 + / - 0.5 is 3 or 4). It will also be understood that subdomains may be identified within a domain or half-domain that possess fewer than all of the structural or functional properties identified in the domain or half-domain from which they are derived. It is also understood that the amino acids comprising any domain type herein need not be contiguous along the backbone of a polypeptide (ie, non-adjacent amino acids may structurally fold to produce a domain, half-domain, or subdomain).

[0142] As used herein, the term "site" when referring to polypeptides is used synonymously with "amino acid residue" and "amino acid side chain" as it relates to amino acid-based embodiments. A site refers to a position within a peptide or polypeptide that can be modified, manipulated, altered, derivatized, or varied within the polypeptide-based molecules of the invention.

[0143] As used herein, the term "termini" or "terminus" when referring to a polypeptide refers to the end of a peptide or polypeptide. Such an end is not limited to the first or last position of a peptide or polypeptide, but may include additional amino acids in the terminal region. The polypeptide-based molecules of the present invention can be characterized as having both an N-terminus (terminated by an amino acid with a free amino group (NH2)) and a C-terminus (terminated by an amino acid with a free carboxyl group (COOH)). The proteins of the present invention are in some cases composed of multiple polypeptide chains held together by disulfide bonds or by non-covalent forces (polymers, oligomers). These types of proteins will have multiple N-termini and C-termini. Alternatively, the termini of the polypeptides can be modified so that they begin or end with a non-polypeptide-based portion (such as an organic conjugate), as the case may be.

[0144] Once any feature has been identified or defined as a desired component of a polypeptide to be encoded by a primary construct or mmRNA of the invention, any of a number of manipulations and / or modifications of these features can be performed by moving, exchanging, inverting, deleting, randomizing, or duplicating them. Furthermore, it should be understood that manipulation of features can produce the same results as modifications to the molecules of the invention. For example, manipulations involving deletion of a domain will result in changes in molecule length, just as modifying a nucleic acid to encode a less than full-length molecule would.

[0145] Modification and manipulation can be achieved by methods known in the art, such as, but not limited to, site-directed mutagenesis. The resulting modified molecules can then be tested for activity using in vitro or in vivo assays (such as those described herein) or any other suitable screening assays known in the art.

[0146] According to the present invention, a polypeptide may comprise a consensus sequence discovered through multiple rounds of experimentation.As used herein, a "consensus" sequence is a single sequence representing a collective population of sequences that allows for variability at one or more sites.

[0147] As recognized by those skilled in the art, protein fragments, functional protein domains and homologous proteins are also considered to be within the scope of the target polypeptide of the present invention. For example, provided herein is any protein fragment of a reference protein having a length of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more than 100 amino acids (meaning a polypeptide sequence that is at least one amino acid residue shorter than a reference polypeptide sequence but is otherwise identical). In another example, any protein having a segment of about 20, about 30, about 40, about 50 or about 100 amino acids that is about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95% or about 100% identical to any sequence described herein can be used according to the present invention. In certain embodiments, the polypeptide to be used according to the present invention comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more mutations, as shown in any sequence provided or mentioned herein.

[0148] Encoded polypeptide

[0149] The primary constructs or mmRNA of the present invention can be designed to encode a polypeptide of interest selected from any one of several target categories, including but not limited to biologics, antibodies, vaccines, therapeutic proteins or peptides, cell penetrating peptides, secreted proteins, plasma membrane proteins, cytoplasmic or cytoskeletal proteins, intracellular membrane-bound proteins, nuclear proteins, proteins associated with human disease, targeting moieties, or those proteins encoded by the human genome for which no therapeutic indication has been identified but which nonetheless have utility in the areas of research and discovery.

[0150] In one embodiment, the primary construct or mmRNA may encode a variant polypeptide having a certain identity to a reference polypeptide sequence. As used herein, "reference polypeptide sequence" refers to a starting polypeptide sequence. The reference sequence can be a wild-type sequence or any sequence that is referenced in designing another sequence. A “reference polypeptide sequence” can be, for example, any protein sequence listed in Table 6 of co-pending U.S. Provisional Patent Application No. 61 / 618,862, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Biologics, U.S. Provisional Patent Application No. 61 / 681,645, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Biologics, U.S. Provisional Patent Application No. 61 / 737,130, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Biologics, U.S. Provisional Patent Application No. 61 / 618,866, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Antibodies, U.S. Provisional Patent Application No. 61 / 681,645, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Biologics, U.S. Provisional Patent Application No. 61 / 681,647, entitled "Modified Polynucleotides for the Production of Antibodies," filed December 14, 2012, U.S. Provisional Patent Application No. 61 / 737,134, entitled "Modified Polynucleotides for the Production of Antibodies," filed April 2, 2012, U.S. Provisional Patent Application No. 61 / 618,868, entitled "Modified Polynucleotides for the Production of Vaccines," filed August 10, 2012, U.S. Provisional Patent Application No. 61 / 681,648, entitled "Modified Polynucleotides for the Production of Vaccines," filed December 14, 2012,135. U.S. Provisional Patent Application No. 61 / 618,873, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Secreted Proteins; U.S. Provisional Patent Application No. 61 / 681,650, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Secreted Proteins; U.S. Provisional Patent Application No. 61 / 737,147, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Secreted Proteins; U.S. Provisional Patent Application No. 61 / 618,878, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins; U.S. Provisional Patent Application No. 61 / 618,879, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins U.S. Provisional Patent Application No. 61 / 681,654, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, filed December 14, 2012; U.S. Provisional Patent Application No. 61 / 737,152, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, filed April 2, 2012; U.S. Provisional Patent Application No. 61 / 618,885, entitled Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins, filed August 10, 2012; U.S. Provisional Patent Application No. 61 / 681,658, entitled Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins, filed December 14, 2012; U.S. Provisional Patent Application No. 61 / 737,152, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, filed April 2, 2012;155. U.S. Provisional Patent Application No. 61 / 618,896, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins; U.S. Provisional Patent Application No. 61 / 668,157, filed July 5, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins; U.S. Provisional Patent Application No. 61 / 681,661, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins; U.S. Provisional Patent Application No. 61 / 737,160, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins; U.S. Provisional Patent Application No. 61 / 737,160, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Nuclear U.S. Provisional Patent Application No. 61 / 618,911, entitled "Modified Polynucleotides for the Production of Nuclear Proteins," filed on August 10, 2012; U.S. Provisional Patent Application No. 61 / 681,667, entitled "Modified Polynucleotides for the Production of Nuclear Proteins," filed on December 14, 2012; U.S. Provisional Patent Application No. 61 / 737,168, entitled "Modified Polynucleotides for the Production of Nuclear Proteins," filed on April 2, 2012; U.S. Provisional Patent Application No. 61 / 618,922, entitled "Modified Polynucleotides for the Production of Proteins," filed on August 10, 2012; and U.S. Provisional Patent Application No. 61 / 681, entitled "Modified Polynucleotides for the Production of Proteins."675, U.S. Provisional Patent Application No. 61 / 737,174, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Proteins, U.S. Provisional Patent Application No. 61 / 618,935, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 681,687, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 737,184, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 618,935, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease Disease, U.S. Provisional Patent Application No. 61 / 618,945, filed on August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 681,696, filed on August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 737,191, filed on December 14, 2012, and U.S. Provisional Patent Application No. 61 / 618, filed on April 2, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease.953. U.S. Provisional Patent Application No. 61 / 681,704, filed on August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease; U.S. Provisional Patent Application No. 61 / 737, filed on December 14, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease;203. International application number PCT / US2013 / 030062, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Biologics and Proteins Associated with Human Disease; International application number PCT / US2013 / 030064, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Secreted Proteins; International application number PCT / US2013 / 030059, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Membrane Proteins; International application number PCT / US2013 / 030066, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins; International application number PCT / US2013 / 030067, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Nuclear and PCT / US2013 / 030061, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease; and Tables 6 and 7 of the following co-pending applications: U.S. Provisional Patent Application No. 61 / 681, filed on August 10, 2012, entitled Modified Polynucleotides for the Production of Cosmetic Proteins and Peptides;720, U.S. Provisional Patent Application No. 61 / 737,213, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Cosmetic Proteins and Peptides, U.S. Provisional Patent Application No. 61 / 681,742, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides, and International Application No. PCT / US2013 / 030070, filed March 9, 2013, entitled Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides; Tables 6, 178, and 179 of the following co-pending applications: and Peptides; in Tables 6, 28, and 29 of co-pending U.S. Provisional Patent Application No. 61 / 618,870, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides; in Tables 6, 56, and 57 of co-pending U.S. Provisional Patent Application No. 61 / 681,649, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides; and in Tables 6, 186, and 187 of co-pending U.S. Provisional Patent Application No. 61 / 737, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides.139; and in Tables 6, 185, and 186 of the co-pending International Application No. PCT / US2013 / 030063, filed March 9, 2013, entitled Modified Polynucleotides; the contents of each of which are incorporated herein by reference in their entirety.

[0151] The term "identity" as known in the art refers to the relationship between the sequences of two or more peptides as determined by comparing sequences. In the art, identity also means the degree of sequence relatedness between peptides as determined by the number of matches between strings with two or more amino acid residues. The identity measure is the percentage of the smaller of the identical matches between two or more sequences with a gapped alignment (if any) solved by a specific mathematical model or computer program (i.e., an "algorithm"). The identity of related peptides can be easily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, AM and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; and Carillo et al., SIAM J. Applied Math. 48, 1073 (1988).

[0152] In some embodiments, a polypeptide variant may have the same or similar activity as a reference polypeptide. Alternatively, a variant may have an altered activity (e.g., increased or decreased) relative to a reference polypeptide. Typically, a variant of a particular polynucleotide or polypeptide of the invention will have at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% but less than 100% sequence identity to the particular reference polynucleotide or polypeptide as determined by sequence alignment programs and parameters described herein and known to those skilled in the art. Such tools for alignment include those of the BLAST suite (Stephen F. Altschul, Thomas L. Madden, Alejandro A. Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.). Other tools are described herein, particularly in the definition of "identity".

[0153] The default parameters in the BLAST algorithm include, for example, an expect threshold of 10, a word length of 28, match / mismatch scores of 1, -2, and linear gap loss. Any filter can be applied, as well as species-specific repeat sequences, such as Homo sapiens, can be selected.

[0154] Biologics

[0155] The polynucleotides, primary constructs, or mmRNA disclosed herein may encode one or more biologics. As used herein, a "biologic" is a molecule of a gene polypeptide produced by the methods provided herein and useful for treating, curing, allergic reactions, preventing, or diagnosing a serious or life-threatening disease or medical condition. According to the present invention, biologics include, but are not limited to, allergen extracts (e.g., for allergy shots and testing), blood components, gene therapy products, human tissue or cell products used in transplantation, vaccines, monoclonal antibodies, cytokines, growth factors, enzymes, thrombolytics, and immunomodulators.

[0156] According to the present invention, one or more biologics currently commercially available or in development can be encoded by the polynucleotides, primary constructs, or mmRNA of the present invention. While not wishing to be bound by theory, it is believed that incorporating the encoded polypeptides of known biologics into the primary constructs or mmRNA of the present invention will result in improved therapeutic efficacy, at least in part due to the specificity, purity, and / or selectivity of the construct design.

[0157] Antibody

[0158] The primary constructs or mmRNA disclosed herein may encode one or more antibodies or fragments thereof. The term "antibody" includes monoclonal antibodies (including full-length antibodies with immunoglobulin Fc regions), antibody compositions with multiple epitope specificities, multispecific antibodies (e.g., bispecific antibodies, double antibodies, and single-chain molecules), and antibody fragments. The term "immunoglobulin" (Ig) is used interchangeably with "antibody" herein. As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies constituting the population are identical, except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in trace amounts. Monoclonal antibodies are highly specific, directed against a single antigenic site.

[0159] The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chain is identical or homologous to a corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired biological activity. The chimeric antibodies of interest herein include, but are not limited to, "primatized" antibodies comprising variable domain antigen-binding sequences derived from non-human primates (e.g., Old World monkeys, apes, etc.) and human constant region sequences.

[0160] "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen-binding and / or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; nanobodies; single-chain antibody molecules formed from antibody fragments; and multispecific antibodies.

[0161] Any of the five immunoglobulin classes, IgA, IgD, IgE, IgG, and IgM, can be encoded by the mmRNA of the present invention, including heavy chains designated α, δ, ε, λ, and μ, respectively. Also included are polynucleotide sequences encoding subclasses γ and μ. Thus, any of the antibody subclasses can be encoded, in part or in whole, and include the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0162] According to the present invention, one or more antibodies or fragments currently commercially available or in development can be encoded by the polynucleotides, primary constructs, or mmRNA of the present invention. While not wishing to be bound by theory, it is believed that incorporation into the primary constructs of the present invention will result in improved therapeutic efficacy, at least in part due to the specificity, purity, and selectivity of the mmRNA design.

[0163] The antibodies encoded in the polynucleotides, primary constructs or mmRNA of the invention can be used to treat conditions or diseases in a number of therapeutic areas, such as, but not limited to, hematology, cardiovascular, CNS, poisoning (including antivenom), dermatology, endocrinology, gastrointestinal, medical imaging, musculoskeletal, oncology, immunology, respiratory system, sensory system, and anti-infective therapeutic areas.

[0164] In one embodiment, the primary constructs or mmRNA disclosed herein may encode monoclonal antibodies and / or variants thereof. Variants of antibodies may also include, but are not limited to, substitution variants, conservative amino acid substitutions, insertion variants, deletion variants, and / or covalent variants. In one embodiment, the primary constructs and / or mmRNA disclosed herein may encode immunoglobulin Fc regions. In another embodiment, the primary constructs and / or mmRNA may encode variant immunoglobulin Fc regions. As a non-limiting example, the primary constructs and / or mmRNA may encode antibodies having variant immunoglobulin Fc regions, as described in U.S. Patent No. 8,217,147, which is incorporated herein by reference in its entirety.

[0165] vaccine

[0166] The primary constructs or mmRNA disclosed herein may encode one or more vaccines. As used herein, a "vaccine" is a biological agent that improves immunity to a specific disease or infectious agent. According to the present invention, one or more vaccines currently commercially available or in development may be encoded by the polynucleotides, primary constructs, or mmRNA of the present invention. While not wishing to be bound by theory, it is believed that incorporation into the primary constructs or mmRNA of the present invention will result in improved therapeutic efficacy, at least in part due to the specificity, purity, and selectivity of the construct design.

[0167] The vaccines encoded in the polynucleotides, primary constructs or mmRNA of the present invention can be used to treat conditions or diseases in a number of therapeutic areas, such as, but not limited to, cardiovascular, CNS, dermatology, endocrinology, oncology, immunology, respiratory, and anti-infective therapeutic areas.

[0168] Therapeutic proteins or peptides

[0169] The primary constructs or mmRNA disclosed herein may encode one or more validated or "in-progress" therapeutic proteins or peptides.

[0170] According to the present invention, one or more therapeutic proteins or peptides currently commercially available or in development can be encoded by the polynucleotides, primary constructs, or mmRNA of the present invention. While not wishing to be bound by theory, it is believed that incorporation into the primary constructs or mmRNA of the present invention will result in improved therapeutic efficacy, at least in part due to the specificity, purity, and selectivity of the construct design.

[0171] The therapeutic proteins and peptides encoded in the polynucleotides, primary constructs or mmRNA of the invention can be used to treat conditions or diseases in a number of therapeutic areas, such as, but not limited to, hematology, cardiovascular, CNS, poisoning (including antivenom), dermatology, endocrinology, genetics, genitourinary, gastrointestinal, musculoskeletal, oncology, and immunology, respiratory, sensory, and anti-infective.

[0172] Cell-penetrating peptides

[0173] The primary constructs or mmRNA disclosed herein may encode one or more cell-penetrating polypeptides. As used herein, a "cell-penetrating polypeptide" or CPP refers to a polypeptide that can facilitate cellular uptake of a molecule. The cell-penetrating polypeptides of the present invention may comprise one or more detectable labels. The polypeptides may be partially labeled or completely labeled. The polynucleotides, primary constructs, or mmRNA may encode a detectable label in whole, in part, or not at all. The cell-penetrating peptide may also include a signal sequence. As used herein, a "signal sequence" refers to a sequence of amino acid residues that bind to the amino terminus of a nascent protein during protein translation. A signal sequence can be used to signal the secretion of the cell-penetrating peptide.

[0174] In one embodiment, the polynucleotide, primary construct or mmRNA may also encode a fusion protein. A fusion protein can be formed by operably linking a charged protein to a therapeutic protein. As used herein, "operably linked" means that when introduced into a cell, the therapeutic protein and the charged protein are connected in such a way that the complex is allowed to be expressed. As used herein, "charged protein" refers to a protein that carries a positive, negative or overall neutral charge. Preferably, the therapeutic protein can be covalently linked to a charged protein in the formation of the fusion protein. The ratio of surface charge to total or surface amino acids can be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9.

[0175] The cell-penetrating polypeptide encoded by the polynucleotide, primary construct, or mmRNA can form a complex after being translated. The complex can include a charged protein linked (e.g., covalently linked) to the cell-penetrating polypeptide. A "therapeutic protein" refers to a protein that, when administered to a cell, has a therapeutic, diagnostic, and / or prophylactic effect and / or elicits a desired biological and / or pharmacological effect.

[0176] In one embodiment, the cell-penetrating polypeptide may comprise a first domain and a second domain. The first domain may comprise a supercharged polypeptide. The second domain may comprise a protein-binding partner. As used herein, "protein-binding partner" includes, but is not limited to, antibodies and functional fragments thereof, scaffold proteins, or peptides. The cell-penetrating polypeptide may further comprise an intracellular binding partner for the protein-binding partner. The cell-penetrating polypeptide may be capable of secretion from a cell into which the polynucleotide, primary construct, or mmRNA may be introduced. The cell-penetrating polypeptide may also be capable of penetrating the first cell.

[0177] In another embodiment, the cell-penetrating polypeptide is capable of penetrating a second cell. The second cell may be from the same region as the first cell, or it may be from a different region. The region may include, but is not limited to, tissues and organs. The second cell may also be located proximal or distal to the first cell.

[0178] In one embodiment, the polynucleotide, primary construct, or mmRNA may encode a cell-penetrating polypeptide that may comprise a protein-binding partner. Protein-binding partners may include, but are not limited to, antibodies, supercharged antibodies, or functional fragments. The polynucleotide, primary construct, or mmRNA may be introduced into a cell into which a cell-penetrating polypeptide comprising a protein-binding partner has been introduced.

[0179] secreted proteins

[0180] Human and other eukaryotic cells are subdivided by membranes into many functionally distinct compartments. Each membrane-bound compartment, or organelle, contains different proteins essential for the organelle's function. Cells use "sorting signals," which are amino acid motifs located within proteins, to target proteins to specific organelles.

[0181] One type of sorting signal, called a signal sequence, signal peptide, or leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER).

[0182] Proteins targeted to the ER via signal sequences can be released into the extracellular space as secretory proteins. Similarly, proteins that reside on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of the "linkers" that hold the protein to the membrane. Although not wishing to be bound by theory, the molecules of the present invention can be used to employ the cellular transport described above. Thus, in some embodiments of the present invention, polynucleotides, primary constructs, or mmRNA are provided to express secretory proteins. Secretory proteins can be secreted from those described herein or those in U.S. Patent Publication No. 20100255574, the contents of which are incorporated herein by reference in their entirety.

[0183] In one embodiment, these can be used to produce large quantities of valuable human gene products.

[0184] plasma membrane proteins

[0185] In some embodiments of the invention, polynucleotides, primary constructs or mmRNA are provided to express plasma membrane proteins.

[0186] Cytoplasmic or cytoskeletal proteins

[0187] In some embodiments of the invention, polynucleotides, primary constructs or mmRNA are provided to express cytoplasmic or cytoskeletal proteins.

[0188] intracellular membrane-bound proteins

[0189] In some embodiments of the invention, polynucleotides, primary constructs, or mmRNA are provided to express intracellular membrane-bound proteins.

[0190] Nucleoprotein

[0191] In some embodiments of the invention, polynucleotides, primary constructs or mmRNA are provided to express nuclear proteins.

[0192] Proteins associated with human diseases

[0193] In some embodiments of the invention, polynucleotides, primary constructs, or mmRNA are provided to express proteins associated with human diseases.

[0194] Other proteins

[0195] In some embodiments of the invention, polynucleotides, primary constructs, or mmRNA are provided to express proteins with currently unknown therapeutic functions.

[0196] Targeting moiety

[0197] In some embodiments of the present invention, polynucleotides, primary constructs, or mmRNA are provided to express targeting moieties. These include protein binding partners or receptors on the cell surface that are used to target cells to specific tissue spaces or interact with specific moieties in vivo or in vitro. Suitable protein binding partners include, but are not limited to, antibodies and functional fragments thereof, scaffold proteins, or peptides. In addition, polynucleotides, primary constructs, or mmRNA can be used to direct the synthesis and extracellular localization of lipids, carbohydrates, or other biological moieties or biomolecules.

[0198] Peptide library

[0199] In one embodiment, the polynucleotides, primary constructs, or mmRNA can be used to generate polypeptide libraries. These libraries can be generated by generating populations of polynucleotides, primary constructs, or mmRNA, each containing different structural or chemical modification designs. In this embodiment, the population of polynucleotides, primary constructs, or mmRNA can contain a variety of encoded polypeptides, including but not limited to antibodies or antibody fragments, protein binding partners, scaffold proteins, and other polypeptides taught herein or known in the art. In a preferred embodiment, the polynucleotide is a primary construct of the present invention, including mmRNA that can be suitable for direct introduction into target cells or cultures, which in turn can synthesize the encoded polypeptides.

[0200] In certain embodiments, multiple variants of a protein, each with different amino acid modifications, can be generated and tested to determine the variant that is optimal with respect to pharmacokinetics, stability, biocompatibility, and / or biological activity or biophysical properties such as expression level. Such a library can contain 10, 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 or more than 10 9 possible variations (including but not limited to, substitutions of one or more residues, deletions, and insertions of one or more residues).

[0201] Antimicrobial and antiviral peptides

[0202] The polynucleotides, primary constructs, and mmRNA of the present invention can be designed to encode one or more antimicrobial peptides (AMPs) or antiviral peptides (AVPs). AMPs and AVPs have been isolated and described from a wide range of animals, such as, but not limited to, microorganisms, invertebrates, plants, amphibians, birds, fish, and mammals (Wang et al., Nucleic Acids Res. 2009; 37 (Database issue): D933-7).For example, antimicrobial polypeptides are described in the Antimicrobial Peptide Database (http: / / aps.unmc.edu / AP / main.php; Wang et al., Nucleic Acids Res. 2009; 37 (Database issue): D933-7), CAMP: Collection of Anti-Microbial Peptides (http: / / www.bicnirrh.res.in / antimicrobial / ); Thomas et al., Nucleic Acids Res. 2010; 38 (Database issue): D774-80), US 5221732, US 5447914, US 5519115, US 5607914, US 5714577, US 5734015, US 5798336, US 5821224, US 5849490, US 5856127, US 5905187, US5994308, US 5998374, US 6107460, US 6191254, US 6211148, US 6300489, US 6329504, US6399370, US 6476189, US 6478825, US 6492328, US 6514701, US 6573361, US 6573361, US6576755, US 6605698, US 6624140, US 6638531, US 6642203, US 6653280, US 6696238, US6727066, US 6730659、US 6743598、US 6743769, US 6747007, US 6790833, US 6794490, US6818407, US 6835536, US 6835713, US 6838435, US 6872705, US 6875907, US 6884776, US6887847, US 6906035, US 6911524, US 6936432, US 7001924, US 7071293, US 7078380, US7091185, US 7094759, US 7166769, US 7244710, US 7314858 and US 7582301, the contents of which are incorporated herein by reference in their entirety.

[0203] The antimicrobial polypeptides described herein can block cell fusion and / or viral entry by one or more enveloped viruses (e.g., HIV, HCV). For example, the antimicrobial polypeptides can comprise or consist of synthetic peptides corresponding to a region of a transmembrane subunit of a viral envelope protein (e.g., HIV-1 gp120 or gp41), e.g., a continuous sequence of at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 amino acids. The amino acid and nucleotide sequences of HIV-1 gp120 or gp41 are described, for example, in Kuiken et al., (2008) "HIV Sequence Compendium," Los Alamos National Laboratory.

[0204] In some embodiments, the antimicrobial polypeptides may have at least about 75%, 80%, 85%, 90%, 95%, 100% sequence homology to the corresponding viral protein sequence. In some embodiments, the antimicrobial polypeptides may have at least about 75%, 80%, 85%, 90%, 95%, or 100% sequence homology to the corresponding viral protein sequence.

[0205] In other embodiments, the antimicrobial polypeptide may comprise or consist of a synthetic peptide corresponding to a region of the binding domain of the capsid binding protein, for example, a contiguous sequence of at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 amino acids. In some embodiments, the antimicrobial polypeptide may have at least about 75%, 80%, 85%, 90%, 95%, or 100% sequence homology to the corresponding sequence of the capsid binding protein.

[0206] The antimicrobial polypeptides described herein can block protease dimerization and inhibit the cleavage of viral proproteins (e.g., HIV Gag-pol processing) into functional proteins, thereby preventing the release of one or more enveloped viruses (e.g., HIV, HCV). In some embodiments, the antimicrobial polypeptides can have at least about 75%, 80%, 85%, 90%, 95%, or 100% sequence homology to the corresponding viral protein sequence.

[0207] In other embodiments, the antimicrobial polypeptide may comprise or consist of a synthetic peptide corresponding to a region of the binding domain of a protease binding protein, e.g., a contiguous sequence of at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 amino acids. In some embodiments, the antimicrobial polypeptide may have at least about 75%, 80%, 85%, 90%, 95%, or 100% sequence homology to the corresponding sequence of the protease binding protein.

[0208] The antimicrobial polypeptides described herein may include polypeptides evolved in vitro against viral pathogens.

[0209] antimicrobial peptides

[0210] Antimicrobial polypeptides (AMPs) are small peptides of variable length, sequence, and structure that have broad-spectrum activity against a wide range of microorganisms, including, but not limited to, bacteria, viruses, fungi, protozoa, parasites, prions, and tumor / cancer cells. (See, e.g., Zaiou, J Mol Med, 2007; 85:317; incorporated herein by reference in its entirety). AMPs have been shown to have a broad spectrum of rapidly acting killing activity, along with the potential for low-level resistance induction and concomitant broad anti-inflammatory effects.

[0211] In some embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) can be less than 10kDa, for example, less than 8kDa, 6kDa, 4kDa, 2kDa or 1kDa. In some embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) is composed of about 6 to about 100 amino acids, for example, about 6 to about 75 amino acids, about 6 to about 50 amino acids, about 6 to about 25 amino acids, about 25 to about 100 amino acids, about 50 to about 100 amino acids, or about 75 to about 100 amino acids. In certain embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) can be composed of about 15 to about 45 amino acids. In some embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) is generally cationic.

[0212] In some embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) can be substantially amphipathic. In certain embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) can be substantially cationic and amphipathic. In some embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) can be cell growth inhibitory against Gram-positive bacteria. In some embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) can be cytotoxic against Gram-positive bacteria. In some embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) can be cell growth inhibitory and cytotoxic against Gram-positive bacteria. In some embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) can be cell growth inhibitory against Gram-negative bacteria. In some embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) can be cytotoxic against Gram-negative bacteria. In some embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) can be cell growth inhibitory and cytotoxic against Gram-positive bacteria. In some embodiments, the antimicrobial polypeptide (e.g., antibacterial polypeptide) can be cell growth inhibitory and cytotoxic against Gram-positive bacteria. In some embodiments, the antimicrobial polypeptide can be cell growth inhibitory against viruses, fungi, protozoa, parasites, prions, or a combination thereof. In some embodiments, the antimicrobial polypeptides may be cytotoxic against viruses, fungi, protozoa, parasites, prions, or a combination thereof. In certain embodiments, the antimicrobial polypeptides may be cytostatic and cytotoxic against viruses, fungi, protozoa, parasites, prions, or a combination thereof. In some embodiments, the antimicrobial polypeptides may be cytotoxic against tumors or cancer cells (e.g., human tumors and / or cancer cells). In some embodiments, the antimicrobial polypeptides may be cytostatic against tumors or cancer cells (e.g., human tumors and / or cancer cells). In certain embodiments, the antimicrobial polypeptides may be cytotoxic and cytostatic against tumors or cancer cells (e.g., human tumors or cancer cells). In some embodiments, the antimicrobial polypeptides may be secreted polypeptides.

[0213] In some embodiments, the antimicrobial polypeptide comprises or consists of a defensin. Exemplary defensins include, but are not limited to, α-defensins (e.g., neutrophil defensin 1, defensin α1, neutrophil defensin 3, neutrophil defensin 4, defensin 5, defensin 6), β-defensins (e.g., β-defensin 1, β-defensin 2, β-defensin 103, β-defensin 107, β-defensin 110, β-defensin 136), and θ-defensins. In other embodiments, the antimicrobial polypeptide comprises or consists of a cathelicidin (e.g., hCAP18).

[0214] antiviral peptides

[0215] Antiviral polypeptides (AVPs) are small peptides of variable length, sequence, and structure that have broad-spectrum activity against a wide range of viruses. See, e.g., Zaiou, J Mol Med, 2007;85:317. AVPs have been shown to have broad-spectrum, rapidly acting killing activity, along with the potential for low-level resistance induction and concomitant broad anti-inflammatory effects. In some embodiments, the antiviral polypeptide is less than 10 kDa, e.g., less than 8 kDa, 6 kDa, 4 kDa, 2 kDa, or 1 kDa. In some embodiments, the antiviral polypeptide comprises or consists of about 6 to about 100 amino acids, e.g., about 6 to about 75 amino acids, about 6 to about 50 amino acids, about 6 to about 25 amino acids, about 25 to about 100 amino acids, about 50 to about 100 amino acids, or about 75 to about 100 amino acids. In certain embodiments, the antiviral polypeptide comprises or consists of about 15 to about 45 amino acids. In some embodiments, the antiviral polypeptide is substantially cationic. In some embodiments, the antiviral polypeptide is substantially amphipathic. In certain embodiments, the antiviral polypeptide is substantially cationic and amphipathic. In some embodiments, the antiviral polypeptide is cytostatic against viruses. In some embodiments, the antiviral polypeptide is cytotoxic against viruses. In some embodiments, the antiviral polypeptide is cytostatic and cytotoxic against viruses. In some embodiments, the antiviral polypeptide is cytostatic against bacteria, fungi, protozoa, parasites, prions, or a combination thereof. In some embodiments, the antiviral polypeptide is cytotoxic against bacteria, fungi, protozoa, parasites, prions, or a combination thereof. In certain embodiments, the antiviral polypeptide is cytostatic and cytotoxic against bacteria, fungi, protozoa, parasites, prions, or a combination thereof. In some embodiments, the antiviral polypeptide is cytotoxic against tumor or cancer cells (e.g., human cancer cells). In some embodiments, the antiviral polypeptide is cytostatic against tumor or cancer cells (e.g., human cancer cells). In certain embodiments, the antiviral polypeptide is cytotoxic and cytostatic to tumor or cancer cells (eg, human cancer cells). In some embodiments, the antiviral polypeptide is a secreted polypeptide.

[0216] Cytotoxic nucleosides

[0217] In one embodiment, the polynucleotides, primary constructs or mmRNA of the present invention may be combined with one or more cytotoxic nucleosides. For example, cytotoxic nucleosides may be incorporated into polynucleotides, primary constructs or mmRNA such as bifunctional modified RNA or mRNA. Cytotoxic nucleoside anticancer agents include but are not limited to adenosine, cytarabine, cytosine arabinoside, 5-fluorouracil, fludarabine, floxuridine, (a combination of tegafur and uracil), tegafur ((RS)-5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione), and 6-mercaptopurine.

[0218] A large number of cytotoxic nucleoside analogs are in clinical use as anticancer agents or have been the subject of clinical trials. Examples of such analogs include, but are not limited to, cytarabine, gemcitabine, troxacitabine, decitabine, tezacitabine, 2′-deoxy-2′-methylenecytidine (DMDC), cladribine, clofarabine, 5-azacytidine, 4′-thio-arabinoside (4′-thio-aracytidine), cyclopentenylcytosine, and 1-(2-C-cyano-2-deoxy-β-D-arabinofuranosyl)-cytosine. Another example of such a compound is fludarabine phosphate. These compounds can be administered systemically and may have typical side effects of cytotoxic agents, such as, but not limited to, little or no specificity for tumor cells relative to proliferating normal cells.

[0219] Many prodrugs of cytotoxic nucleoside analogs have also been reported in the art. Examples include, but are not limited to, N4-behenoyloxy-1-β-D-arabinofuranosylcytosine, N4-octadecyl-1-β-D-arabinofuranosylcytosine, N4-palmitoyl-1-(2-C-cyano-2-deoxy-β-D-arabinofuranosyl)cytosine and P-4055 (cytosine arabinoside 5'-elidal ester). In general, these prodrugs can be converted into active drugs mainly in the liver and systemic circulation and show little or no selective release of active drugs in tumor tissue. For example, a prodrug of 5'-deoxy-5-fluorocytidine (and ultimately 5-fluorouracil), capecitabine, is metabolized in both the liver and tumor tissue. A series of capecitabine analogs containing "groups that are easily hydrolyzed under physiological conditions" have been claimed by Fujiu et al. (U.S. Patent No. 4,966,891) and are incorporated herein by reference. The series described by Fujiu includes N4 alkyl and aralkyl carbamates of 5'-deoxy-5-fluorocytidine with the suggestion that these compounds will be activated by hydrolysis under normal physiological conditions to provide 5'-deoxy-5-fluorocytidine.

[0220] A series of cytarabine N4-carbamates have been reported by the people such as Fadl (Pharmazie.1995,50,382-7, incorporated herein by reference), wherein compound is designed to be converted into cytarabine in liver and blood plasma.WO 2004 / 041203, incorporated herein by reference, discloses the prodrug of gemcitabine, some of which are N4-carbamates. These compounds are designed to overcome the gastrointestinal toxicity of gemcitabine and are intended to provide gemcitabine by hydrolysis release in liver and blood plasma after absorbing complete prodrug from gastrointestinal tract. Nomura et al. (Bioorg Med.Chem.2003,11,2453-61, incorporated herein by reference) describe the acetal derivatives of 1-(3-C-ethynyl-β-D-ribose-pentofuranosyl) cytosine, which produce the intermediate that needs to be further hydrolyzed under acidic conditions to produce cytotoxic nucleoside compounds when bioreduction.

[0221] Cytotoxic nucleosides that can be used as chemotherapeutic agents also include, but are not limited to, pyrazolo[3,4-D]-pyrimidine, allopurinol, azathioprine, capecitabine, cytarabine, fluorouracil, mercaptopurine, 6-thioguanine, acyclovir, ara-adenosine, ribavirin, 7-deaza-adenosine, 7-deaza-guanosine, 6-aza-uracil, 6-aza-cytidine, thymidine ribonucleotide, 5-bromodeoxyuridine, 2-chloro-purine, and inosine, or a combination thereof.

[0222] Flanking region: untranslated region (UTR)

[0223] The untranslated region (UTR) of a gene is transcribed but not translated. The 5′UTR begins at the transcription start site and continues to the start codon but does not include the start codon; whereas the 3′UTR begins immediately following the stop codon and continues until the transcription termination signal. There is increasing evidence for the regulatory role played by UTRs in terms of the stability of nucleic acid molecules and translation. The regulatory features of UTRs can be incorporated into the polynucleotides, primary constructs, and / or mmRNA of the present invention to enhance the stability of the molecules. The specific features can also be incorporated to ensure controlled downregulation of transcripts in the event that the transcripts are misdirected to undesirable organ sites.

[0224] 5′UTR and translation initiation

[0225] Natural 5'UTRs carry features that play a role in translation initiation. They possess signature sequences like the Kozak sequence, which is generally known to be involved in the process by which ribosomes initiate translation of many genes. The Kozak sequence has a consensus CCR(A / G)CCAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG), which is followed by another "G". 5'UTRs are also known to form secondary structures involved in the binding of elongation factors.

[0226] By engineering features typically found in genes that are abundantly expressed in specific target organs, the stability and protein production of the polynucleotides, primary constructs, or mmRNA of the present invention can be enhanced. For example, the introduction of a 5'UTR of a liver-expressed mRNA (such as albumin, serum amyloid A, apolipoprotein A / B / E, transferrin, alpha-fetoprotein, erythropoietin, or Factor VIII) can be used to enhance the expression of nucleic acid molecules (such as mmRNA) in hepatic cell lines or in the liver. Likewise, it is possible to use 5′UTRs from other tissue-specific mRNAs to improve expression in these tissues: muscle (MyoD, Myosin, Myoglobin, Myogenin, Herculin), endothelial cells (Tie-1, CD36), myeloid cells (C / EBP, AML1, G-CSF, GM-CSF, CD11b, MSR, Fr-1, i-NOS), leukocytes (CD45, CD18), adipose tissue (CD36, GLUT4, ACRP30, Adiponectin), and lung epithelial cells (SP-A / B / C / D).

[0227] Other non-UTR sequences can be incorporated into the 5' (or 3' UTR) UTR. For example, introns or portions of intronic sequences can be incorporated into the flanking regions of the polynucleotides, primary constructs, or mmRNA of the present invention. Incorporation of intronic sequences can increase protein production and mRNA levels.

[0228] 3′UTR and AU-rich elements

[0229] 3′UTRs are known to have stretches of adenosine and uridine embedded within them. These AU-rich signature sequences are particularly common in genes with high turnover rates. Based on their sequence characteristics and functional properties, AU-rich elements (AREs) can be divided into three categories (Chen et al., 1995): Class I AREs contain several dispersed copies of the AUUUA motif within a U-rich region. C-Myc and MyoD contain Class I AREs. Class II AREs have two or more overlapping UUAUUUA(U / A)(U / A) nonamers. Molecules containing this type of ARE include GM-CSF and TNF-a. Class III AREs are less clearly defined. These U-rich regions do not contain the AUUUA motif. c-Jun and myogenin are two well-studied examples of this category. Most proteins that bind to AREs are known to destabilize the messenger, while members of the ELAV family (most notably HuR) have been shown to increase the stability of mRNA. HuR binds to all three types of AREs. Engineering a HuR-specific binding site into the 3'UTR of a nucleic acid molecule will result in HuR binding and, therefore, stabilization of the message in vivo.

[0230] The introduction, removal or modification of AU-rich elements in the 3′UTR can be used to regulate the stability of the polynucleotides, primary constructs or mmRNA of the present invention. When engineering specific polynucleotides, primary constructs or mmRNA, one or more copies of AREs can be introduced to make the polynucleotides, primary constructs or mmRNA of the present invention less stable and thereby reduce translation and reduce the production of the resulting protein. Similarly, AREs can be identified and removed or mutated to increase intracellular stability and thus increase translation and the production of the resulting protein. Transfection experiments can be performed in relevant cell lines using the polynucleotides, primary constructs or mmRNA of the present invention, and protein production can be measured at different time points after transfection. For example, cells can be transfected with different ARE engineered molecules, and the protein produced at 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours and 7 days after transfection can be measured using an ELISA kit for the relevant protein.

[0231] Incorporation of microRNA binding sites

[0232] MicroRNA (or miRNA) is a non-coding RNA of 19 to 25 nucleotides in length that binds to the 3'UTR of a nucleic acid molecule and downregulates gene expression by reducing nucleic acid molecule stability or by inhibiting translation. The polynucleotides, primary constructs, or mmRNA of the present invention may comprise one or more microRNA target sequences, microRNA sequences, or microRNA seeds. Such sequences may correspond to any known microRNA such as those taught in U.S. Publication US2005 / 0261218 and U.S. Publication US2005 / 0059005, the contents of which are incorporated herein by reference in their entirety.

[0233] The microRNA sequence comprises a "seed" region, i.e., a sequence in the region of positions 2 to 8 of the mature microRNA, which has perfect Watson-Crick complementarity with the miRNA target sequence. The microRNA seed may comprise positions 2 to 8 or 2 to 7 of the mature microRNA. In some embodiments, the microRNA seed may comprise 7 nucleotides (e.g., nucleotides 2 to 8 of the mature microRNA), wherein the seed complementary site in the corresponding miRNA target is flanked by an adenine (A) opposite to microRNA position 1. In some embodiments, the microRNA seed may comprise 6 nucleotides (e.g., nucleotides 2 to 7 of the mature microRNA), wherein the seed complementary site in the corresponding miRNA target is flanked by an adenine (A) opposite to microRNA position 1. See, e.g., Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP; Mol Cell. 2007 July 6; 27(1): 91-105; each of which is incorporated herein by reference in its entirety. The bases of the microRNA seed have complete complementarity with the target sequence. By engineering the microRNA target sequence into the 3′UTR of the polynucleotides, primary constructs, or mmRNA of the present invention, molecules can be targeted for degradation or reduced translation, provided that the microRNA in question is available. This approach will reduce the risk of off-target effects during nucleic acid molecule delivery. Identification of microRNAs, microRNA target regions, their expression patterns, and roles in biology have been reported (Bonauer et al., Curr Drug Targets 2010 11:943-949; Anand and Cheresh Curr Opin Hematol 2011 18:171-176; Contreras and Rao Leukemia 2012 26:404-413 (Dec 20, 2011. doi:10.1038 / leu.2011.356); Bartel Cell 2009 136:215-233; Landgraf et al., Cell, 2007 129:1401-1414; each of which is herein incorporated by reference in its entirety).

[0234] For example, if the nucleic acid molecule is mRNA and is not intended to be delivered to the liver but is ultimately delivered to the liver, then if one or more target sites for miR-122 (a microRNA abundant in the liver) are engineered into the 3'UTR of the polynucleotide, primary construct, or mmRNA, miR-122 can inhibit the expression of the target gene. The introduction of one or more binding sites for different microRNAs can be engineered to further reduce the lifespan, stability, and protein translation of the polynucleotide, primary construct, or mmRNA.

[0235] As used herein, the term "microRNA site" refers to a microRNA target site or microRNA recognition site or any nucleotide sequence to which a microRNA binds or associates. It should be understood that "binding" can follow traditional Watson-Crick hybridization rules or can reflect any stable association of a microRNA with a target sequence at or near a microRNA site.

[0236] Conversely, for the purposes of the polynucleotides, primary constructs, or mmRNA of the present invention, microRNA binding sites can be engineered (i.e., removed) from their naturally occurring sequences to increase protein expression in specific tissues. For example, miR-122 binding sites can be removed to improve protein expression in the liver. Regulation of expression in various tissues can be achieved by introducing or removing one or more microRNA binding sites.

[0237] Examples of tissues in which microRNAs are known to regulate mRNA, and therefore protein expression, include, but are not limited to, liver (miR-122), muscle (miR-133, miR-206, miR-208), endothelial cells (miR-17-92, miR-126), bone marrow cells (miR-142-3p, miR-142-5p, miR-16, miR-21, miR-223, miR-24, miR-27), adipose tissue (let-7, miR-30c), heart (miR-1d, miR-149), kidney (miR-192, miR-194, miR-204), and lung epithelial cells (let-7, miR-133, miR-126). MicroRNAs can also regulate complex biological processes such as angiogenesis (miR-132) (Anand and Cheresh Curr Opin Hematol 2011 18: 171-176; incorporated herein by reference in its entirety). In the polynucleotides, primary constructs, or mmRNA of the present invention, microRNA binding sites involved in such processes can be removed or introduced to tailor polynucleotide, primary construct, or mmRNA expression to biologically relevant cell types or to the context of relevant biological processes. A list of microRNAs, miR sequences, and miR binding sites is listed in Table 9 of U.S. Provisional Application No. 61 / 753,661, filed January 17, 2013, Table 9 of U.S. Provisional Application No. 61 / 754,159, filed January 18, 2013, and Table 7 of U.S. Provisional Application No. 61 / 758,921, filed January 31, 2013, each of which is incorporated herein by reference in its entirety.

[0238] Finally, by understanding the expression patterns of microRNAs in different cell types, polynucleotides, primary constructs, or mmRNA can be engineered for more targeted expression in specific cell types or only under specific biological conditions. By introducing tissue-specific microRNA binding sites, polynucleotides, primary constructs, or mmRNA that are optimal for protein expression in tissues or in the context of biological conditions can be designed. Examples of the use of microRNAs for driving tissue or disease-specific gene expression are listed (Getner and Naldini, Tissue Antigens. 2012, 80: 393-403; incorporated herein by reference in their entirety). In addition, microRNA seed sites can be incorporated into mRNA to reduce expression in certain cells, which results in biological improvements. An example of this is the incorporation of miR-142 sites into lentiviral vectors expressing UGT1A1. The presence of the miR-142 seed site reduces expression in hematopoietic cells and, therefore, in antigen-presenting cells, resulting in the absence of an immune response to virally expressed UGT1A1 (Schmitt et al., Gastroenterology 2010; 139:999-1007; Gonzalez-Asequinolaza et al., Gastroenterology 2010, 139:726-729; both are incorporated herein by reference in their entireties). Incorporating the miR-142 site into the modified mRNA can not only reduce expression of the protein encoded in hematopoietic cells, but also reduce or eliminate the immune response to the protein encoded by the mRNA. Incorporating the miR-142 seed site(s) into the mRNA will be important in the treatment of patients with complete protein deficiency (UGT1A1 type I, LDLR-deficient patients, CRIM-negative Pompe patients, etc.).

[0239] Transfection experiments can be performed using engineered polynucleotides, primary constructs, or mmRNA in relevant cell lines, and protein production can be measured at different time points after transfection. For example, cells can be transfected with polynucleotides, primary constructs, or mmRNA engineered with different microRNA binding sites, and protein production at 6 hours, 12 hours, 24 hours, 48 ​​hours, and 7 days after transfection can be measured using an ELISA kit for the relevant protein. In vivo experiments can also be performed using molecules engineered with microRNA binding sites to detect changes in tissue-specific expression of the formulated polynucleotides, primary constructs, or mmRNA.

[0240] 5′ capping

[0241] The 5' cap structure of mRNA is involved in nuclear export, thereby increasing mRNA stability, and binds to mRNA cap binding protein (CBP), which is responsible for mRNA stability and translational capacity in cells through association of CBP with poly(A) binding protein to form mature circular mRNA species. The cap further helps remove 5' proximal introns during mRNA splicing.

[0242] Endogenous mRNA molecules can be 5'-capped, thereby generating a 5'-ppp-5'-triphosphate linkage between the terminal guanosine cap residue and the sense nucleotide transcribed at the 5' end of the mRNA molecule. This 5'-guanylate cap can then be methylated to generate an N7-methyl-guanylate residue. The ribose sugars of the terminal and / or anteterminal transcribed nucleotides of the 5' end of the mRNA can also optionally be 2'-O-methylated. 5'-decapping by hydrolysis and cleavage of the guanylate cap structure can target nucleic acid molecules, such as mRNA molecules, for degradation.

[0243] Modifications to the polynucleotides, primary constructs, and mmRNA of the present invention can produce a non-hydrolyzable cap structure, thereby preventing decapping and thereby increasing the mRNA half-life. Because cap structure hydrolysis requires cleavage of the 5'-ppp-5' phosphodiester linkage, modified nucleotides can be used during the capping reaction. For example, the vaccinia capping enzyme from New England Biolabs (Ipswich, MA) can be used with α-thio-guanosine nucleotides according to the manufacturer's instructions to form a thiophosphate linkage in the 5'-ppp-5' cap. Alternatively, modified guanosine nucleotides such as α-methyl-phosphonate and seleno-phosphate nucleotides can be used.

[0244] Additional modifications include, but are not limited to, 2'-O-methylation of the ribose sugar of the 5'-terminal and / or 5'-preterminal nucleotides of the mRNA (as described above) at the 2'-hydroxyl group of the sugar ring. A variety of different 5' cap structures can be used to generate the 5' cap of nucleic acid molecules such as mRNA molecules.

[0245] Cap analogs, also referred to herein as synthetic cap analogs, chemical caps, chemical cap analogs, or structural or functional cap analogs, differ in their chemical structure from the natural (i.e., endogenous, wild-type, or physiological) 5' cap while retaining cap function. Cap analogs can be chemically (i.e., non-enzymatically) or enzymatically synthesized and / or attached to nucleic acid molecules.

[0246] For example, the anti-reverse cap analog (ARCA) cap comprises two guanines linked by a 5′-5′-triphosphate group, wherein one of the guanines comprises an N7 methyl group as well as a 3′-O-methyl group (i.e., N7,3′-O-dimethyl-guanosine-5′-triphosphate-5′-guanosine (m 7G-3'mppp-G; which can be equivalently designated as 3'O-Me-m7G(5')ppp(5')G). The 3'-O atom of the other unmodified guanine becomes attached to the 5'-terminal nucleotide of the capped nucleic acid molecule (e.g., mRNA or mmRNA). The N7- and 3'-O-methylated guanines provide the terminal portion of the capped nucleic acid molecule (e.g., mRNA or mmRNA).

[0247] Another exemplary cap is mCAP, which is similar to ARCA but has a 2′-O-methyl group on guanosine (ie, N7, 2′-O-dimethyl-guanosine-5′-triphosphate-5′-guanosine, mCAP). 7 Gm-ppp-G).

[0248] Although cap analogs allow for concomitant capping of nucleic acid molecules in in vitro transcription reactions, up to 20% of transcripts may remain uncapped. This, along with the structural differences between cap analogs and the endogenous 5' cap structure of nucleic acids produced by endogenous cellular transcription machinery, can lead to reduced translational capacity and reduced cellular stability.

[0249] The polynucleotides, primary constructs, and mmRNA of the present invention can also be enzymatically capped after transcription to produce a more authentic 5′ cap structure. As used herein, the phrase “more authentic” refers to a feature that closely reflects or mimics an endogenous or wild-type feature in structure or function. That is, a “more authentic” feature is a better representation of endogenous, wild-type, natural, or physiological cellular function and / or structure compared to synthetic features or analogs of the prior art, or a feature that outperforms the corresponding endogenous, wild-type, natural, or physiological feature in one or more aspects. Non-limiting examples of more authentic 5′ cap structures of the present invention are those that have, among other things, enhanced binding of cap-binding proteins, increased half-life, reduced sensitivity to 5′ endonucleases, and / or reduced 5′ decapping compared to synthetic 5′ cap structures known in the art (or compared to wild-type, natural, or physiological 5′ cap structures). For example, a recombinant vaccinia virus capping enzyme and a recombinant 2'-O-methyltransferase can form a canonical 5'-5'-triphosphate linkage between the 5' terminal nucleotide of an mRNA and a guanine cap nucleotide, wherein the cap guanine comprises N7 methylation and the 5' terminal nucleotide of the mRNA comprises a 2'-O-methyl group. This structure is referred to as a cap 1 structure. This cap results in higher translational capacity and cellular stability and reduced activation of cellular proinflammatory cytokines compared to, for example, other 5' cap analog structures known in the art. Cap structures include, but are not limited to, 7mG(5')ppp(5')N,pN2p (cap 0), 7mG(5')ppp(5')NlmpNp (cap 1), and 7mG(5')-ppp(5')NlmpN2mp (cap 2).

[0250] Because the polynucleotide, primary construct, or mmRNA can be capped after transcription, and because this approach is more efficient, nearly 100% of the polynucleotide, primary construct, or mmRNA can be capped, compared to approximately 80% when a cap analog is attached to the mRNA during an in vitro transcription reaction.

[0251] According to the present invention, the 5' end cap may comprise an endogenous cap or a cap analog. According to the present invention, the 5' end cap may comprise a guanine analog. Useful guanine analogs include, but are not limited to, inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

[0252] Viral sequence

[0253] Additional viral sequences, such as, but not limited to, translation enhancer sequences of barley yellow dwarf virus (BYDV-PAV), sheep pulmonary adenomatosis retrovirus (JSRV), and / or endemic intranasal tumor virus (see, e.g., International Publication No. WO2012129648; herein incorporated by reference in its entirety), can be engineered and inserted into the 3′UTR of the polynucleotides, primary constructs, or mmRNA of the present invention and can stimulate translation of the construct in vitro and in vivo. Transfection experiments can be performed in relevant cell lines and protein production can be measured by ELISA at 12 hours, 24 hours, 48 ​​hours, 72 hours, and 7 days after transfection.

[0254] IRES sequence

[0255] In addition, polynucleotides, primary constructs or mmRNA that may contain an internal ribosome entry site (IRES) are provided. First identified as a characteristic picornavirus RNA, IRES plays an important role in the initiation of protein synthesis in the absence of a 5' cap structure. IRES can be used as a sole ribosome binding site or as one of multiple ribosome binding sites of mRNA. Polynucleotides, primary constructs or mmRNA containing more than one functional ribosome binding site can encode several peptides or polypeptides ("polycistronic nucleic acid molecules") that are independently translated by ribosomes. When the polynucleotide, primary construct or mmRNA has an IRES, a second translatable region is further optionally provided. Examples of IRES sequences that can be used in accordance with the present invention include, but are not limited to, those from picornaviruses (e.g., FMDV), insect viruses (CFFV), polioviruses (PV), encephalomyocarditis virus (ECMV), foot-and-mouth disease virus (FMDV), hepatitis C virus (HCV), classical swine fever virus (CSFV), murine leukemia virus (MLV), simian immunodeficiency virus (SIV), or cricket paralysis virus (CrPV).

[0256] poly-A tail

[0257] During RNA processing, long chains of adenine nucleotides (poly-A tails) can be added to polynucleotides such as mRNA molecules to increase stability. Immediately after transcription, the 3' end of the transcript can be cleaved to release the 3' hydroxyl group. Poly-A polymerase then adds adenine nucleotide chains to the RNA. The process known as polyadenylation adds a poly-A tail that can be, for example, between about 100 and 250 residues long.

[0258] It has been discovered that unique poly-A tail lengths provide certain advantages to the polynucleotides, primary constructs, or mmRNA of the present invention.

[0259] In general, the poly-A tail of the present invention is greater than 30 nucleotides in length. In another embodiment, the poly-A tail is greater than 35 nucleotides in length (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,500, and 3,000 nucleotides). In some embodiments, the polynucleotide, primary construct, or mmRNA includes about 30 to about 3,000 nucleotides (e.g., 30 to 50, 30 to 100, 30 to 250, 30 to 500, 30 to 750, 30 to 1,000, 30 to 1,500, 30 to 2,000, 30 to 2,500, 50 to 100, 50 to 250, 50 to 500, 50 to 750, 50 to 1,000, 50 to 1,500, 50 to 2,000, 50 to 2,500, 50 to 3,000, 100 to 500, 100 to 750, 100 to 1,000, 100 to 1,500, 100 to 2,000, 100 to 2,500, 100 to 3,000, 500 to 750, 500 to 1,000, 500 to 1,500, 500 to 2,000, 500 to 2,500, 500 to 3,000, 1,000 to 1,500, 1,000 to 2,000, 1,000 to 2,500, 1,000 to 3,000, 1,500 to 2,000, 1,500 to 2,500, 1,500 to 3,000, 2,000 to 3,000, 2,000 to 2,500, and 2,500 to 3,000).

[0260] In one embodiment, the poly-A tail is designed relative to the length of the overall polynucleotide, primary construct, or mmRNA. This design can be based on the length of the coding region, the length of a specific feature or region (such as the first region or flanking regions), or the length of the final product expressed from the polynucleotide, primary construct, or mmRNA.

[0261] In this context, the poly-A tail may be greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the length of the polynucleotide, primary construct or mmRNA or its characteristics. The poly-A tail can also be designed as part of the polynucleotide, primary construct or mmRNA to which it belongs. In this context, the poly-A tail can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% or more of the total length of the construct or the total length of the construct minus the poly-A tail. In addition, engineered binding sites and conjugation of the polynucleotide, primary construct or mmRNA to poly-A binding proteins can enhance expression.

[0262] Alternatively, multiple different nucleotides, primary constructs, or mmRNA can be linked together to PABP (poly-A binding protein) via the 3' end using modified nucleotides at the 3' end of the poly-A tail. Transfection experiments can be performed in relevant cell lines and protein production can be measured by ELISA at 12 hours, 24 hours, 48 ​​hours, 72 hours, and 7 days after transfection.

[0263] In one embodiment, the polynucleotide primary constructs of the present invention are designed to include a polyA-G quadruplex. A G quadruplex is a cyclic, hydrogen-bonded array of four guanine nucleotides that can be formed by G-rich sequences in both DNA and RNA. In this embodiment, the G quadruplex is incorporated at the end of the poly-A tail. The resulting mmRNA constructs are assayed at various time points for stability, protein production, and other parameters including half-life. The polyA-G quadruplex has been found to result in protein production equivalent to at least 75% of that observed using the 120-nucleotide poly-A tail alone.

[0264] Quantification

[0265] In one embodiment, the polynucleotides, primary constructs, or mmRNA of the present invention can be quantified in exosomes derived from one or more body fluids. As used herein, "body fluid" includes peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, bronchoalveolar lavage fluid, semen, prostatic fluid, Cowper's fluid or pre-ejaculatory fluid, sweat, fecal matter, hair, tears, cystic fluid, pleural and peritoneal fluid, pericardial fluid, lymphatic fluid, chyme, chyle, bile, interstitial fluid, menstrual blood, pus, sebum, vomitus, vaginal secretions, mucosal secretions, watery stools, pancreatic juice, lavage fluid from the sinus cavities, bronchopulmonary aspirate, blastocyst cavity fluid, and umbilical cord blood. Alternatively, the exosomes can be harvested from an organ selected from the group consisting of lung, heart, pancreas, stomach, intestine, bladder, kidney, ovary, testis, skin, colon, breast, prostate, brain, esophagus, liver, and placenta.

[0266] In the quantitative method, a sample of no more than 2 mL is obtained from the subject and exosomes are separated by size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunosorbent capture, affinity purification, microfluidic separation, or a combination thereof. In the analysis, the level or concentration of the polynucleotide, primary construct, or mmRNA can be the expression level, presence, absence, truncation, or change of the construct administered. Advantageously, the level is related to one or more clinical phenotypes or to the determination of biomarkers for human diseases. The determination can be performed using construct-specific probes, cell counting, qRT-PCR, real-time PCR, PCR, flow cytometry, electrophoresis, mass spectrometry, or a combination thereof, while exosomes can be separated using immunohistochemical methods such as enzyme-linked immunosorbent assay (ELISA) methods. Exosomes can also be separated by size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunosorbent capture, affinity purification, microfluidic separation, or a combination thereof.

[0267] These methods give researchers the ability to monitor the levels of remaining or delivered polynucleotides, primary constructs, or mmRNA in real time. This is possible because the polynucleotides, primary constructs, or mmRNA of the present invention differ from their endogenous forms due to structural or chemical modifications.

[0268] II. Design and Synthesis of mmRNA

[0269] Polynucleotides, primary constructs, or mmRNA for use in accordance with the present invention can be prepared according to any available technique, including but not limited to chemical synthesis, enzymatic synthesis, which is often referred to as in vitro transcription (IVT), or enzymatic or chemical cleavage of a longer precursor. Methods for synthesizing RNA are known in the art (see, e.g., Gait, MJ (ed.) Oligonucleotide synthesis: a practical approach, Oxford [Oxfordshire], Washington, DC: IRL Press, 1984; and Herdewijn, P. (ed.) Oligonucleotide synthesis: methods and applications, Methods in Molecular Biology, Vol. 288 (Clifton, NJ) Totowa, NJ: Humana Press, 2005; both incorporated herein by reference).

[0270] The method for designing and synthesizing the primary construct of the present invention includes the steps of gene construction, mRNA production (with or without modification) and purification. In the enzymatic synthesis method, a target polynucleotide sequence encoding the target polypeptide is first selected for incorporation into a vector, which is amplified to produce a cDNA template. Optionally, the target polynucleotide sequence and / or any flanking sequences can be codon optimized. The cDNA template is then used to produce mRNA by in vitro transcription (IVT). After production, the mRNA can undergo purification and cleanup processes. The steps are provided in more detail below.

[0271] Gene construction

[0272] The steps of gene construction may include, but are not limited to, gene synthesis, vector amplification, plasmid purification, plasmid linearization and cleanup, and cDNA template synthesis and cleanup.

[0273] gene synthesis

[0274] In the case of target polypeptide or target being selected for generation, primary construct is designed. In primary construct, the first district of the connection nucleoside of coding target polypeptide can be constructed using the open reading frame (ORF) of selected nucleic acid (DNA or RNA) transcript. ORF can comprise wild-type ORF, its isoform, variant or fragment. As used herein, " open reading frame " or " ORF " means the nucleic acid sequence (DNA or RNA) that can encode target polypeptide. ORF often starts with initiation codon ATG and ends with nonsense or termination codon or signal.

[0275] In addition, the nucleotide sequence of the first district can be codon optimized. Codon optimization methods are known in the art and can be applied to achieve one or more of several goals. These goals include matching the codon frequency in the target and host organism to ensure correct folding; biasing the GC content to increase mRNA stability or reduce secondary structure; minimizing tandem repeat codons or base runs that may damage gene construction or expression, customizing transcription and translation control regions, inserting or removing protein trafficking sequences, removing / adding post-translational modification sites (such as glycosylation sites) in the encoded protein, adding, removing or reorganizing protein domains, inserting or deleting restriction sites, modifying ribosome binding sites and mRNA degradation sites, so as to adjust the translation rate so as to allow different domains of the protein to fold correctly, or so as to reduce or eliminate problematic secondary structures in the mRNA. Codon optimization tools, algorithms and services are known in the art, and non-limiting examples include services from GeneArt (Life Technologies), DNA2.0 (Menlo Park CA) and / or proprietary methods. In one embodiment, an optimization algorithm is used to optimize the ORF sequence. The codon selection for each amino acid is given in Table 1.

[0276] Table 1. Codon usage

[0277]

[0278] In some embodiments of the present invention, the features that can be considered as beneficial can be encoded by the primary construct and can be located on the side of the ORF as the first or second flanking region. The flanking region can be incorporated into the primary construct before and / or after the optimization of the ORF. It is not required that the primary construct include both 5' and 3' flanking regions. Examples of such features include, but are not limited to, untranslated regions (UTRs), Kozak sequences, oligo (dT) sequences, and detectable tags and can include a multiple cloning site that can have XbaI recognition.

[0279] In some embodiments, 5'UTR and / or 3'UTR may be provided as flanking regions. Multiple 5' or 3'UTRs may be included in the flanking regions and may have the same or different sequences. Any portion of the flanking region (including without any portion) may be codon optimized and any portion may independently include one or more different structural modifications or chemical modifications before and / or after codon optimization. The combination of features may be included in the first flanking region and the second flanking region and may be included in other features. For example, the ORF may be flanked by a 5'UTR that may include a strong Kozak translation initiation signal and / or a 3'UTR that may include an oligo (dT) sequence for templated addition of a poly-A tail. The 5'UTR may include a first polynucleotide fragment and a second polynucleotide fragment from the same and / or different genes, such as the 5'UTR described in U.S. Patent Application Publication No. 20100293625, which is incorporated herein by reference in its entirety.

[0280] Tables 2 and 3 provide lists of exemplary UTRs that can be used as flanking regions in the primary constructs of the present invention. A list of 5' untranslated regions of the present invention is shown in Table 2. Variants of the 5'UTR can be used in which one or more nucleotides are added to the end or removed, including A, T, C, or G.

[0281] Table 2. 5′ untranslated region

[0282]

[0283] A representative list of 3' untranslated regions of the invention is shown in Table 3. Variants of the 3' UTR can be used in which one or more nucleotides are added to the terminus or removed, including A, T, C, or G.

[0284] Table 3. 3′ untranslated region

[0285]

[0286]

[0287]

[0288]

[0289]

[0290]

[0291]

[0292]

[0293]

[0294]

[0295]

[0296]

[0297] It should be understood that those listed in the above table are examples and that any UTR from any gene can be incorporated into the corresponding first or second flanking region of the primary construct. In addition, multiple wild-type UTRs of any known gene can be used. Providing artificial UTRs that are not variants of wild-type genes is also within the scope of the present invention. These UTRs or portions thereof can be placed in the same orientation as in the transcript from which they are selected or can be altered in orientation or position. Thus, the 5' or 3' UTR can be reversed, shortened, extended, or chimeric with one or more other 5' or 3' UTRs. As used herein, the term "altered" when it relates to a UTR sequence means that the UTR has been altered in some way relative to the reference sequence. For example, a 3' or 5' UTR can be altered relative to a wild-type or natural UTR by a change in orientation or position as taught above or by the inclusion of additional nucleotides, deletion of nucleotides, exchange of nucleotides, or transposition. Any of these changes that produce an "altered" UTR (whether 3' or 5') comprises a variant UTR.

[0298] In one embodiment, a double, triple, or quadruple UTR, such as a 5' or 3' UTR, may be used. As used herein, a "double" UTR is one in which two copies of the same UTR are encoded in tandem or substantially in tandem. For example, a double β-globin 3' UTR may be used as described in U.S. Patent Publication No. 20100129877, the contents of which are incorporated herein by reference in their entirety.

[0299] UTRs with patterning are also within the scope of the present invention. As used herein, "patterned UTRs" are those that reflect a repeating or alternating pattern, such as ABABAB or AABBAABBABB or ABCABCABC or variants thereof, repeated once, twice, or more than three times. In these patterns, each letter A, B, or C represents a different UTR at the nucleotide level.

[0300] In one embodiment, the flanking regions are selected from families of transcripts whose proteins share a common function, structure, or characteristic feature. For example, the target polypeptide may belong to a family of proteins expressed in a specific cell, tissue, or at a certain time during development. The UTR from any of these genes can be exchanged for any other UTR of the same or different protein family to form a new chimeric primary transcript. As used herein, "protein family" is broadly used to refer to a group of two or more target polypeptides that share at least one function, structure, feature, location, origin, or expression pattern.

[0301] After optimization (if necessary), the primary construct components are reconstructed and transformed into vectors such as, but not limited to, plasmids, viruses, cosmids, and artificial chromosomes. For example, the optimized constructs can be reconstructed and transformed into chemically competent E. coli, yeast, Neurospora, Zea mays, Drosophila, etc., where high copy plasmid-like or chromosomal structures are generated by the methods described herein.

[0302] The untranslated region may also include a translation enhancer element (TEE). As a non-limiting example, TEEs may include those described in US Application No. 20090226470, which is incorporated herein by reference in its entirety, and those known in the art.

[0303] stop codon

[0304] In one embodiment, primary construct of the present invention can comprise at least two stop codons before 3 ' untranslated region (UTR). Stop codon can be selected from TGA, TAA and TAG. In one embodiment, primary construct of the present invention comprises stop codon TGA and an other stop codon. In another embodiment, other stop codon can be TAA. In another embodiment, primary construct of the present invention comprises three stop codons.

[0305] Vector amplification

[0306] The vector containing the primary construct is then amplified and expressed using methods known in the art such as, but not limited to, the Invitrogen PURELINK TM Plasmids were isolated and purified using the HiPure Maxiprep kit (Carlsbad, CA) for maxi prep.

[0307] Plasmid linearization

[0308] The plasmid can then be linearized using methods known in the art, such as, but not limited to, restriction enzymes and buffers. The linearization reaction can be purified using methods including, for example, Invitrogen's PURELINK TMPCR mini kit (Carlsbad, CA) and HPLC-based purification methods, such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reversed-phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC) and Invitrogen's standard PURELINK TM PCR kit (Carlsbad, CA). The purification method can be modified depending on the size of the linearization reaction being performed. The linearized plasmid is then used to generate cDNA for in vitro transcription (IVT) reactions.

[0309] cDNA template synthesis

[0310] The cDNA template can be synthesized by subjecting the linearized plasmid to polymerase chain reaction (PCR). Table 4 is a list of primers and probes that can be used in the PCR reaction of the present invention. It should be understood that the list is not exhaustive and that the primer-probe design for any amplification is within the scope of those skilled in the art. The probe may also include chemically modified bases to increase the base pairing fidelity and base pairing strength to the target molecule. Such modifications may include 5-methyl-cytidine, 2,6-di-amino-purine, 2'-fluorine, phosphorothioate or locked nucleic acid.

[0311] Table 4. Primers and probes

[0312]

[0313]

[0314] *UFP is the universal forward primer; URP is the universal reverse primer.

[0315] In one embodiment, the cDNA may be submitted for sequencing analysis before undergoing transcription.

[0316] mRNA production

[0317] Methods for mRNA or mmRNA may include, but are not limited to, in vitro transcription, cDNA template removal and RNA cleanup, and mRNA capping and / or tailing reactions.

[0318] In vitro transcription

[0319] The cDNA produced in the previous step can be transcribed using an in vitro transcription (IVT) system. The system typically includes a transcription buffer, nucleotide triphosphates (NTPs), an RNase inhibitor, and a polymerase. NTPs can be homemade, can be selected from suppliers, or can be synthesized as described herein. NTPs can be selected from, but are not limited to, those described herein, including natural and non-natural (modified) NTPs. Polymerases can be selected from, but are not limited to, T7 RNA polymerase, T3 RNA polymerase, and mutant polymerases such as, but not limited to, polymerases that can be incorporated into modified nucleic acids.

[0320] RNA polymerase

[0321] Any number of RNA polymerases or variants may be used in the design of the primary constructs of the present invention.

[0322] RNA polymerases can be modified by inserting or deleting amino acids into the RNA polymerase sequence. As a non-limiting example, RNA polymerases can be modified to exhibit increased ability to incorporate 2' modified nucleotide triphosphates compared to unmodified RNA polymerases (see International Publication No. WO2008078180 and U.S. Pat. No. 8,101,385; herein incorporated by reference in their entirety).

[0323] Variant can be obtained by evolving RNA polymerase, optimizing RNA polymerase amino acid and / or nucleotide sequence and / or by using other methods known in the art. As non-limiting examples, T7 RNA polymerase variant can use the continuous directed evolution system proposed by Esvelt et al. (Nature (2011) 472 (7344): 499-503; Incorporated herein in its entirety by reference) evolve, wherein the clone of T7 RNA polymerase can encode at least one sudden change, such as, but not limited to, the lysine at position 93 is replaced by threonine (K93T), I4M, A7T, E63V, V64D, A65E, D66Y, T76N, C125R, S128R, A136T, N165S, G175R, H176L, Y178H, F182L, L196F, G198V , D208Y, E222K, S228A, Q239R, T243N, G259D, M267I, G280C, H300R, D351A, A354S, E356D, L360P, A383V, Y385C, D388Y, S397R, M401T, N410S, K450R, P451T, G452V, E484A, H523L, H524N, G542V, E565K, K577E, K577M, N601S, S684Y, L699I, K713E, N748D, Q754R, E775K, A827V, D851N, or L864F. As another non-limiting example, a T7 RNA polymerase variant may encode at least one mutation as described in U.S. Publication Nos. 20100120024 and 20070117112, which are incorporated herein by reference in their entirety. Variants of RNA polymerases may also include, but are not limited to, substitution variants, conservative amino acid substitutions, insertion variants, deletion variants, and / or covalent variants.

[0324] In one embodiment, the primary construct can be designed to be recognized by wild-type or variant RNA polymerases. In doing so, the primary construct can be modified to include sites or regions of sequence variation from the wild-type or parent primary construct.

[0325] In one embodiment, the primary construct can be designed to contain at least one substitution and / or insertion upstream of the RNA polymerase binding or recognition site, downstream of the RNA polymerase binding or recognition site, upstream of the TATA box sequence, downstream of the TATA box sequence of the primary construct but upstream of the coding region of the primary construct, within the 5'UTR, before the 5'UTR and / or after the 5'UTR.

[0326] In one embodiment, the 5'UTR of the primary construct can be replaced by the insertion of at least one region and / or string of nucleotides of the same base. The region and / or string of nucleotides can include, but are not limited to, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 nucleotides and the nucleotides can be natural and / or non-natural. As a non-limiting example, the group of nucleotides can include strings of 5 to 8 adenines, cytosines, thymines, any other nucleotides disclosed herein, and / or combinations thereof.

[0327] In one embodiment, the 5'UTR of the primary construct can be replaced by the insertion of at least two regions and / or strings of nucleotides of two different bases, such as, but not limited to, adenine, cytosine, thymine, any other nucleotide disclosed herein, and / or combinations thereof. For example, the 5'UTR can be replaced by inserting 5 to 8 adenine bases followed by 5 to 8 cytosine bases. In another example, the 5'UTR can be replaced by inserting 5 to 8 cytosine bases followed by 5 to 8 adenine bases.

[0328] In one embodiment, primary construct may include at least one replacement and / or insertion in the transcription start site downstream that can be identified by RNA polymerase.As non-limiting examples, at least one replacement and / or insertion can occur in the downstream of the transcription start site by replacing at least one nucleic acid in the district close to the transcription start site downstream (such as but not limited to +1 to +6).The change in the district of the nucleic acid acid close to the transcription start site downstream can affect the initial rate, increase the apparent nucleotide triphosphate (NTP) reaction constant value and increase the dissociation of short transcript and transcription complex so as to eliminate (curing) initial transcription (Brieba et al., Biochemistry (2002) 41:5144-5149; Incorporated herein in its entirety by reference).The modification, replacement and / or insertion of at least one nucleic acid can cause the silent mutation of nucleotide sequence or can cause the sudden change in amino acid sequence.

[0329] In one embodiment, the primary construct may include the substitution of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, or at least 13 guanine bases downstream of the transcription start site.

[0330] In one embodiment, primary construct can comprise the replacement of at least 1, at least 2, at least 3, at least 4, at least 5 or at least 6 guanine bases in the district just downstream of the transcription start site.As non-limiting examples, if the nucleotide in the described district is GGGAGA, the guanine base can be replaced by at least 1, at least 2, at least 3 or at least 4 adenine nucleotides so.In another non-limiting examples, if the nucleotide in the described district is GGGAGA, the guanine base can be replaced by at least 1, at least 2, at least 3 or at least 4 cytosine bases so.In another non-limiting examples, if the nucleotide in the described district is GGGAGA, the guanine base can be replaced by at least 1, at least 2, at least 3 or at least 4 thymine and / or any nucleotide described herein so.

[0331] In one embodiment, primary construct can comprise at least one replacement and / or insertion of the start codon upstream.For the sake of clarity, it will be understood by those skilled in the art that the start codon is first codon in the protein coding region, and the transcription start site is the site at which transcription begins.Primary construct can include but is not limited to at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 or at least 8 replacements and / or insertions of nucleotide bases.Nucleotide base can insert or replace at 1, at least 1, at least 2, at least 3, at least 4 or at least 5 positions upstream of the start codon.The nucleotide inserted and / or replaced can be identical base (for example, all A or all C or all T or all G), two different bases (for example, A and C, A and T or C and T), three different bases (for example, A, C and T or A, C and T) or at least four different bases. As non-limiting examples, the guanine base upstream of the coding region in the primary construct can be replaced by adenine, cytosine, thymine or any nucleotide described herein. In another non-limiting example, the replacement of the guanine base in the primary construct can be designed to remain in the district downstream of the transcription start site and a guanine base before the start codon (see Esvelt et al. Nature (2011) 472 (7344): 499-503; Incorporated herein as a whole by reference). As non-limiting examples, at least 5 nucleotides can be inserted into 1 position upstream of the transcription start site but upstream of the start codon and the at least 5 nucleotides can be the same base type.

[0332] cDNA template removal and purification

[0333] The cDNA template can be removed using methods known in the art such as, but not limited to, treatment with deoxyribonuclease I (DNase I). RNA cleanup can also include purification methods such as, but not limited to, those from Beckman Coulter (Danvers, MA). System, HPLC-based purification methods, such as but not limited to strong anion exchange HPLC, weak anion exchange HPLC, reversed phase HPLC (RP-HPLC) and hydrophobic interaction HPLC (HIC-HPLC).

[0334] Capping and / or tailing reactions

[0335] The primary construct or mmRNA may also undergo a capping and / or tailing reaction. The capping reaction can be performed by methods known in the art to add a 5' cap to the 5' end of the primary construct. Methods for capping include, but are not limited to, using vaccinia capping enzyme (New England Biolabs, Ipswich, MA).

[0336] The poly-A tailing reaction can be performed by methods known in the art such as, but not limited to, 2'O-methyltransferase and methods as described herein. If the primary construct generated from the cDNA does not include poly-T, it may be beneficial to perform the poly-A tailing reaction before cleaning up the primary construct.

[0337] mRNA purification

[0338] Primary construct or mmRNA purification may include but is not limited to mRNA or mmRNA purification, quality assurance and quality control. mRNA or mmRNA purification may be performed by methods known in the art such as but not limited to Beads (Beckman Coulter Genomics, Danvers, MA), poly-T beads, LNA TM oligo-T capture probe ( Inc, Vedbaek, Denmark), or HPLC-based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC). The term "purified" when used with respect to polynucleotides, such as "purified mRNA or mmRNA," refers to polynucleotides that are separated from at least one contaminant. As used herein, a "contaminant" is any substance that makes another substance unsuitable, impure, or of low quality. Thus, purified polynucleotides (e.g., DNA and RNA) are present in a form or arrangement that is different from that in which they are found in nature, or in a form or arrangement that is different from that which existed before they were subjected to a treatment or purification method.

[0339] Quality assurance and / or quality control checks may be performed using methods such as, but not limited to, gel electrophoresis, UV absorbance, or analytical HPLC.

[0340] In another embodiment, the mRNA or mmRNA may be sequenced by methods including, but not limited to, reverse transcriptase PCR.

[0341] In one embodiment, mRNA or mmRNA can be quantified using methods such as, but not limited to, ultraviolet visible spectroscopy (UV / Vis). A non-limiting example of a UV / Vis spectrometer is Spectrometer (ThermoFisher, Waltham, MA). The quantified mRNA or mmRNA can be analyzed to determine whether the mRNA or mmRNA is of the appropriate size and to check that no degradation of the mRNA or mmRNA has occurred. Degradation of the mRNA or mmRNA can be checked by methods such as, but not limited to, agarose gel electrophoresis, HPLC-based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC), liquid chromatography-mass spectrometry (LCMS), capillary electrophoresis (CE), and capillary gel electrophoresis (CGE).

[0342] signal sequence

[0343] The primary construct or mmRNA may also encode additional features that help transport the polypeptide to therapeutically relevant sites. One such feature that helps protein transport is a signal sequence. As used herein, a "signal sequence" or "signal peptide" is a polynucleotide or polypeptide of about 9 to 200 nucleotides (3 to 60 nucleic acids) in length, respectively, that is incorporated into the 5' (or N-terminus) of the coding region or the encoded polypeptide, respectively. Adding these sequences allows the encoded polypeptide to be transported to the endoplasmic reticulum through one or more secretory pathways. Some signal sequences are cleaved from the protein by a signal peptidase after the protein is transported.

[0344] Table 5 is a representative list of protein signal sequences that may be incorporated for encoding by the polynucleotides, primary constructs, or mmRNA of the present invention.

[0345] Table 5. Signal sequence

[0346]

[0347]

[0348]

[0349]

[0350]

[0351]

[0352]

[0353] In the table, SS is the secretion signal and MLS is the mitochondrial leader signal. The primary constructs or mmRNA of the present invention can be designed to encode any signal sequence of SEQ ID NOs 94 to 155, or fragments or variants thereof. These sequences can be included at the beginning, middle, or end of the polypeptide coding region or alternatively in the flanking regions. In addition, any polynucleotide primary construct of the present invention may also contain one or more sequences defined by SEQ ID NOs 32-93. These can be in the first region or in any of the flanking regions.

[0354] Additional signal sequences that can be used in the present invention include those taught, for example, in databases such as those found at http: / / www.signalpeptide.de / or http: / / proline.bic.nus.edu.sg / spdb / . Those described in U.S. Patents 8,124,379, 7,413,875, and 7,385,034 are also within the scope of the present invention, and the contents of each of the patents are incorporated herein by reference in their entirety.

[0355] Target selection

[0356] According to the present invention, the primary construct comprises at least a first region of linked nucleosides encoding at least one polypeptide of interest. The polypeptides of interest or "targets" or proteins and peptides of the present invention are listed in Table 6 of the following co-pending applications: U.S. Provisional Patent Application No. 61 / 618,862, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Biologics; U.S. Provisional Patent Application No. 61 / 681,645, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Biologics; U.S. Provisional Patent Application No. 61 / 737,130, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Biologics; U.S. Provisional Patent Application No. 61 / 618,866, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Antibodies; U.S. Provisional Patent Application No. 61 / 681,645, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Biologics; U.S. Provisional Patent Application No. 61 / 681,647, entitled "Modified Polynucleotides for the Production of Antibodies," filed December 14, 2012, U.S. Provisional Patent Application No. 61 / 737,134, entitled "Modified Polynucleotides for the Production of Antibodies," filed April 2, 2012, U.S. Provisional Patent Application No. 61 / 618,868, entitled "Modified Polynucleotides for the Production of Vaccines," filed August 10, 2012, U.S. Provisional Patent Application No. 61 / 681,648, entitled "Modified Polynucleotides for the Production of Vaccines," filed December 14, 2012, U.S. Provisional Patent Application No. 61 / 737,135, entitled "Modified Polynucleotides for the Production of Vaccines," filed April 2, 2012,873, U.S. Provisional Patent Application No. 61 / 681,650, filed on August 10, 2012, entitled Modified Polynucleotides for the Production of Secreted Proteins, U.S. Provisional Patent Application No. 61 / 737,147, filed on December 14, 2012, entitled Modified Polynucleotides for the Production of Secreted Proteins, U.S. Provisional Patent Application No. 61 / 618,878, filed on April 2, 2012, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, U.S. Provisional Patent Application No. 61 / 681,654, filed on August 10, 2012, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, and U.S. Provisional Patent Application No. 61 / 681,654, filed on December 14, 2012, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins. and U.S. Provisional Patent Application No. 61 / 737,152, entitled Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins, filed on April 2, 2012; U.S. Provisional Patent Application No. 61 / 618,885, entitled Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins, filed on August 10, 2012; and U.S. Provisional Patent Application No. 61 / 681,658, entitled Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins, filed on December 14, 2012.155. U.S. Provisional Patent Application No. 61 / 618,896, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins; U.S. Provisional Patent Application No. 61 / 668,157, filed July 5, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins; U.S. Provisional Patent Application No. 61 / 681,661, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins; U.S. Provisional Patent Application No. 61 / 737,160, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins; U.S. Provisional Patent Application No. 61 / 737,160, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Nuclear U.S. Provisional Patent Application No. 61 / 618,911, entitled "Modified Polynucleotides for the Production of Nuclear Proteins," filed on August 10, 2012; U.S. Provisional Patent Application No. 61 / 681,667, entitled "Modified Polynucleotides for the Production of Nuclear Proteins," filed on December 14, 2012; U.S. Provisional Patent Application No. 61 / 737,168, entitled "Modified Polynucleotides for the Production of Nuclear Proteins," filed on April 2, 2012; U.S. Provisional Patent Application No. 61 / 618,922, entitled "Modified Polynucleotides for the Production of Proteins," filed on August 10, 2012; and U.S. Provisional Patent Application No. 61 / 681, entitled "Modified Polynucleotides for the Production of Proteins."675, U.S. Provisional Patent Application No. 61 / 737,174, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Proteins, U.S. Provisional Patent Application No. 61 / 618,935, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 681,687, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 737,184, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 618,935, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease Disease, U.S. Provisional Patent Application No. 61 / 618,945, filed on August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 681,696, filed on August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, U.S. Provisional Patent Application No. 61 / 737,191, filed on December 14, 2012, and U.S. Provisional Patent Application No. 61 / 618, filed on April 2, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease.953. U.S. Provisional Patent Application No. 61 / 681,704, filed on August 10, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease; U.S. Provisional Patent Application No. 61 / 737, filed on December 14, 2012, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease;203. International application number PCT / US2013 / 030062, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Biologics and Proteins Associated with Human Disease; International application number PCT / US2013 / 030064, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Secreted Proteins; International application number PCT / US2013 / 030059, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Membrane Proteins; International application number PCT / US2013 / 030066, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins; International application number PCT / US2013 / 030067, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Nuclear and PCT / US2013 / 030061, filed on March 9, 2013, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease; and Tables 6 and 7 of the following co-pending applications: U.S. Provisional Patent Application No. 61 / 681, filed on August 10, 2012, entitled Modified Polynucleotides for the Production of Cosmetic Proteins and Peptides;720, U.S. Provisional Patent Application No. 61 / 737,213, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Cosmetic Proteins and Peptides, U.S. Provisional Patent Application No. 61 / 681,742, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides, and International Application No. PCT / US2013 / 030070, filed March 9, 2013, entitled Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides; Tables 6, 178, and 179 of the following co-pending applications: and Peptides; in Tables 6, 28, and 29 of co-pending U.S. Provisional Patent Application No. 61 / 618,870, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides; in Tables 6, 56, and 57 of co-pending U.S. Provisional Patent Application No. 61 / 681,649, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides; and in Tables 6, 186, and 187 of co-pending U.S. Provisional Patent Application No. 61 / 737, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides.139; and in Tables 6, 185, and 186 of the co-pending International Application No. PCT / US2013 / 030063, filed March 9, 2013, entitled Modified Polynucleotides; the contents of each of which are incorporated herein by reference in their entirety.

[0357] As a non-limiting example, the targets of the present invention are shown in Table 6, which, in addition to the name and description of the gene encoding the polypeptide of interest, also includes the ENSEMBL transcript ID (ENST), the sequence number of the referenced application, and the target number mentioned in the referenced application for the description of the target. Sequences related to the targets listed in Table 6 of co-pending International Application No. PCT / US2013 / 030062, filed March 9, 2013, entitled Modified Polynucleotides for the Production of Biologics and Proteins Associated with Human Disease, International Application No. PCT / US2013 / 030061, filed March 9, 2013, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease, International Application No. PCT / US2013 / 030068, filed March 9, 2013, entitled Modified Polynucleotides for the Production of Cosmetic Proteins and Peptides, and International Application No. PCT / US2013 / 030070, filed March 9, 2013, entitled Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides, are incorporated herein by reference in their entireties. For any particular gene, one or more variants or isoforms may exist. When these exist, they are also shown in the table. Those skilled in the art will understand that what is disclosed in the table are potential flanking regions. These are encoded in each ENST transcript 5' (upstream) or 3' (downstream) of the ORF or coding region. The coding region is explicitly and specifically disclosed by teaching the ENSP sequence. Therefore, the sequences taught to flank the protein-encoding sequence are considered flanking regions. It is also possible to further characterize the 5' and 3' flanking regions by using one or more available databases or algorithms. Databases annotate the features contained in the flanking regions of ENST transcripts and these are available in the art.

[0358] Table 6. Targets

[0359]

[0360]

[0361]

[0362]

[0363]

[0364]

[0365]

[0366]

[0367] Protein cleavage signals and sites

[0368] In one embodiment, the polypeptide of the present invention may include at least one protein cleavage signal comprising at least one protein cleavage site. The protein cleavage site may be located at the N-terminus, the C-terminus, any space between the N-terminus and the C-terminus, such as, but not limited to, in the middle between the N-terminus and the C-terminus, between the N-terminus and the midpoint, between the midpoint and the C-terminus, and combinations thereof.

[0369] The polypeptides of the present invention may include, but are not limited to, proprotein convertase (or prohormone convertase), thrombin, or factor Xa protein cleavage signals. Proprotein convertases are a family of nine proteases comprising seven basic amino acid-specific subtilisin-like serine proteases related to yeast kexins, designated prohormone convertases 1 / 3 (PC1 / 3), PC2, furin, PC4, PC5 / 6, paired basic amino acid cleavage enzyme 4 (PACE4), and PC7; and two other subtilases that cleave at non-basic residues, designated subtilisin kexin isozyme 1 (SKI-1) and proprotein convertase subtilisin kexin 9 (PCSK9). Non-limiting examples of protein cleavage signal amino acid sequences are listed in Table 7. In Table 7, "X" refers to any amino acid, "n" can be 0, 2, 4, or 6 amino acids, and "*" refers to a protein cleavage site. In Table 7, SEQ ID NO: 158 refers to when n = 4 and SEQ ID NO: 159 refers to when n = 6.

[0370] Table 7. Protein cleavage site sequences

[0371]

[0372] In one embodiment, the primary constructs and mmRNA of the present invention can be engineered such that the primary constructs or mmRNA contain at least one encoded protein cleavage signal. The encoded protein cleavage signal can be located before the start codon, after the start codon, before the coding region, within the coding region, such as, but not limited to, in the middle of the coding region, between the start codon and the midpoint, between the midpoint and the stop codon, after the coding region, before the stop codon, between two stop codons, after the stop codon, and combinations thereof.

[0373] In one embodiment, the primary constructs or mmRNA of the present invention may include at least one encoded protein cleavage signal containing at least one protein cleavage site. The encoded protein cleavage signal may include, but is not limited to, proprotein convertase (or prohormone convertase), thrombin, and / or Factor Xa protein cleavage signals. One skilled in the art can use Table 1 above or other known methods to determine appropriate encoded protein cleavage signals for inclusion in the primary constructs or mmRNA of the present invention. For example, starting with the signals in Table 7 and taking into account the codons in Table 1, signals for the primary constructs that can generate protein signals in the resulting polypeptide can be designed.

[0374] In one embodiment, the polypeptides of the invention include at least one protein cleavage signal and / or site.

[0375] As non-limiting examples, U.S. Patent No. 7,374,930 and U.S. Publication No. 20090227660 (incorporated herein by reference in their entireties) use a furin cleavage site to cleave the N-terminal methionine of GLP-1 in an expression product from the Golgi apparatus of a cell. In one embodiment, a polypeptide of the invention includes at least one protein cleavage signal and / or site, provided that the polypeptide is not GLP-1.

[0376]

[00146] In one embodiment, the primary constructs or mmRNA of the present invention include at least one encoded protein cleavage signal and / or site.

[0377]

[00146] In one embodiment, the primary construct or mmRNA of the present invention includes at least one encoded protein cleavage signal and / or site, with the proviso that the primary construct or mmRNA does not encode GLP-1.

[0378] In one embodiment, the primary constructs or mmRNA of the present invention may include more than one coding region. Where multiple coding regions are present in the primary constructs or mmRNA of the present invention, the multiple coding regions may be separated by encoded protein cleavage sites. As a non-limiting example, the primary constructs or mmRNA may be represented in the form of an ordered pattern. One such pattern follows the form AXBY, wherein A and B are coding regions that may be the same or different coding regions and / or may encode the same or different polypeptides, and X and Y are encoded protein cleavage signals that may encode the same or different protein cleavage signals. A second such pattern follows the form AXYBZ, wherein A and B are coding regions that may be the same or different coding regions and / or may encode the same or different polypeptides, and X, Y, and Z are encoded protein cleavage signals that may encode the same or different protein cleavage signals. A third pattern follows the form ABXCY, wherein A, B, and C are coding regions that may be the same or different coding regions and / or may encode the same or different polypeptides, and X and Y are encoded protein cleavage signals that may encode the same or different protein cleavage signals.

[0379] In one embodiment, the polypeptides, primary constructs, and mmRNA may further comprise a sequence encoding a protein cleavage site, such that the polynucleotides, primary constructs, and mmRNA can be released from the carrier region or fusion partner by treatment with a protease specific for the protein cleavage site.

[0380] In one embodiment, the polypeptides, primary constructs, and mmRNA of the present invention may include a sequence encoding a 2A peptide. In one embodiment, this sequence can be used to separate the coding regions of two or more target polypeptides. As a non-limiting example, the sequence encoding the 2A peptide may be between coding region A and coding region B (A-2Apep-B). The presence of the 2A peptide will cause a long protein to be broken down into protein A, protein B, and 2A peptide. Protein A and protein B may be the same or different target polypeptides. In another embodiment, the 2A peptide can be used in the polynucleotides, primary constructs, and / or mmRNA of the present invention to produce two, three, four, five, six, seven, eight, nine, ten, or more proteins.

[0381] Incorporation of post-transcriptional control regulators

[0382] In one embodiment, the polynucleotides, primary constructs, and / or mmRNA of the present invention may include at least one post-transcriptional control modulator. These post-transcriptional control modulators may be, but are not limited to, small molecules, compounds, and regulatory sequences. As non-limiting examples, post-transcriptional control may be performed using small molecules identified by PTC Therapeutics Inc. (South Plainfield, NJ), using their GEMS TM(Gene Expression Modulation from Small-Molecules) screening technology to achieve this.

[0383] Post-transcriptional control modulators can be gene expression modulators screened by the methods detailed in International Publication No. WO2006022712 or the gene expression modulators described, which are incorporated herein by reference in their entirety. Methods for identifying RNA regulatory sequences involved in translational control are described in International Publication No. WO2004067728, which is incorporated herein by reference in its entirety; methods for identifying compounds that modulate the untranslated region-dependent expression of a gene are described in International Publication No. WO2004065561, which is incorporated herein by reference in its entirety.

[0384]

[00146] In one embodiment, the polynucleotides, primary constructs, and / or mmRNA of the invention may include at least one post-transcriptional control regulator located in the 5' and / or 3' untranslated region of the polynucleotides, primary constructs, and / or mmRNA of the invention.

[0385] In another embodiment, the polynucleotides, primary constructs and / or mmRNA of the present invention may include at least one post-transcriptional control regulator to regulate premature translation termination. The post-transcriptional control regulator may be a compound described in International Publication Nos. WO2004010106, WO2006044456, WO2006044682, WO2006044503, and WO2006044505, or a compound discovered by the methods outlined in the international publications, each of which is incorporated herein by reference in its entirety. As a non-limiting example, the compound may bind to a region of 28S ribosomal RNA to regulate premature translation termination (see, for example, WO2004010106, incorporated herein by reference in its entirety).

[0386] In one embodiment, the polynucleotides, primary constructs, and / or mmRNA of the present invention may include at least one post-transcriptional control regulator to alter protein expression. As a non-limiting example, VEGF expression may be modulated using compounds described in International Publication Nos. WO2005118857, WO2006065480, WO2006065479, and WO2006058088, or compounds discovered by the methods described therein, each of which is incorporated herein by reference in its entirety.

[0387] The polynucleotides, primary constructs, and / or mmRNA of the present invention may include at least one post-transcriptional control regulator to control translation. In one embodiment, the post-transcriptional control regulator may be an RNA regulatory sequence. As a non-limiting example, RNA regulatory sequences can be identified by the methods described in International Publication No. WO2006071903, which is incorporated herein by reference in its entirety.

[0388] III. Modification

[0389] As used herein, in the context of a polynucleotide (e.g., a primary construct or an mRNA molecule), the term "modification" or, where appropriate, "modified" refers to modifications relative to A, G, U, or C ribonucleotides. Generally, in this context, these terms are not intended to refer to ribonucleotide modifications in the naturally occurring 5' terminal mRNA cap moiety. In the context of a polypeptide, the term "modification" refers to modifications as compared to the canonical set of 20 amino acid moieties).

[0390] The modifications can be various modifications. In some embodiments, the coding region, flanking regions, and / or terminal regions may comprise one, two, or more (optionally different) nucleoside or nucleotide modifications. In some embodiments, the modified polynucleotide, primary construct, or mmRNA introduced into the cell may exhibit reduced degradation in the cell compared to the unmodified polynucleotide, primary construct, or mmRNA.

[0391] Polynucleotides, primary constructs, and mmRNA may include any useful modifications, such as modifications to sugars, nucleobases, or internucleoside linkages (e.g., to linkages to phosphates / to phosphodiester linkages / to phosphodiester backbones). One or more atoms of a pyrimidine nucleobase may be replaced or substituted with an optionally substituted amino group, an optionally substituted thiol group, an optionally substituted alkyl group (e.g., methyl or ethyl) or a halo group (e.g., chloro or fluoro). In certain embodiments, modifications (e.g., one or more modifications) may be present in each of the sugar and internucleoside linkages. Modifications according to the present invention may be modifications of ribonucleic acid (RNA) to deoxyribonucleic acid (DNA), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA), or hybrids thereof. Additional modifications are described herein.

[0392] As described herein, the polynucleotides, primary constructs, and mmRNA of the present invention do not substantially induce an innate immune response in the cells into which the mRNA is introduced. Characteristics of the induced innate immune response include 1) increased expression of proinflammatory cytokines, 2) activation of intracellular PRRs (RIG-I, MDA5, etc.), and / or 3) termination or reduction of protein translation.

[0393] In certain embodiments, it may be desirable that intracellular degradation is introduced into the modified nucleic acid molecule in the cell. For example, if the precise timing of protein production is required, the degradation of the modified nucleic acid molecule may be preferred. Therefore, in some embodiments, the invention provides a modified nucleic acid molecule containing a degradation domain, which can be acted upon in a directed manner within the cell. On the other hand, the disclosure provides polynucleotides comprising nucleosides or nucleotides, which can destroy the combination of a major groove effect (e.g., in combination) partner with the polynucleotides (e.g., wherein the modified nucleotides have a reduced binding affinity to the major groove effect partner compared to unmodified nucleotides).

[0394] Polynucleotides, primary constructs, and mmRNA may optionally include other agents (e.g., RNAi-inducing agents, RNAi agents, siRNA, shRNA, miRNA, antisense RNA, ribozymes, catalytic DNA, tRNA, RNA that induces triple helix formation, aptamers, vectors, etc.). In some embodiments, polynucleotides, primary constructs, or mmRNA may include one or more messenger RNAs (mRNAs) and one or more modified nucleosides or nucleotides (e.g., mmRNA molecules). Details of these polynucleotides, primary constructs, and mmRNA are provided below.

[0395] Polynucleotides and primary constructs

[0396] The polynucleotides, primary constructs, and mmRNA of the present invention include a first region of linked nucleosides encoding a polypeptide of interest, a first flanking region located at the 5' end of the first region, and a second flanking region located at the 3' end of the first region.

[0397] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) includes n number of linked nucleosides having Formula (Ia) or Formula (Ia-1):

[0398]

[0399] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0400] in

[0401] U is O, S, N (R U ) nu or C(R U ) nu , where nu is an integer from 0 to 2 and each R U are independently H, halo or optionally substituted alkyl;

[0402] --- is a single key or does not exist;

[0403] R 1’ 、R 2′ 、R 1” 、R 2” 、R 1 、R 2 、R 3 、R 4 and R 5 each independently represents, if present, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; wherein the combination of R3 with one or more of R1′, R1″, R2′, R2″, or R5 (e.g., the combination of R1′ with R3, the combination of R1″ with R3, the combination of R2′ with R3, the combination of R2″ with R3) or a combination of R5 and R3) can be joined together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); wherein the combination of R5 and one or more of R1′, R1″, R2′, or R2″ (e.g., the combination of R1′ and R5, the combination of R1″ and R5, the combination of R2′ and R5, or the combination of R2″ and R5) can be joined together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); and wherein R 4 With R 1’ 、R 1” 、R 2′ 、R 2” 、R 3 or R 5 and m' and m" are each independently an integer from 0 to 3 (e.g., from 0 to 2, from 0 to 1, from 1 to 3, or from 1 to 2);

[0404] Y 1 、Y 2 and Y 3 Each independently is O, S, Se, -NR N1 -, optionally substituted alkylene or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent;

[0405] Each Y 4 is independently H, hydroxy, thiol, borane, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;

[0406] Each Y 5 is independently O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene;

[0407] n is an integer from 1 to 100,000; and

[0408] B is a nucleobase (eg, purine, pyrimidine, or a derivative thereof), wherein B and R 1’ Combination of B and R 2′ Combination of B and R 1” A combination of B and R 2” The combination of can optionally form a bicyclic group (e.g., a bicyclic heterocyclic group) together with the carbon atoms to which they are attached or wherein B, R 1” and R 3 Combination of B, R 2” and R 3 The combination of can optionally form a tricyclic or tetracyclic group (e.g., a tricyclic or tetracyclic heterocyclic group, as in Formulas (IIo)-(IIp) herein). In some embodiments, the polynucleotide, primary construct, or mmRNA includes a modified ribose sugar. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (Ia-2) to (Ia-5); or a pharmaceutically acceptable salt or stereoisomer thereof.

[0409]

[0410] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (Ib) or Formula (Ib-1):

[0411] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0412] in

[0413] U is O, S, N (R U ) nu or C(R U ) nu, where nu is an integer from 0 to 2 and each R U are independently H, halo or optionally substituted alkyl;

[0414] --- is a single key or does not exist;

[0415] R 1 、R 3′ 、R 3” and R 4 each independently represents H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; and wherein R 1 With R 3′ A combination of or 1 With R 3” Combinations of can be taken together to form optionally substituted alkylene or optionally substituted heteroalkylene (e.g., to produce locked nucleic acids);

[0416] Each R 5 is independently H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, or absent;

[0417] Y 1 、Y 2 and Y 3 Each independently is O, S, Se, -NR N1 -, optionally substituted alkylene or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aryl;

[0418] Each Y 4 is independently H, hydroxy, thiol, borane, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;

[0419] n is an integer from 1 to 100,000; and

[0420] B is a nucleobase.

[0421] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) includes n number of linked nucleosides having Formula (Ic):

[0422] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0423] in

[0424] U is O, S, N (R U ) nu or C(R U ) nu , where nu is an integer from 0 to 2 and each R U are independently H, halo or optionally substituted alkyl;

[0425] --- is a single key or does not exist;

[0426] B 1 、B 2 and B 3 each independently represents a nucleobase (e.g., a purine, pyrimidine, or a derivative thereof, as described herein), H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl, wherein B 1 、B 2 and B 3 One and only one of is a nucleobase;

[0427] R b1 、R b2 、R b3 、R 3 and R 5 each independently represents H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl;

[0428] Y 1 、Y 2 and Y 3 Each independently is O, S, Se, -NR N1 -, optionally substituted alkylene or optionally substituted heteroalkylene, wherein R N1is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aryl;

[0429] Each Y 4 is independently H, hydroxy, thiol, borane, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;

[0430] Each Y 5 is independently O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene;

[0431] n is an integer from 1 to 100,000; and

[0432] The ring in which U is included may include one or more double bonds.

[0433] In a specific embodiment, the ring including U does not have a U-CB 3 R b3 Between or CB 3 R b3 -C B2 R b2 Double bonds between.

[0434] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) includes n number of linked nucleosides having Formula (Id):

[0435] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0436] in

[0437] U is O, S, N (R U ) nu or C(R U ) nu , where nu is an integer from 0 to 2 and each R U are independently H, halo or optionally substituted alkyl;

[0438] Each R 3 is independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl;

[0439] Y 1 、Y 2 and Y 3 Each independently is O, S, Se, -NR N1 -, optionally substituted alkylene or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aryl;

[0440] Each Y 4 is independently H, hydroxy, thiol, borane, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;

[0441] Each Y 5 is independently O, S, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene;

[0442] n is an integer from 1 to 100,000; and

[0443] B is a nucleobase (eg, purine, pyrimidine, or a derivative thereof).

[0444] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) includes n number of linked nucleosides having Formula (Ie):

[0445] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0446] in

[0447] U' and U" are each independently O, S, N(R U ) nu or C(R U ) nu , where nu is an integer from 0 to 2 and each R U are independently H, halo or optionally substituted alkyl;

[0448] Each R 6 is independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl;

[0449] Each Y5′ is independently O, S, optionally substituted alkylene (e.g., methylene or ethylene), or optionally substituted heteroalkylene;

[0450] n is an integer from 1 to 100,000; and

[0451] B is a nucleobase (eg, purine, pyrimidine, or a derivative thereof).

[0452] In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) includes n number of linked nucleosides having Formula (If) or Formula (If-1):

[0453] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0454] in

[0455] U' and U" are each independently O, S, N, N(R U ) nu or C(R U ) nu , where nu is an integer from 0 to 2 and each R U is independently H, halo, or optionally substituted alkyl (eg, U' is O and U" is N);

[0456] --- is a single key or does not exist;

[0457] R 1’ 、R 2′ 、R 1” 、R 2” 、R 3 and R 4 each independently represents H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; and wherein R 1’ With R 3 Combination of R 1” With R 3 Combination of R 2’ With R 3 A combination of or 2” With R 3 combinations of can be taken together to form optionally substituted alkylene or optionally substituted heteroalkylene (e.g., to produce locked nucleic acids); m' and m" are each independently an integer from 0 to 3 (e.g., from 0 to 2, from 0 to 1, from 1 to 3, or from 1 to 2);

[0458] Y 1 、Y 2 and Y 3 Each independently is O, S, Se, -NR N1 -, optionally substituted alkylene or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent;

[0459] Each Y 4 is independently H, hydroxy, thiol, borane, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;

[0460] Each Y 5 is independently O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene;

[0461] n is an integer from 1 to 100,000; and

[0462] B is a nucleobase (eg, purine, pyrimidine, or a derivative thereof).

[0463] In some embodiments of the polynucleotide, primary construct, or mmRNA (e.g., Formulas (Ia), (Ia-1) to (Ia-3), (Ib) to (If), and (IIa) to (IIp)), the ring including U has one or two double bonds.

[0464] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), R 1 、R 1’ and R 1” Each (if present) is H. In other embodiments, R 2 、R 2′ and R 2” Each (if present) is independently H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In specific embodiments, alkoxyalkoxy is -(CH2) s2 (OCH2CH2) s1 (CH2)s3 OR', wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and R' is H or C 1-20 In some embodiments, s2 is 0, s1 is 1 or 2, s3 is 0 or 1, and R' is C 1-6 alkyl.

[0465] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), R 2 、R 2’ and R 2” Each (if present) is H. In other embodiments, R 1 、R 1′ and R 1” Each (if present) is independently H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In specific embodiments, alkoxyalkoxy is -(CH2) s2 (OCH2CH2) s1 (CH2) s3 OR', wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and R' is H or C 1-20 In some embodiments, s2 is 0, s1 is 1 or 2, s3 is 0 or 1, and R' is C 1-6 alkyl.

[0466] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), R 3 、R 4 and R 5 Each is independently H, halo (e.g., fluoro), hydroxy, optionally substituted alkyl, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In specific embodiments, R3 H, R 4 H, R 5 H, or R 3 、R 4 and R 5 are all H. In a specific embodiment, R 3 C 1-6 Alkyl, R 4 C 1-6 Alkyl, R 5 C 1-6 Alkyl, or R 3 、R 4 and R 5 All are C 1-6 In a specific embodiment, R 3 and R 4 Both are H, and R 5 C 1-6 alkyl.

[0467] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), R 3 and R 5 are joined together to form an optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbon atoms to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl such as a trans-3′,4′ analog wherein R 3 and R 5 are linked together to form heteroalkylene (e.g., -(CH2) b1 O(CH2) b2 O(CH2) b3 -, wherein b1, b2 and b3 are each independently an integer from 0 to 3).

[0468] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), R 3 With R 1’ 、R 1” 、R 2′ 、R 2” or R 5One or more of the following are joined together to form an optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbon atoms to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl, R 3 With R 1’ 、R 1” 、R 2′ 、R 2” or R 5 One or more of the groups are linked together to form a heteroalkylene group (e.g., -(CH2) b1 O(CH2) b2 O(CH2) b3 -, wherein b1, b2 and b3 are each independently an integer from 0 to 3).

[0469] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), R 5 With R 1’ 、R 1” 、R 2′ or R 2” One or more of the following are joined together to form an optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbon atoms to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl, R 5 With R 1’ 、R 1” 、R 2′ or R 2” One or more of the groups are linked together to form a heteroalkylene group (e.g., -(CH2) b1 O(CH2) b2 O(CH2) b3 -, wherein b1, b2 and b3 are each independently an integer from 0 to 3).

[0470] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), each Y 2 are independently O, S or -NR N1 -, where R N1is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aryl. 2 NR N1 -, where R N1 is H or an optionally substituted alkyl group (e.g., C 1-6 alkyl, such as methyl, ethyl, isopropyl or n-propyl).

[0471] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), each Y 3 are independently O or S.

[0472] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), R 1 For H; each R 2 are independently H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy (e.g., -(CH2) s2 (OCH2CH2) s1 (CH2) s3 OR', wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and R' is H or C 1-20 Alkyl, such as where s2 is 0, s1 is 1 or 2, s3 is 0 or 1, and R' is C 1-6 alkyl); each Y 2 are independently O or -NR N1 -, where R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., wherein R N1 is H or an optionally substituted alkyl group (e.g., C 1-6 alkyl, such as methyl, ethyl, isopropyl or n-propyl); and each Y 3 is independently O or S (e.g., S). In other embodiments, R 3Y is H, halo (e.g., fluoro), hydroxy, optionally substituted alkyl, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. 1 are independently O or -NR N1 -, where R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., wherein R N1 is H or an optionally substituted alkyl group (e.g., C 1-6 alkyl, such as methyl, ethyl, isopropyl or n-propyl); and each Y 4 and R is independently H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino.

[0473] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), each R 1 are independently H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy (e.g., -(CH2) s2 (OCH2CH2) s1 (CH2) s3 OR', wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and R' is H or C 1-20 Alkyl, such as where s2 is 0, s1 is 1 or 2, s3 is 0 or 1, and R' is C 1-6 alkyl); R 2 For H; each Y 2 are independently O or -NR N1 -, where R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., wherein R N1 is H or an optionally substituted alkyl group (e.g., C 1-6 alkyl, such as methyl, ethyl, isopropyl or n-propyl); and each Y 3 is independently O or S (e.g., S). In other embodiments, R 3Y is H, halo (e.g., fluoro), hydroxy, optionally substituted alkyl, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. 1 are independently O or -NR N1 -, where R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., wherein R N1 is H or an optionally substituted alkyl group (e.g., C 1-6 alkyl, such as methyl, ethyl, isopropyl or n-propyl); and each Y 4 and R is independently H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino.

[0474] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), the ring including U is in a β-D (e.g., β-D-ribose) configuration.

[0475] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), the ring including U is in an α-L (e.g., α-L-ribose) configuration.

[0476] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), one or more B is not pseudouridine (ψ) or 5-methyl-cytidine (m 5 C) In some embodiments, from about 10% to about 100% of the n number of B nucleobases are not ψ or m 5C (e.g., 10% to 20%, 10% to 35%, 10% to 50%, 10% to 60%, 10% to 75%, 10% to 90%, 10% to 95%, 10% to 98%, 10% to 99%, 20% to 35%, 20% to 50%, 20% to 60%, 20% to 75%, 20% to 90%, 20% to 95%, 20% to 99%). 8%, 20% to 99%, 20% to 100%, 50% to 60%, 50% to 75%, 50% to 90%, 50% to 95%, 50% to 98%, 50% to 99%, 50% to 100%, 75% to 90%, 75% to 95%, 75% to 98%, 75% to 99%, and 75% to 100% of the n number of Bs are not ψ or m 5 C) In some embodiments, B is not ψ or m 5 C.

[0477] In some embodiments of the polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IV1), and (IXa)-(IXr)), when B is an unmodified nucleobase selected from cytosine, guanine, uracil, and adenine, then Y 1 、Y 2 or Y 3 At least one of them is not O.

[0478] In some embodiments, the polynucleotide, primary construct, or mmRNA includes a modified ribose. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (IIa) to (IIc):

[0479] or a pharmaceutically acceptable salt or stereoisomer thereof. In a specific embodiment, U is O or C(R U ) nu , where nu is an integer from 0 to 2 and each R U is independently H, halo or optionally substituted alkyl (eg, U is -CH2- or -CH-). In other embodiments, R 1 、R 2 、R 3 、R 4 and R 5and each independently represents H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent (e.g., each R 1 and R 2 are independently H, halo, hydroxy, optionally substituted alkyl or optionally substituted alkoxy; each R 3 and R 4 are independently H or optionally substituted alkyl; and R 5 is H or hydroxyl), and It is a single bond or a double bond.

[0480] In specific embodiments, the polynucleotide or mmRNA includes n number of linked nucleosides having Formula (IIb-1) to (IIb-2):

[0481] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, U is O or C(R U ) nu , where nu is an integer from 0 to 2 and each R U is independently H, halo or optionally substituted alkyl (eg, U is -CH2- or -CH-). In other embodiments, R 1 and R 2 and each independently represents H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent (e.g., each R 1 and R 2 is independently H, halo, hydroxy, optionally substituted alkyl, or optionally substituted alkoxy, e.g., H, halo, hydroxy, alkyl, or alkoxy). In specific embodiments, R 2 is hydroxy or optionally substituted alkoxy (eg, methoxy, ethoxy, or any alkoxy described herein).

[0482] In specific embodiments, the polynucleotide, primary construct, or mmRNA includes n number of linked nucleosides having Formula (IIc-1) to (IIc-4):

[0483] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, U is O or C(R U ) nu , where nu is an integer from 0 to 2 and each R U is independently H, halo or optionally substituted alkyl (eg, U is -CH2- or -CH-). In some embodiments, R 1 、R 2 and R 3 and each independently represents H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent (e.g., each R 1 and R 2 is independently H, halo, hydroxy, optionally substituted alkyl, or optionally substituted alkoxy, for example, H, halo, hydroxy, alkyl, or alkoxy; and each R 3 is independently H or optionally substituted alkyl)). In a specific embodiment, R 2 is an optionally substituted alkoxy group (e.g., methoxy or ethoxy or any alkoxy group described herein). In specific embodiments, R 1 is an optionally substituted alkyl group, and R 2 In other embodiments, R 1 is a hydroxyl group, and R 2 is an optionally substituted alkyl. In other embodiments, R 3 is an optionally substituted alkyl group.

[0484] In some embodiments, the polynucleotide, primary construct, or mmRNA includes a non-cyclic modified ribose. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (IId) to (IIf):

[0485] or a pharmaceutically acceptable salt or stereoisomer thereof.

[0486] In some embodiments, the polynucleotide, primary construct, or mmRNA includes a non-cyclic modified hexitol. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (IIg) to (IIj):

[0487] or a pharmaceutically acceptable salt or stereoisomer thereof.

[0488] In some embodiments, the polynucleotide, primary construct, or mmRNA includes a sugar moiety with a contracted or expanded ribose ring. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (IIk) to (IIm):

[0489] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1’ 、R 1” 、R 2′ and R 2” are each independently H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, or absent; and wherein R 2′ With R 3 A combination of or 2” With R 3 Combinations of can be taken together to form optionally substituted alkylene or optionally substituted heteroalkylene.

[0490] In some embodiments, the polynucleotide, primary construct, or mmRNA includes a locked modified ribose. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (IIn):

[0491] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3′ O, S or -NR N1 -, where R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aryl, and R 3” is optionally substituted alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-) or optionally substituted heteroalkylene (e.g., -CH2NH-, -CH2CH2NH-, -CH2OCH2-, or -CH2CH2OCH2-) (e.g., R 3′ is O and R 3”is an optionally substituted alkylene group (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-)).

[0492] In some embodiments, the polynucleotide, primary construct, or mmRNA includes n number of linked nucleosides having Formula (IIn-1) to (IIn-2):

[0493] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3′ O, S or -NR N1 -, where R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aryl, and R 3” is optionally substituted alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-) or optionally substituted heteroalkylene (e.g., -CH2NH-, -CH2CH2NH-, -CH2OCH2-, or -CH2CH2OCH2-) (e.g., R 3′ is O and R 3” is an optionally substituted alkylene group (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-)).

[0494] In some embodiments, the polynucleotide, primary construct, or mmRNA includes a locked modified ribose sugar that forms a tetracyclic heterocyclic group. In some embodiments, the polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) includes n number of linked nucleosides having Formula (IIo):

[0495] or a pharmaceutically acceptable salt thereof, wherein R 12a 、R 12c 、T 1’ 、T 1” 、T 2′ 、T 2” 、V 1 and V 3 As described herein.

[0496] Any formula of the polynucleotide, primary construct, or mmRNA may include one or more nucleobases described herein (eg, Formulas (bl) to (b43)).

[0497] In one embodiment, the present invention provides methods of making a polynucleotide, primary construct, or mmRNA, wherein the polynucleotide comprises n number of nucleosides having Formula (Ia) as defined herein:

[0498]

[0499] The method comprises allowing a compound of formula (IIIa) as defined herein:

[0500]

[0501] React with RNA polymerase and cDNA template.

[0502] In another embodiment, the present invention provides a method of amplifying a polynucleotide, primary construct, or mmRNA comprising at least one nucleotide (e.g., mmRNA molecule), the method comprising reacting a compound of Formula (IIIa) as defined herein with a primer, a cDNA template, and an RNA polymerase.

[0503] In one embodiment, the present invention provides methods of making a polynucleotide, primary construct, or mmRNA comprising at least one nucleotide (e.g., mmRNA molecule), wherein the polynucleotide comprises n number of nucleosides having Formula (Ia) as defined herein:

[0504]

[0505] The method comprises allowing a compound of formula (IIIa-1) as defined herein:

[0506]

[0507] React with RNA polymerase and cDNA template.

[0508] In another embodiment, the present invention provides a method of amplifying a polynucleotide, primary construct, or mmRNA comprising at least one nucleotide (e.g., mmRNA molecule), the method comprising:

[0509] The compound of formula (IIIa-1) as defined herein is reacted with a primer, a cDNA template and an RNA polymerase.

[0510] In one embodiment, the present invention provides a method of preparing a modified mRNA comprising at least one nucleotide (e.g., mmRNA molecule), wherein the polynucleotide comprises n number of nucleosides having Formula (Ia-2) as defined herein:

[0511]

[0512] The method comprises allowing a compound of formula (IIIa-2) as defined herein:

[0513]

[0514] React with RNA polymerase and cDNA template.

[0515] In another embodiment, the present invention provides a method of amplifying a modified mRNA comprising at least one nucleotide (e.g., mmRNA molecule), the method comprising:

[0516] The compound of formula (IIIa-2) as defined herein is reacted with a primer, a cDNA template and an RNA polymerase.

[0517] In some embodiments, the reaction can be repeated from 1 to about 7,000 times.In any of the embodiments herein, B can be a nucleobase of formula (bl) to (b43).

[0518] The polynucleotides, primary constructs, and mmRNA may optionally include 5' and / or 3' flanking regions, which are described herein.

[0519] Modified RNA (mmRNA) molecules

[0520] The present invention also includes structural units of modified RNA (mmRNA) molecules, such as modified ribonucleosides and modified ribonucleotides. For example, these structural units can be used to prepare the polynucleotides, primary constructs, or mmRNA of the present invention.

[0521] In some embodiments, the building block molecule has formula (IIIa) or (IIIa-1):

[0522]

[0523] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein substituents are as described herein (e.g., for Formula (Ia) and (Ia-1)), and wherein when B is an unmodified nucleobase selected from cytosine, guanine, uracil, and adenine, then Y 1 、Y 2 or Y 3 At least one of them is not O.

[0524] In some embodiments, the building block molecules that may be incorporated into the polynucleotide, primary construct, or mmRNA have Formula (IVa) to (IVb):

[0525] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (b1) to (b43)). In specific embodiments, Formula (IVa) or (IVb) is combined with a modified uracil (e.g., any one of Formulas (b1) to (b9), (b21) to (b23), and (b28) to (b31), such as Formula (b1), (b8), (b28), (b29), or (b30)). In specific embodiments, Formula (IVa) or (IVb) is combined with a modified cytosine (e.g., any one of Formulas (b10) to (b14), (b24), (b25), and (b32) to (b36), such as Formula (b10) or (b32)). In specific embodiments, Formula (IVa) or (IVb) is combined with a modified guanine (e.g., any one of Formulas (b15) to (b17) and (b37) to (b40)). In specific embodiments, Formula (IVa) or (IVb) is combined with a modified adenine (e.g., any one of Formulas (b18) to (b20) and (b41) to (b43)).

[0526] In some embodiments, the building block molecules that may be incorporated into the polynucleotide, primary construct, or mmRNA have Formula (IVc) to (IVk):

[0527] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (b1) to (b43)). In specific embodiments, one of Formulas (IVc) to (IVk) is combined with a modified uracil (e.g., any one of Formulas (b1) to (b9), (b21) to (b23), and (b28) to (b31), such as Formula (b1), (b8), (b28), (b29), or (b30)). In specific embodiments, one of Formulas (IVc) to (IVk) is combined with a modified cytosine (e.g., any one of Formulas (b10) to (b14), (b24), (b25), and (b32) to (b36), such as Formula (b10) or (b32)). In specific embodiments, one of Formulae (IVc) to (IVk) is combined with a modified guanine (e.g., any one of Formulae (b15) to (b17) and (b37) to (b40)). In specific embodiments, one of Formulae (IVc) to (IVk) is combined with a modified adenine (e.g., any one of Formulae (b18) to (b20) and (b41) to (b43)).

[0528] In other embodiments, the building block molecules that may be incorporated into the polynucleotides, primary constructs, or mmRNA have Formula (Va) or (Vb):

[0529]

[0530] (Vb), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (eg, any one of (b1) to (b43)).

[0531] In other embodiments, the building block molecules that may be incorporated into the polynucleotides, primary constructs, or mmRNA have Formula (IXa) to (IXd):

[0532] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (b1) to (b43)). In specific embodiments, one of Formulas (IXa) to (IXd) is combined with a modified uracil (e.g., any one of Formulas (b1) to (b9), (b21) to (b23), and (b28) to (b31), such as Formula (b1), (b8), (b28), (b29), or (b30)). In specific embodiments, one of Formulas (IXa) to (IXd) is combined with a modified cytosine (e.g., any one of Formulas (b10) to (b14), (b24), (b25), and (b32) to (b36), such as Formula (b10) or (b32)). In specific embodiments, one of Formulae (IXa) to (IXd) is combined with a modified guanine (e.g., any one of Formulae (b15) to (b17) and (b37) to (b40)). In specific embodiments, one of Formulae (IXa) to (IXd) is combined with a modified adenine (e.g., any one of Formulae (b18) to (b20) and (b41) to (b43)).

[0533] In other embodiments, the building block molecules that may be incorporated into the polynucleotides, primary constructs, or mmRNA have Formula (IXe) to (IXg):

[0534] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (b1) to (b43)). In specific embodiments, one of Formulae (IXe) to (IXg) is combined with a modified uracil (e.g., any one of Formulae (b1) to (b9), (b21) to (b23), and (b28) to (b31), such as Formulae (b1), (b8), (b28), (b29), or (b30)). In specific embodiments, one of Formulae (IXe) to (IXg) is combined with a modified cytosine (e.g., any one of Formulae (b10) to (b14), (b24), (b25), and (b32) to (b36), such as Formulae (b10) or (b32)). In specific embodiments, one of Formulae (IXe) to (IXg) is combined with a modified guanine (e.g., any one of Formulae (b15) to (b17) and (b37) to (b40)). In specific embodiments, one of Formulae (IXe) to (IXg) is combined with a modified adenine (e.g., any one of Formulae (b18) to (b20) and (b41) to (b43)).

[0535] In other embodiments, the building block molecules that may be incorporated into the polynucleotides, primary constructs, or mmRNA have Formula (IXh) to (IXk):

[0536] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (b1) to (b43)). In specific embodiments, one of Formulae (IXh) to (IXk) is combined with a modified uracil (e.g., any one of Formulae (b1) to (b9), (b21) to (b23), and (b28) to (b31), such as Formulae (b1), (b8), (b28), (b29), or (b30)). In specific embodiments, one of Formulae (IXh) to (IXk) is combined with a modified cytosine (e.g., any one of Formulae (b10) to (b14), (b24), (b25), and (b32) to (b36), such as Formulae (b10) or (b32)). In specific embodiments, one of Formulae (IXh) to (IXk) is combined with a modified guanine (e.g., any one of Formulae (b15) to (b17) and (b37) to (b40)). In specific embodiments, one of Formulae (IXh) to (IXk) is combined with a modified adenine (e.g., any one of Formulae (b18) to (b20) and (b41) to (b43)).

[0537] In other embodiments, the building block molecules that may be incorporated into the polynucleotides, primary constructs, or mmRNA have Formula (IXl) to (IXr):

[0538] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R1 and R2 is independently an integer from 0 to 5 (e.g., from 0 to 3, from 1 to 3, or from 1 to 5) and B is as described herein (e.g., any one of (b1) to (b43)). In specific embodiments, one of Formulas (IXl) to (IXr) is combined with a modified uracil (e.g., any one of Formulas (b1) to (b9), (b21) to (b23), and (b28) to (b31), such as Formula (b1), (b8), (b28), (b29), or (b30)). In specific embodiments, one of Formulas (IXl) to (IXr) is combined with a modified cytosine (e.g., any one of Formulas (b10) to (b14), (b24), (b25), and (b32) to (b36), such as Formula (b10) or (b32)). In specific embodiments, one of Formulae (IXl) to (IXr) is combined with a modified guanine (e.g., any one of Formulae (b15) to (b17) and (b37) to (b40)). In specific embodiments, one of Formulae (IXl) to (IXr) is combined with a modified adenine (e.g., any one of Formulae (b18) to (b20) and (b41) to (b43)).

[0539] In some embodiments, the building block molecules that may be incorporated into the polynucleotide, primary construct, or mmRNA may be selected from the group consisting of:

[0540] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (eg, from 0 to 3, from 1 to 3, or from 1 to 5).

[0541] In some embodiments, the building block molecules that may be incorporated into the polynucleotide, primary construct, or mmRNA may be selected from the group consisting of:

[0542] A pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (eg, from 0 to 3, from 1 to 3, or from 1 to 5) and s1 is as described herein.

[0543] In some embodiments, a building block molecule that can be incorporated into a nucleic acid (e.g., RNA, mRNA, polynucleotide, primary construct, or mmRNA) is a modified uridine (e.g., selected from the group consisting of:

[0544] 124) and or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y 1 、Y 3 、Y 4 、Y 6 and r is as described herein (eg, each r is independently an integer from 0 to 5, such as from 0 to 3, from 1 to 3, or from 1 to 5)).

[0545] In some embodiments, the building block molecule that may be incorporated into the polynucleotide, primary construct, or mmRNA is a modified cytidine (e.g., selected from the group consisting of:

[0546] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y 1 、Y 3 、Y 4 、Y 6and r is as described herein (e.g., each r is independently an integer from 0 to 5, such as from 0 to 3, from 1 to 3, or from 1 to 5). For example, a building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA can be:

[0547] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (eg, from 0 to 3, from 1 to 3, or from 1 to 5).

[0548] In some embodiments, the building block molecule that may be incorporated into the polynucleotide, primary construct, or mmRNA is a modified adenosine (e.g., selected from the group consisting of:

[0549] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y 1 、Y 3 、Y 4 、Y 6 and r is as described herein (eg, each r is independently an integer from 0 to 5, such as from 0 to 3, from 1 to 3, or from 1 to 5)).

[0550] In some embodiments, the building block molecule that may be incorporated into the polynucleotide, primary construct, or mmRNA is a modified guanosine (e.g., selected from the group consisting of:

[0551] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y 1 、Y 3 、Y 4 、Y 6 and r is as described herein (eg, each r is independently an integer from 0 to 5, such as from 0 to 3, from 1 to 3, or from 1 to 5)).

[0552] In some embodiments, the chemical modification may include replacing the C group at C-5 of the ring (e.g., for pyrimidine nucleosides such as cytosine or uracil) with N (e.g., with >NR N1 The group replaces the >CH group at C-5, where R N 1 is H or an optionally substituted alkyl). For example, a building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA can be:

[0553] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (eg, from 0 to 3, from 1 to 3, or from 1 to 5).

[0554] In another embodiment, the chemical modification may include replacing the hydrogen at C-5 of cytosine with a halo (e.g., Br, Cl, F, or I) or an optionally substituted alkyl (e.g., methyl). For example, a building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA can be: 244) or or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (eg, from 0 to 3, from 1 to 3, or from 1 to 5).

[0555] In yet another embodiment, the chemical modification may include a fused ring formed by an NH2 at the C-4 position and a carbon atom at the C-5 position. For example, a building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA can be:

[0556] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (eg, from 0 to 3, from 1 to 3, or from 1 to 5).

[0557] Sugar modifications

[0558] Modified nucleosides and nucleotides (e.g., building block molecules) that can be incorporated into polynucleotides, primary constructs, or mmRNA (e.g., RNA or mRNA, as described herein) can be modified on the sugar of the ribonucleic acid. For example, the 2' hydroxyl (OH) group can be modified or replaced by a variety of different substituents. Exemplary substituents at the 2'-position include, but are not limited to, H, halo, optionally substituted C 1-6 Alkyl; optionally substituted C 1-6 Alkoxy; optionally substituted C 6-10 Aryloxy; optionally substituted C 3-8 Cycloalkyl; optionally substituted C 3-8 Cycloalkoxy; optionally substituted C 6-10 Aryloxy; optionally substituted C 6-10Aryl-C 1-6 Alkoxy, optionally substituted C 1-12 (Heterocyclyl)oxy; sugar (e.g., ribose, pentose, or any sugar described herein); polyethylene glycol (PEG), -O(CH2CH2O) n CH2CH2OR, wherein R is H or optionally substituted alkyl, and n is an integer from 0 to 20 (e.g., from 0 to 4, from 0 to 8, from 0 to 10, from 0 to 16, from 1 to 4, from 1 to 8, from 1 to 10, from 1 to 16, from 1 to 20, from 2 to 4, from 2 to 8, from 2 to 10, from 2 to 16, from 2 to 20, from 4 to 8, from 4 to 10, from 4 to 16, and from 4 to 20); "locked" nucleic acids (LNAs) in which the 2'-hydroxyl group is separated by a C 1-6 Alkylene or C 1-6 The heteroalkylene bridge is attached to the 4'-carbon of the same ribose sugar, where exemplary bridges include methylene, propylene, ether, or amino bridges; aminoalkyl as defined herein; aminoalkoxy as defined herein; amino as defined herein; and amino acid as defined herein.

[0559] In general, RNA includes a glycosyl ribose sugar that is a 5-membered ring with an oxygen. Exemplary, non-limiting modified nucleotides include replacement of the oxygen in the ribose sugar (e.g., with S, Se, or an alkylene group such as methylene or ethylene); addition of a double bond (e.g., to replace the ribose sugar with a cyclopentenyl or cyclohexenyl group); ring contraction of the ribose sugar (e.g., to form a 4-membered ring of cyclobutane or propylene oxide); ring expansion of the ribose sugar (e.g., to form a 6- or 7-membered ring with an additional carbon or heteroatom that also has a phosphoramidate backbone, as for anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino); polycyclic forms (e.g., tricyclic; and "unlocked" forms). , such as glycol nucleic acids (GNAs) (e.g., R-GNA or S-GNA, in which ribose is replaced by an ethylene glycol unit linked to a phosphodiester bond), threose nucleic acids (TNA, in which ribose is replaced by an α-L-threofuranosyl-(3′→2′)), and peptide nucleic acids (PNA, in which a 2-amino-ethyl-glycine linkage replaces ribose and the phosphodiester backbone). The sugar group may also include one or more carbons having a stereochemical configuration opposite to that of the corresponding carbon in ribose. Thus, a polynucleotide, primary construct, or mmRNA molecule may include nucleotides containing, for example, arabinose as a sugar.

[0560] Modifications on nucleobases

[0561] The present disclosure provides modified nucleosides and nucleotides. As described herein, "nucleoside" is defined as a compound containing a combination of a sugar molecule (e.g., pentose or ribose) or a derivative thereof and an organic base (e.g., purine or pyrimidine) or a derivative thereof (also referred to herein as "core base"). As described herein, "nucleotide" is defined as a nucleoside comprising a phosphate group. Modified nucleotides can be synthesized by any useful method as described herein (e.g., chemical method, enzymatic method or recombinant method to include one or more modified or non-natural nucleosides).

[0562] Modified nucleotide base pairing encompasses not only standard adenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs, but also base pairs formed between nucleotides and / or modified nucleotides comprising non-standard or modified bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors allows hydrogen bonding between a non-standard base and a standard base or between two complementary non-standard base structures. An example of such non-standard base pairing is base pairing between the modified nucleotide inosine and adenine, cytosine, or uracil.

[0563] Modified nucleosides and nucleotides may comprise modified nucleobases. Examples of nucleobases found in RNA include, but are not limited to, adenine, guanine, cytosine, and uracil. Examples of nucleobases found in DNA include, but are not limited to, adenine, guanine, cytosine, and thymine. These nucleobases may be modified or completely replaced to provide polynucleotides, primary constructs, or mmRNA molecules with enhanced properties (e.g., enhanced resistance to nucleases by disrupting the binding of the major groove binding partner). Table 8 below identifies the chemical face of each canonical nucleotide. Circles identify atoms comprising the corresponding chemical region.

[0564] Table 8

[0565]

[0566] In some embodiments, B is a modified uracil. Exemplary modified uracils include those having formula (b1) to (b5):

[0567] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0568] in

[0569] Is a single bond or a double bond;

[0570] T 1’ 、T 1” 、T 2′ and T 2”are each independently H, optionally substituted alkyl, optionally substituted alkoxy or optionally substituted thioalkoxy, or T 1’ With T 1” Combination or T 2′ With T 2” of combinations connected together (e.g., as T 2 (in) to form O (oxo), S (thio) or Se (seleno);

[0571] V 1 and V 2 Each independently is O, S, N(R Vb ) nv or C(R Vb ) nv , where nv is an integer from 0 to 2 and each R Vb is independently H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl (e.g., substituted with an N-protecting group such as any described herein (e.g., trifluoroacetyl)), optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group such as any described herein (e.g., trifluoroacetyl)), optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, or optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein (e.g., those selected from (1) to (21) for alkyl));

[0572] R 10 is H, halo, optionally substituted amino acid, hydroxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aminoalkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl;

[0573] R 11 is H or optionally substituted alkyl;

[0574] R 12ais H, optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, or optionally substituted carbamoylalkyl; and

[0575] R 12c is H, halo, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted amino, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl or optionally substituted aminoalkynyl.

[0576] Other exemplary modified uracils include those having formulae (b6) to (b9):

[0577] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0578] in

[0579] Is a single bond or a double bond;

[0580] T 1’ 、T 1” 、T 2′ and T 2” are each independently H, optionally substituted alkyl, optionally substituted alkoxy or optionally substituted thioalkoxy, or T 1’ With T 1” of combinations connected together (e.g., as T 1 (in) or T 2′ With T 2” of combinations connected together (e.g., as T 2 to form O (oxo), S (thio) or Se (seleno), or each T 1 and T 2 are independently O (oxo), S (thio), or Se (seleno);

[0581] W 1 and W 2 Each independently is N(R Wa ) nw or C(R Wa ) nw , where nw is an integer from 0 to 2 and each R Wa is independently H, optionally substituted alkyl, or optionally substituted alkoxy;

[0582] Each V3 are independently O, S, N(R Va ) nv or C(R Va ) nv , where nv is an integer from 0 to 2 and each R Va and optionally substituted alkyl, optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy, optionally substituted aminoalkyl (e.g., substituted with an N-protecting group such as any described herein (e.g., trifluoroacetyl or sulfoalkyl)), optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group such as any described herein (e.g., trifluoroacetyl or sulfoalkyl)), optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group such as any described herein (e.g., trifluoroacetyl or sulfoalkyl)). wherein R is an optionally substituted alkyl group, ... Va and R 12c Together with the carbon atom to which they are attached, they may form an optionally substituted cycloalkyl group, an optionally substituted aryl group, or an optionally substituted heterocyclyl group (e.g., a 5-membered or 6-membered ring);

[0583] R 12a is H, optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy and / or an O-protecting group), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, optionally substituted carbamoylalkyl, or absent;

[0584] R 12bis H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkaryl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted aminoacid, optionally substituted alkoxycarbonylacyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy and / or an O-protecting group), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, or optionally substituted carbamoylalkyl,

[0585] where R 12b With T 1’ A combination of or 12b With R 12c may be linked together to form an optionally substituted heterocyclic group; and

[0586] R 12c is H, halo, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted amino, optionally substituted aminoalkyl, optionally substituted aminoalkenyl or optionally substituted aminoalkynyl.

[0587] Other exemplary modified uracils include those having formulae (b28) to (b31):

[0588] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0589] in

[0590] T 1 and T 2 Each is independently O (oxo), S (thio) or Se (seleno);

[0591] Each R Vb’ and R Vb”and R is independently H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkyl (e.g., substituted with an N-protecting group such as any described herein (e.g., trifluoroacetyl or sulfoalkyl)), optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group such as any N-protecting group described herein (e.g., trifluoroacetyl), optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylacyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy and / or an O-protecting group), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, or optionally substituted carbamoylalkyl (e.g., optionally substituted with any substituent described herein, such as those selected from (1) to (21) for alkyl) (e.g., R Vb’ is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted aminoalkyl, e.g., substituted with an N-protecting group such as any N-protecting group described herein (e.g., trifluoroacetyl or sulfoalkyl);

[0592] R 12a is H, optionally substituted alkyl, optionally substituted carboxyaminoalkyl, optionally substituted aminoalkyl (e.g., substituted with an N-protecting group such as any described herein (e.g., trifluoroacetyl or sulfoalkyl)), optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; and

[0593] R 12b is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl (e.g., substituted with an N-protecting group, such as any described herein (e.g., trifluoroacetyl or sulfoalkyl)),

[0594] optionally substituted alkoxycarbonylacyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl or optionally substituted carbamoylalkyl.

[0595] In a specific embodiment, T 1is O (oxo), and T 2 is S (thio) or Se (seleno). In other embodiments, T 1 is S (thio), and T 2 is O (oxo) or Se (seleno). In some embodiments, R Vb’ is H, optionally substituted alkyl or optionally substituted alkoxy.

[0596] In other embodiments, each R 12a and R 12b is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted hydroxyalkyl. 12a is H. In other embodiments, R 12a and R 12b Both are H.

[0597] In some embodiments, R 12b Each R Vb’ R is independently optionally substituted aminoalkyl (e.g., substituted with an N-protecting group such as any described herein (e.g., trifluoroacetyl or sulfoalkyl)), optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group such as any described herein (e.g., trifluoroacetyl)). In some embodiments, the amino and / or alkyl of the optionally substituted aminoalkyl is substituted with one or more of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted sulfoalkyl, optionally substituted carboxyl (e.g., substituted with an O-protecting group), optionally substituted hydroxy (e.g., substituted with an O-protecting group), optionally substituted carboxylalkyl (e.g., substituted with an O-protecting group), optionally substituted alkoxycarbonylalkyl (e.g., substituted with an O-protecting group), or an N-protecting group. In some embodiments, the optionally substituted aminoalkyl is substituted with optionally substituted sulfoalkyl or optionally substituted alkenyl. In specific embodiments, R 12a and R Vb” Both are H. In a specific embodiment, T 1 is O (oxo), and T 2 It is S (sulfo) or Se (seleno).

[0598] In some embodiments, R Vb’ is an optionally substituted alkoxycarbonylalkyl group or an optionally substituted carbamoylalkyl group.

[0599] In a specific embodiment, R 12a 、R 12b 、R 12c or R VaAn optional substituent is a polyethylene glycol group (e.g., -(CH2) s2 (OCH2CH2) s1 (CH2) s3 OR', wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and R' is H or C 1-20 alkyl); or an amino-polyethylene glycol group (e.g., -NR N1 (CH2) s2 (CH2CH2O) s1 (CH2) s3 NR N1 , wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and each R N1 are independently hydrogen or optionally substituted C 1-6 alkyl).

[0600] In some embodiments, B is a modified cytosine. Exemplary modified cytosines include compounds of formula (b10) to (b14):

[0601] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0602] in

[0603] T 3′ and T 3” are each independently H, optionally substituted alkyl, optionally substituted alkoxy or optionally substituted thioalkoxy, or T 3′ With T 3” of combinations connected together (e.g., as T 3 (in) to form O (oxo), S (thio) or Se (seleno);

[0604] Each V 4 are independently O, S, N(R Vc ) nv or C(R Vc ) nv , where nv is an integer from 0 to 2 and each R Vcis independently H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, or optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, such as those selected from (1) to (21) for alkyl), wherein R 13b With R Vc can be combined to form an optionally substituted heterocyclic group;

[0605] Each V 5 are independently N(R Vd ) nv or C(R Vd ) nv , where nv is an integer from 0 to 2 and each R Vd and (e.g., optionally substituted with any substituent described herein, such as those selected from (1) to (21) for alkyl) (e.g., V 5 is -CH or N);

[0606] R 13a and R 13b are each independently H, optionally substituted acyl, optionally substituted acyloxyalkyl, optionally substituted alkyl or optionally substituted alkoxy, wherein R 13b With R 14 can be combined to form an optionally substituted heterocyclic group;

[0607] Each R 14 is independently H, halo, hydroxy, thiol, optionally substituted acyl, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl (e.g., substituted with an O-protecting group), optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted acyloxyalkyl, optionally substituted amino (e.g., -NHR, wherein R is H, alkyl, aryl, or phosphoryl), azido, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkyl; and

[0608] R 15 and R 16Each is independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.

[0609] Other exemplary modified cytosines include those having formulae (b32) to (b35):

[0610] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0611] in

[0612] T 1 and T 3 Each is independently O (oxo), S (thio) or Se (seleno);

[0613] R 13a and R 13b are each independently H, optionally substituted acyl, optionally substituted acyloxyalkyl, optionally substituted alkyl or optionally substituted alkoxy, wherein R 13b With R 14 can be combined to form an optionally substituted heterocyclic group;

[0614] Each R 14 is independently H, halo, hydroxy, thiol, optionally substituted acyl, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl (e.g., substituted with an O-protecting group), optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted acyloxyalkyl, optionally substituted amino (e.g., -NHR, wherein R is H, alkyl, aryl, or phosphoryl), azido, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted aminoalkyl (e.g., hydroxyalkyl, alkyl, alkenyl, or alkynyl), optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; and

[0615] R 15 and R 16 are each independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl (e.g., R 15 is H, and R 16 is H or optionally substituted alkyl).

[0616] In some embodiments, R 15 is H, and R 16 is H or optionally substituted alkyl. In a specific embodiment, R 14is H, acyl or hydroxyalkyl. In some embodiments, R 14 In some embodiments, R 14 and R 15 Both are H. In some embodiments, R 15 and R 16 Both are H. In some embodiments, R 14 and R 15 and R 16 Each is H. In other embodiments, R 13a and R 13b Each is independently H or optionally substituted alkyl.

[0617] Other non-limiting examples of modified cytosine include compounds of formula (b36):

[0618] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0619] in

[0620] Each R 13b are independently H, optionally substituted acyl, optionally substituted acyloxyalkyl, optionally substituted alkyl or optionally substituted alkoxy, wherein R 13b With R 14b can be combined to form an optionally substituted heterocyclic group;

[0621] Each R 14a and R 14b is independently H, halo, hydroxy, thiol, optionally substituted acyl, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl (e.g., substituted with an O-protecting group), optionally substituted hydroxyalkenyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted acyloxyalkyl, optionally substituted amino (e.g., -NHR, where R is H, alkyl, aryl, phosphoryl, optionally substituted aminoalkyl, or optionally substituted carboxyaminoalkyl), azido, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkheterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; and

[0622] R 15 Each is independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.

[0623] In a specific embodiment, R 14b is an optionally substituted amino acid (e.g., optionally substituted lysine).14a For H.

[0624] In some embodiments, B is a modified guanine. Exemplary modified guanines include compounds of formula (b15) to (b17):

[0625] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0626] in

[0627] T 4’ 、T 4” 、T 5′ 、T 5” 、T 6’ and T 6” are each independently H, optionally substituted alkyl or optionally substituted alkoxy, and wherein T 4’ With T 4” Combinations of (for example, such as T 4 (in) or T 5′ With T 5” Combinations of (for example, such as T 5 (in) or T 6’ With T 6” Combinations of (for example, such as T 6 ) are linked together to form O (oxo), S (thio) or Se (seleno);

[0628] V 5 and V 6 Each independently is O, S, N(R Vd ) nv or C(R Vd ) nv , where nv is an integer from 0 to 2 and each R Vd is independently H, halo, thiol, optionally substituted amino acid, cyano, amidine, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, such as those selected from (1) to (21) for alkyl), optionally substituted thioalkoxy, or optionally substituted amino; and

[0629] R 17 、R 18 、R 19a 、R 19b 、R 21 、R 22 、R 23 and R 24Each is independently H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, optionally substituted amino, or optionally substituted amino acid.

[0630] Exemplary modified guanosines include compounds of formula (b37) to (b40):

[0631] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0632] in

[0633] T 4’ are each independently H, optionally substituted alkyl or optionally substituted alkoxy, and each T 4 are independently O (oxo), S (thio), or Se (seleno);

[0634] R 18 、R 19a 、R 19b and R 21 Each is independently H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, optionally substituted amino, or optionally substituted amino acid.

[0635] In some embodiments, R 18 is H or optionally substituted alkyl. In other embodiments, T 4 In some embodiments, R 19a and R 19b Each is independently H or optionally substituted alkyl.

[0636] In some embodiments, B is a modified adenine. Exemplary modified adenines include compounds of formula (b18) to (b20):

[0637] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0638] in

[0639] Each V 7 are independently O, S, N(R Ve ) nv or C(R Ve ) nv , where nv is an integer from 0 to 2 and each R Veis independently H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, such as those selected from (1) to (21) for alkyl);

[0640] Each R 25 is independently H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, or optionally substituted amino;

[0641] R 26a and R 26b are each independently H, optionally substituted acyl, optionally substituted amino acid, optionally substituted carbamoylalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, or a polyethylene glycol group (e.g., —(CH 2 ) s2 (OCH2CH2) s1 (CH2) s3 OR', wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and R' is H or C 1-20 alkyl); or an amino-polyethylene glycol group (e.g., -NR N1 (CH2) s2 (CH2CH2O) s1 (CH2) s3 NR N1 , wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and each R N1 are independently hydrogen or optionally substituted C 1-6 alkyl);

[0642] Each R 27 is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted thioalkoxy, or optionally substituted amino;

[0643] Each R 28 is independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; and

[0644] Each R 29and R is independently H, optionally substituted acyl, optionally substituted amino acid, optionally substituted carbamoylalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted alkoxy, or optionally substituted amino.

[0645] Exemplary modified adenines include compounds of formula (b41) to (b43):

[0646] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0647] in

[0648] Each R 25 is independently H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, or optionally substituted amino;

[0649] R 26a and R 26b are each independently H, optionally substituted acyl, optionally substituted amino acid, optionally substituted carbamoylalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, or a polyethylene glycol group (e.g., —(CH 2 ) s2 (OCH2CH2) s1 (CH2) s3 OR', wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and R' is H or C 1-20 alkyl); or an amino-polyethylene glycol group (e.g., -NR N1 (CH2) s2 (CH2CH2O) s1 (CH2) s3 NR N1 , wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and each R N1 are independently hydrogen or optionally substituted C 1-6 alkyl); and

[0650] Each R 27 and R is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted thioalkoxy, or optionally substituted amino.

[0651] In some embodiments, R 26a is H, and R 26b In some embodiments, R 26a and R 26b Each is independently an optionally substituted alkyl. In a specific embodiment, R 27 is optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy. 25 is an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted thioalkoxy group.

[0652] In a specific embodiment, R 26a 、R 26b or R 29 An optional substituent is a polyethylene glycol group (e.g., -(CH2) s2 (OCH2CH2) s1 (CH2) s3 OR', wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and R' is H or C 1-20 alkyl); or an amino-polyethylene glycol group (e.g., -NR N1 (CH2) s2 (CH2CH2O) s1 (CH2) s3 NR N1 , wherein s1 is an integer from 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer from 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6 or 1 to 10), and each R N1 are independently hydrogen or optionally substituted C 1-6 alkyl).

[0653] In some embodiments, B may have formula (b21):

[0654] wherein X12 is independently O, S, optionally substituted alkylene (eg, methylene) or optionally substituted heteroalkylene, xa is an integer from 0 to 3, and R 12a and T 2 As described herein.

[0655] In some embodiments, B may have formula (b22):

[0656] where R 10’R is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl or optionally substituted carbamoylalkyl, and R 11 、R 12a 、T 1 and T 2 As described herein.

[0657] In some embodiments, B can have formula (b23):

[0658] where R 10 is optionally substituted heterocyclyl (e.g., optionally substituted furanyl, optionally substituted thienyl, or optionally substituted pyrrolyl), optionally substituted aryl (e.g., optionally substituted phenyl or optionally substituted naphthyl), or any substituent described herein (e.g., for R 10 For example); and where R 11 (eg, H or any substituent described herein), R 12a (eg, H or any substituent described herein), T 1 (eg, oxo or any substituent described herein) and T 2 (eg, oxo or any substituent described herein) is as described herein.

[0659] In some embodiments, B can have formula (b24):

[0660] wherein R14′ is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkaryl, optionally substituted alkheterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl, and R 13a 、R 13b 、R 15 and T 3 As described herein.

[0661] In some embodiments, B may have formula (b25):

[0662] where R 14’ is optionally substituted heterocyclyl (e.g., optionally substituted furanyl, optionally substituted thienyl, or optionally substituted pyrrolyl), optionally substituted aryl (e.g., optionally substituted phenyl or optionally substituted naphthyl), or any substituent described herein (e.g., for R 14 or R 14’ For example); and where R 13a (eg, H or any substituent described herein), R 13b (eg, H or any substituent described herein), R 15 (eg, H or any substituent described herein) and T 3 (eg, oxo or any substituent described herein) is as described herein.

[0663] In some embodiments, B is a nucleobase selected from the group consisting of cytosine, guanine, adenine, and uracil. In some embodiments, B can be:

[0664]

[0665] In some embodiments, the modified nucleobase is a modified uracil. Exemplary nucleobases and nucleosides having modified uracil include pseudouridine (ψ), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s 2 U), 4-thio-uridine (s 4 U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho 5 U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridine or 5-bromo-uridine), 3-methyl-uridine (m 3 U), 5-methoxy-uridine (mo 5 U), uridine 5-oxyacetic acid (cmo 5 U), uridine 5-oxyacetate (mcmo 5 U), 5-carboxymethyl-uridine (cm 5 U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm 5 U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm 5 U), 5-methoxycarbonylmethyl-uridine (mcm 5 U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm 5 s 2 U), 5-aminomethyl-2-thio-uridine (nm 5 s 2U), 5-methylaminomethyl-uridine (mnm 5 U), 5-methylaminomethyl-2-thio-uridine (mnm 5 s 2 U), 5-methylaminomethyl-2-seleno-uridine (mnm 5 se 2 U), 5-carbamoylmethyl-uridine (ncm 5 U), 5-carboxymethylaminomethyl-uridine (cmnm 5 U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm 5 s 2 U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurine methyl-uridine (τm 5 U), 1-taurine methyl-pseudouridine, 5-taurine methyl-2-thio-uridine (τm 5 s 2 U), 1-taurine methyl-4-thio-pseudouridine, 5-methyl-uridine (m 5 U, i.e., with the nucleobase deoxythymidine), 1-methylpseudouridine (m 1 ψ), 5-methyl-2-thio-uridine (m 5 s 2 U), 1-methyl-4-thio-pseudouridine (m 1 s 4 ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m 3 ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m 5 D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine (also known as 1-methylpseudouridine (m 1 ψ))、3-(3-amino-3-carboxypropyl)uridine (acp 3 U), 1-methyl-3-(3-amino-3-carboxypropyl) pseudouridine (acp 3 ψ), 5-(isopentenylaminomethyl)uridine (inm 5 U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm 5 s 2 U), α-thio-uridine, 2′-O-methyl-uridine (Um), 5,2′-O-dimethyl-uridine (m 5Um), 2′-O-methyl-pseudouridine (ψm), 2-thio-2′-O-methyl-uridine (s 2 Um), 5-methoxycarbonylmethyl-2′-O-methyl-uridine (mcm 5 Um), 5-carbamoylmethyl-2′-O-methyl-uridine (ncm 5 Um), 5-carboxymethylaminomethyl-2′-O-methyl-uridine (cmnm 5 Um), 3,2′-O-dimethyl-uridine (m 3 Um), 5-(isopentenylaminomethyl)-2′-O-methyl-uridine (inm 5 Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine, 2'-OH-ara-uridine, 5-(2-methoxycarbonylvinyl)uridine, and 5-[3-(1-E-propenylamino)uridine.

[0666] In some embodiments, the modified nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having modified cytosine include 5-azacytidine, 6-azacytidine, pseudoisocytidine, 3-methylcytidine (m 3 C), N4-acetyl-cytidine (ac 4 C), 5-formyl-cytidine (f 5 C), N4-methyl-cytidine (m 4 C), 5-methyl-cytidine (m 5 C), 5-halogenated cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm 5 C), 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine (s 2 C), 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, lysine (k2C), α-thio-cytidine, 2′-O-methyl-cytidine (Cm), 5,2′-O-dimethyl-cytidine (m 5 Cm), N4-acetyl-2′-O-methyl-cytidine (ac 4 Cm), N4,2′-O-dimethyl-cytidine (m 4 Cm), 5-formyl-2′-O-methyl-cytidine (f 5Cm), N4,N4,2′-O-trimethyl-cytidine (m 4 2Cm), 1-thio-cytidine, 2'-F-ara-cytidine, 2'-F-cytidine, and 2'-OH-ara-cytidine.

[0667] In some embodiments, the modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides with modified adenine include 2-amino-purine, 2,6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine (m 1 A), 2-methyl-adenine (m 2 A), N6-methyl-adenosine (m 6 A), 2-methylthio-N6-methyl-adenosine (ms 2 m 6 A), N6-isopentenyl-adenosine (i 6 A), 2-methylthio-N6-isopentenyl-adenosine (ms 2 i 6 A), N6-(cis-hydroxyisopentenyl)adenosine (io 6 A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms 2 io 6 A), N6-glycylcarbamoyl-adenosine (g 6 A), N6-threonylcarbamoyl-adenosine (t 6 A), N6-methyl-N6-threonylcarbamoyl-adenosine (m 6 t 6 A), 2-methylthio-N6-threonylcarbamoyl-adenosine (ms 2 g 6 A), N6, N6-dimethyl-adenosine (m 6 2A), N6-hydroxynorvalylcarbamoyl-adenosine (hn 6 A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenosine (ms 2 hn 6 A), N6-acetyl-adenosine (ac 6A), 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, α-thio-adenosine, 2′-O-methyl-adenosine (Am), N6,2′-O-dimethyl-adenosine (m 6 Am), N6,N6,2′-O-trimethyl-adenosine (m 6 2Am), 1,2′-O-dimethyl-adenosine (m 1 Am), 2′-O-ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1-thio-adenosine, 8-azido-adenosine, 2′-F-ara-adenosine, 2′-F-adenosine, 2′-OH-ara-adenosine, and N6-(19-amino-pentaoxahonadecanyl)-adenosine.

[0668] In some embodiments, the modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having modified guanine include inosine (I), 1-methyl-inosine (m 1 I), Y nucleoside (wyosine) (imG), methyl Y nucleoside (mimG), 4-demethyl-Y nucleoside (imG-14), iso-Y nucleoside (imG2), wyosine (yW), peroxy wyosine (o2yW), hydroxy wyosine (OHyW), undermodified hydroxy wyosine (OHyW*), 7-deaza-guanosine, braided glycoside (Q), epoxy braided glycoside (oQ), galactosyl-braided glycoside (galQ), mannosyl-braided glycoside (manQ), 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), archaeoside (G + ), 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine (m 7 G), 6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methyl-guanosine (m 1 G), N2-methyl-guanosine (m 2 G), N2,N2-dimethyl-guanosine (m 2 2G), N2,7-dimethyl-guanosine (m 2,7 G), N2,N2,7-dimethyl-guanosine (m 2,2,7 G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2-dimethyl-6-thio-guanosine, α-thio-guanosine, 2′-O-methyl-guanosine (Gm), N2-methyl-2′-O-methyl-guanosine (m 2 Gm), N2,N2-dimethyl-2′-O-methyl-guanosine (m 22Gm), 1-methyl-2′-O-methyl-guanosine (m 1 Gm), N2,7-dimethyl-2′-O-methyl-guanosine (m 2,7 Gm), 2′-O-methyl-inosine (Im), 1,2′-O-dimethyl-inosine (m 1 Im) and 2′-O-ribosylguanosine (phosphate) (Gr(p)).

[0669] The nucleobases of the nucleotides can be independently selected from purines, pyrimidines, purines or pyrimidine analogs. For example, the nucleobases can each be independently selected from adenine, cytosine, guanine, uracil or hypoxanthine. In another embodiment, the nucleobase can also include, for example, naturally occurring and synthetic derivatives of the base, including pyrazolo[3,4-d]pyrimidine, 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo (e.g., 8-bromo), 8-amino, 8-thiol, 8-thiouracil ...8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thiouracil, 8-thio -thioalkyl, 8-hydroxy and other 8-substituted adenines and guanines, 5-halo, specifically 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, deazaguanine, 7-deazaguanine, 3-deazaguanine, deazaadenine, 7-deazaadenine, 3-deazaadenine, pyrazolo[3,4-d]pyrimidine, imidazo[1,5-a]1,3,5-triazinone, 9-deazapurine, imidazo[4,5-d]pyrazine, thiazolo[4,5-d]pyrimidine, pyrazin-2-one, 1,2,4-triazine, pyridazine; and 1,3,5-triazine. When the abbreviations A, G, C, T, or U are used to depict nucleotides, each letter refers to its representative base and / or derivative, for example, A includes adenine or an adenine analog, such as 7-deazaadenine).

[0670] Modifications on internucleoside linkages

[0671] The modified nucleotides that can be incorporated into polynucleotides, primary constructs or mmRNA molecules can be modified on internucleoside linkages (e.g., phosphate backbones). In the context of polynucleotide backbones herein, the phrases "phosphate" and "phosphodiester" are used interchangeably. The backbone phosphate group can be modified by replacing one or more oxygen atoms with different substituents. In addition, modified nucleosides and nucleotides may include all replacements of unmodified phosphate moieties with another internucleoside linkage as described herein. The example of the modified phosphate group includes, but is not limited to, phosphorothioate, selenophosphate, borane phosphate (boranophosphate), borane phosphate (boranophosphate ester), hydrogen phosphonate, phosphoramidate, diaminophosphate, alkyl or aryl phosphonate and phosphotriester. The two non-connected oxygens that phosphorodithioate has are replaced by sulfur. The phosphate linker can also be modified by replacing the connected oxygen with nitrogen (bridging phosphoramidate), sulfur (bridging phosphorothioate) and carbon (bridging methylene-phosphonate).

[0672] α-Thio-substituted phosphate moieties are provided to impart stability to RNA and DNA polymers through non-natural phosphorothioate backbone linkages. Phosphorothioate DNA and RNA have increased nuclease resistance and therefore have a longer half-life in the cellular environment. Phosphorothioate-linked polynucleotides, primary constructs, or mmRNA molecules are also expected to reduce innate immune responses through weaker binding / activation of cellular innate immune molecules.

[0673] In specific embodiments, modified nucleosides include α-thio-nucleosides (e.g., 5′-O-(1-phosphorothioate)-adenosine, 5′-O-(1-phosphorothioate)-cytidine (α-thio-cytidine), 5′-O-(1-phosphorothioate)-guanosine, 5′-O-(1-phosphorothioate)-uridine, or 5′-O-(1-phosphorothioate)-pseudouridine).

[0674] Other internucleoside linkages that may be employed in accordance with the present invention, including internucleoside linkages that do not contain a phosphorus atom, are described herein below.

[0675] Combinations of modified sugars, nucleobases, and internucleoside linkages

[0676] The polynucleotides, primary constructs, and mmRNA of the present invention may include combinations of modifications to sugars, nucleobases, and / or internucleoside linkages. These combinations may include any one or more modifications described herein. For example, any nucleotide described herein in Formulas (Ia), (Ia-1) to (Ia-3), (Ib) to (If), (IIa) to (IIp), (IIb-1), (IIb-2), (IIc-1) to (IIc-2), (IIn-1), (IIn-2), (IVa) to (IV1), and (IXa)-(IXr) may be combined with any nucleobase described herein (e.g., in Formulas (b1) to (b43) or any other described herein).

[0677] Synthesis of peptides, primary constructs, and mmRNA molecules

[0678] The polypeptides, primary constructs, and mmRNA molecules for use according to the present invention can be prepared according to any useful technique as described herein. Modified nucleosides and nucleotides used in the synthesis of the polynucleotides, primary constructs, and mmRNA molecules disclosed herein can be prepared from readily available starting materials using the following general methods and procedures. Where typical or preferred process conditions (e.g., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.) are provided, a skilled artisan will be able to optimize and develop additional process conditions. Optimal reaction conditions may vary depending on the specific reactants or solvents used, but such conditions can be determined by a person skilled in the art through conventional optimization procedures.

[0679] The processes described herein can be monitored by any suitable method known in the art. For example, the monitoring can be performed by spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometry (eg, UV-visible), or mass spectrometry, or by chromatography, such as high performance liquid chromatography (HPLC) or thin layer chromatography, to monitor product formation.

[0680] Preparation of the polypeptides, primary constructs, and mmRNA molecules of the present invention may involve protection and deprotection of various chemical groups. The need for protection and deprotection, as well as the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene et al., Protective Groups in Organic Synthesis, 2nd ed., Wiley & Sons, 1991, which is incorporated herein by reference in its entirety.

[0681] The reactions of the processes described herein can be carried out in a suitable solvent, which can be easily selected by those skilled in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), intermediates, or products at the temperature at which the reaction is carried out (i.e., a temperature that can range from the freezing temperature of the solvent to the boiling temperature of the solvent). A given reaction can be carried out in one solvent or in a mixture of more than one solvent. Depending on the specific reaction steps, a suitable solvent can be selected for the specific reaction steps.

[0682] The resolution of the racemic mixture of modified nucleosides and nucleotides can be carried out by any of a variety of methods known in the art. Illustrative methods include the fractional recrystallization using "chiral resolution acid", which is an optically active, salified organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as tartaric acid, diacetyl tartaric acid, dibenzoyl tartaric acid, mandelic acid, malic acid, lactic acid or various optically active camphorsulfonic acids in the form of D and L. The resolution of the racemic mixture can also be carried out by eluting on a post that is filled with an optically active resolving agent (for example, dinitrobenzoylphenylglycine). Suitable elution solvent compositions can be determined by those skilled in the art.

[0683] Modified nucleosides and nucleotides (e.g., building block molecules) can be prepared according to the synthetic methods described in Ogata et al., J. Org. Chem. 74:2585-2588 (2009); Purmal et al., Nucl. Acids Res. 22(1):72-78, (1994); Fukuhara et al., Biochemistry, 1(4):563-568 (1962); and Xu et al., Tetrahedron, 48(9):1729-1740 (1992), each of which is incorporated herein by reference in its entirety.

[0684] The polypeptides, primary constructs, and mmRNA of the present invention may or may not be uniformly modified along the entire length of the molecule. For example, one or more or all types of nucleotides (e.g., purines or pyrimidines, or any one or more or all of A, G, U, C) may or may not be present in a polynucleotide of the present invention or within a given predetermined sequence region thereof (e.g., Figure 1 In some embodiments, all nucleotides X in a polynucleotide of the invention (or in a given sequence region thereof) are modified, wherein X can be any one of the nucleotides A, G, U, C, or any one of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C, or A+G+C.

[0685] Different sugar modifications, nucleotide modifications, and / or internucleoside linkages (e.g., backbone structures) may be present at different positions in a polynucleotide, primary construct, or mmRNA. One of ordinary skill in the art will appreciate that nucleotide analogs or other modifications may be located at any position in a polynucleotide, primary construct, or mmRNA so that the function of the polynucleotide, primary construct, or mmRNA is not substantially diminished. Modifications may also be 5' or 3' terminal modifications. The polynucleotides, primary constructs, or mmRNA may comprise from about 1% to about 100% modified nucleotides (relative to the overall nucleotide content or relative to one or more types of nucleotides, i.e., any one or more of A, G, U, or C), or any intermediate percentage (e.g., 1% to 20%, 1% to 25%, 1% to 50%, 1% to 60%, 1% to 70%, 1% to 80%, 1% to 90%, 1% to 95%, 10% to 20%, 10% to 25%, 10% to 50%, 10% to 60%, 10% to 70%, 10% to 80%, 10% to 90%, 10% to 95%). %, 10% to 100%, 20% to 25%, 20% to 50%, 20% to 60%, 20% to 70%, 20% to 80%, 20% to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100%).

[0686] In some embodiments, the polynucleotides, primary constructs, or mmRNA include modified pyrimidines (e.g., modified uracil / uridine / U or modified cytosine / cytidine / C). In some embodiments, the uracil or uridine (typically: U) in the polynucleotides, primary constructs, or mmRNA molecules may be modified with about 1% to about 100% modified uracil or modified uridine (e.g., 1% to 20%, 1% to 25%, 1% to 50%, 1% to 60%, 1% to 70%, 1% to 80%, 1% to 90%, 1% to 95%, 10% to 20%, 10% to 25%, 10% to 50%, 10% to 60%, 10% to 70%, 10% to 80%, 10% to 90%, 10% to 95%, 10% to 100%, 20% to 25%, 25% to 30%, 30% to 40%, 35% to 50%, 35% to 60%, 35% to 70%, 35% to 80%, 35% to 90%, 35% to 100%, 35% to 20%, 35% to 40%, 35% to 5 ... % to 100%, 20% to 50%, 20% to 60%, 20% to 70%, 20% to 80%, 20% to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100% of the modified uracil or modified uridine). The modified uracil or uridine can be replaced by a compound having a single unique structure or by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures, as described herein). In some embodiments, the cytosine or cytidine (generally: C) in the polynucleotide, primary construct, or mmRNA molecule may be modified with about 1% to about 100% modified cytosine or modified cytidine (e.g., 1% to 20%, 1% to 25%, 1% to 50%, 1% to 60%, 1% to 70%, 1% to 80%, 1% to 90%, 1% to 95%, 10% to 20%, 10% to 25%, 10% to 50%, 10% to 60%, 10% to 70%, 10% to 80%, 10% to 90%, 10% to 95%, 10% to 100%, 20% to 25%, 25% to 30%, 30% to 40%, 35% to 50%, 35% to 60%, 35% to 70%, 35% to 80%, 35% to 90%, 35% to 100%, % to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100% of modified cytosine or modified cytidine) replacements.The modified cytosine or cytidine can be replaced by a compound having a single unique structure or by a plurality of compounds having different structures (eg, 2, 3, 4, or more unique structures, as described herein).

[0687] In some embodiments, the present disclosure provides methods of synthesizing a polynucleotide, primary construct, or mmRNA (e.g., the first region, first flanking region, or second flanking region) that includes n number of linked nucleosides having Formula (Ia-1):

[0688] The method comprises

[0689] a) making a nucleotide of formula (IV-1):

[0690]

[0691] Reaction with a phosphoramidite compound of formula (V-1):

[0692]

[0693] where Y 9 is H, hydroxyl, phosphoryl, pyrophosphate, sulfate, amino, thiol, an optionally substituted amino acid, or a peptide (e.g., comprising 2 to 12 amino acids); and each P 1 、P 2 and P 3 are independently suitable protecting groups; and refers to a solid support;

[0694] So as to provide a polynucleotide, primary construct or mmRNA of Formula (VI-1):

[0695]

[0696] b) oxidizing or sulfiding the polynucleotide, primary construct, or mmRNA of Formula (V) to produce the polynucleotide, primary construct, or mmRNA of Formula (VII-1):

[0697]

[0698] c) removing the protecting groups to produce the polynucleotide, primary construct, or mmRNA of Formula (Ia).

[0699] In some embodiments, steps a) and b) are repeated from 1 to about 10,000 times. In some embodiments, the method further comprises a nucleotide (e.g., mmRNA molecule) selected from the group consisting of A, C, G, and U adenosine, cytosine, guanosine, and uracil. In some embodiments, the nucleobase can be a pyrimidine or a derivative thereof. In some embodiments, the polynucleotide, primary construct, or mmRNA is translatable.

[0700] Other components of polynucleotides, primary constructs, and mmRNA are optional and, in some embodiments, beneficial. For example, a 5' untranslated region (UTR) and / or a 3' UTR are provided, either or both of which may independently contain one or more different nucleotide modifications. In such embodiments, nucleotide modifications may also be present in the translatable region. Also provided are polynucleotides, primary constructs, and mmRNA containing Kozak sequences.

[0701] Exemplary syntheses of modified nucleotides for incorporation into modified nucleic acids or mmRNA (eg, RNA or mRNA) are provided below in Schemes 1 to 11. Scheme 1 provides a general method for phosphorylating nucleotides, including modified nucleosides.

[0702] Solution 1

[0703]

[0704] Various protecting groups can be used to control the reaction. For example, Scheme 2 provides the use of multiple protection and deprotection steps to promote phosphorylation at the 5' position of the sugar rather than the 2' and 3' hydroxyl groups.

[0705] Option 2

[0706]

[0707] Modified nucleotides can be synthesized in any useful manner. Schemes 3, 4, and 7 provide exemplary methods for synthesizing modified nucleotides having modified purine nucleobases; and Schemes 5 and 6 provide exemplary methods for synthesizing modified nucleotides having modified pseudouridine or pseudoisocytidine, respectively.

[0708] Option 3

[0709]

[0710] Option 4

[0711]

[0712] Option 5

[0713]

[0714] Option 6

[0715]

[0716] Option 7

[0717]

[0718] Schemes 8 and 9 provide exemplary syntheses of modified nucleotides. Scheme 10 provides a non-limiting biocatalytic method for producing nucleotides.

[0719] Option 8

[0720]

[0721] Option 9

[0722]

[0723] Plan 10

[0724]

[0725] Scheme 11 provides an exemplary synthesis of modified uracils in which the N1 position is modified with R as provided elsewhere. 12b Modified, and the 5' position of the ribose is phosphorylated. 1 、T 2 、R 12a 、R 12b and r as provided herein. This synthesis and its optimized versions can be used to modify other pyrimidine and purine nucleobases (see, e.g., Formulas (b1) to (b43)) and / or to place one or more phosphate groups (e.g., at the 5' position of the sugar). This alkylation reaction can also be used to include one or more optionally substituted alkyl groups at any reactive group (e.g., amino group) in any nucleobase described herein (e.g., amino group in the Watson-Crick base pairing plane of cytosine, uracil, adenine, and guan...

Claims

1. Use of a composition in the preparation of a medicament for producing erythropoietin (EPO) in vivo, comprising contacting a mammalian cell, tissue or organism with the composition, wherein: The composition comprises lipid nanoparticles, wherein the lipid nanoparticles comprise a biodegradable cationic lipid, a neutral lipid, cholesterol, and a PEGylated lipid, wherein the lipid nanoparticles encapsulate at least one mRNA encoding EPO, wherein the mRNA comprises: (a) an open reading frame consisting of nucleotides selected from the group consisting of 1-methyl-pseudouridine, cytidine, adenosine and guanosine; (b) 5'-UTR including Kozak sequence; (c) at least one 5' cap structure; (d) 3'-UTR; and (e) a 3' tailing sequence for connecting nucleosides, The nucleotides of the open reading frame are codon-optimized to increase the number of nucleotides containing guanosine and cytidine.

2. The method according to claim 1, wherein the mRNA encoding the EPO comprises a sequence selected from the group consisting of SEQ ID NO:

173.

3. The method according to claim 1, wherein the 3' tailing sequence of the linked nucleosides comprises 140 nucleotides. The method according to claim 1 , wherein the 3′ tailing sequence of the linked nucleosides comprises 160 nucleotides. The use according to claim 1 , wherein the mRNA comprises a 5′ end cap of Cap1. The use according to claim 1 , wherein the biodegradable cationic lipid comprises an ester bond.

7. The use according to claim 1, wherein the drug is administered to mammalian cells, tissues or organisms at a total daily dose of between 1 ug and 150 ug of mRNA encoding EPO.

8. The use according to claim 1, wherein the drug is administered to mammalian cells, tissues or organisms in two or more equal or unequal divided doses.

Citation Information

Cited By

  • In vivo production of proteins

    CN112390871A